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Diabetic peripheral neuropathy (DPN) is a prevalent diabetic complication with 
scarce treatment options. Impaired neuronal mitochondrial bioenergetics contributes to 
the pathophysiologic progression of DPN and may be a focal point for disease 
management. We have demonstrated that modulating Hsp90 and Hsp70 with the small-
molecule drug KU-32 ameliorates psychosensory, electrophysiologic, morphologic, and 
bioenergetic deficits of DPN in animal models of type 1 diabetes. The current study used 
mouse models of type 1 and type 2 diabetes to determine the relationship of changes in 
sensory neuron mitochondrial bioenergetics to the onset of and recovery from DPN. The 
onset of DPN showed a tight temporal correlation with a decrease in mitochondrial 
bioenergetics in a genetic model of type 2 diabetes. In contrast, sensory hypoalgesia 
developed 10 weeks before the occurrence of significant declines in sensory neuron 
mitochondrial bioenergetics in the type 1 model. KU-32 therapy improved mitochondrial 
bioenergetics in both the type 1 and type 2 models, and this tightly correlated with a 
decrease in DPN. Mechanistically, improved mitochondrial function following KU-32 
therapy required Hsp70, since the drug was ineffective in diabetic Hsp70 knockout mice. 
Our data indicate that changes in mitochondrial bioenergetics may rapidly contribute to 
nerve dysfunction in type 2 diabetes, but not type 1 diabetes, and that modulating Hsp70 
offers an effective approach toward correcting sensory neuron bioenergetic deficits and 
DPN in both type 1 and type 2 diabetes.  
We also sought to determine whether KU-596, an analogue of KU-32, offers similar 
therapeutic potential for treating DPN. Similar to KU-32, KU-596 improved 





the drug could not improve DPN in Hsp70 KO mice. Transcriptomic analysis using RNA 
sequencing (RNA-Seq) of DRG from diabetic wild type (WT) and Hsp70 KO mice 
revealed that KU-596 modulated transcription of genes involved in inflammatory 
pathways independently of Hsp70. In contrast, the effects of KU-596 on genes involved 
in the production of reactive oxygen species (ROS) are Hsp70-dependent. Our data 
indicate that modulation of molecular chaperones offers an effective approach towards 
correcting nerve dysfunction, and that normalization of inflammatory pathways alone by 
novologue therapy seems to be insufficient to reverse the deficits associated with 
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Chapter 1: Introduction 
1.1. Diabetes Mellitus 
1.1.1. Overview of Diabetes Mellitus 
Diabetes mellitus is a metabolic disorder that characterized by chronic 
hyperglycemia and impaired carbohydrate, lipid and protein metabolism resulting from 
defects in insulin secretion, insulin action, or both. It is associated with reduced life 
expectancy, significant morbidity due to specific diabetes related microvascular 
complications (retinopathy, nephropathy and neuropathy), increased risk of 
macrovascular complications (ischemic heart disease, stroke and peripheral vascular 
disease), and diminished quality of life (WHO, 2006; WHO, 2013a).  
First recognized around 1500 B.C.E. by the ancient Egyptians, diabetes mellitus was 
considered a rare condition in which a person urinated excessively and lost weight. The 
term diabetes mellitus reflects the fact that the urine of those affected had a sweet taste. 
When the disease was first recognized, no effective treatment was available, and diabetes 
was uniformly fatal within weeks to months after its diagnosis owing to insulin 
deficiency. With recent advances in our understanding towards the underlying causes of 
diabetes and the approaches to its prevention and treatment, many effective therapies are 
available for the controlling of hyperglycemia and its associated complications. Although 
diabetes is still associated with a reduced life expectancy, the outlook for patients with 
this disease has improved dramatically. However, although scientific advances have led 
to effective strategies for preventing and controlling diabetes, the pathway to cure has 





has been made toward conquering the disease during the past 200 years, with tremendous 
increase in the prevalence of diabetes worldwide (Polonsky, 2012). 
Diabetes mellitus has become a worldwide epidemic that is among one of the most 
common and serious medical conditions humankind has had to face. Recent estimates 
indicate that there are an estimate of 382 million people in the world with diabetes and 
this is projected to increase to 592 million by 2035 (Guariguata, 2012; Guariguata, 2013; 
Whiting et al., 2011). According to a recent report released by the Centers for Disease 
Control and Prevention (CDC), 29.1 million people or 9.3% of the population in the 
United States have diabetes, with 8.1 million people being undiagnosed (CDC, 2014). As 
the number of people with diabetes grows worldwide, the disease takes an ever-
increasing proportion of national health care budgets, having caused at least $548 billion 
in health expenditure in 2013 (Guariguata, 2013). In the US alone, the total cost of 
diagnosed diabetes in 2012 was $245 billion, including $176 billion in direct costs, and 
$69 billion for reduced productivity (American Diabetes, 2014). 
1.1.2. Clinical Features and Diagnostic Criteria of Diabetes Mellitus 
Diabetes mellitus normally presents with symptoms of polyuria, polydipsia and 
weight loss, and is sometimes accompanied by polyphagia and blurred vision. Impaired 
growth and susceptibility to certain infections may also present as clinical features of 
chronic hyperglycemia. Uncontrolled diabetes may lead to acute, life-threatening 
consequences such as diabetic ketoacidosis (DKA) or the nonketotic hyperosmolar 
syndrome (NKHS) (American Diabetes, 2013).  
With progression of the disease, chronic hyperglycemia often leads to long-term 





renal failure; peripheral neuropathy with risk of foot ulceration, amputations, and Charcot 
joints; and autonomic neuropathy causing gastrointestinal, genitourinary, and 
cardiovascular symptoms and sexual dysfunction. Hypertension and abnormalities of 
lipoprotein metabolism often coexist with diabetes, especially in patients with type 2 
diabetes. In addition, patients with diabetes have an increased incidence of atherosclerotic 
cardiovascular, peripheral arterial, and cerebrovascular disease (American Diabetes, 
2013).  
Diabetes mellitus is diagnosed on the basis of American Diabetes Association (ADA) 
recommendations, incorporating fasting plasma glucose (FPG), 2h values in the oral 
glucose tolerance test (OGTT) and HbA1c (Glycated hemoglobin) criteria (Table 1.1-1). 
FPG measures the plasma glucose level in a person who has been fasting for at least 8 
hours and is the preferred method due to its convenience and low cost, however, it is not 
as powerful as the OGTT with respect to accuracy (NIDDK, 2011). Also performed after 
an at least 8-hour fast, the OGTT involves oral ingestion of a standard dose of glucose 
(75g) and measurement of plasma glucose levels two hours later, which indicates the 
efficiency of insulin to promote glucose uptake. HbA1c is a form of hemoglobin that is 
formed in a non-enzymatic glycation pathway by hemoglobin's exposure to plasma 
glucose. Whereas normal levels of glucose produce a normal amount of glycated 
hemoglobin, the fraction of glycated hemoglobin increases in a predictable way as the 
plasma glucose level increases. Since the HbA1c level could reflect average blood 
glucose levels over a 2- to 3-month period, it is a good tool for determining long-term 
glycemic condition. As a widely used biomarker of chronic glycemia, the HbA1c test 





complications, thus it plays a critical role in the disease management of diabetic patients 
(American Diabetes, 2013).  
In 1997 and 2003, the Expert Committee on Diagnosis and Classification of Diabetes 
Mellitus recognized an intermediate group of individuals whose glucose levels do not 
meet criteria for diabetes, yet are higher than those considered normal (1997; 2003). 
These people are defined as having impaired fasting glucose (IFG) or impaired glucose 
tolerance (IGT) (Table 1.1-1), which are referred to as prediabetic states. Though IFG 
and IGT should not be viewed as clinical entities on their own, they are considered as risk 
factors for diabetes as well as cardiovascular diseases. The presence of IFG and IGT are 
closely associated with obesity, dyslipidemia with high triglycerides and/or low HDL 
cholesterol, and hypertension, which are also risk factors for diabetes. HbA1c also serves 
as a measure for the tendency to develop diabetes: an HbA1c range of 5.7-6.4% has been 
used to identify individuals with high risk for future diabetes, to whom the term 
prediabetes is applicable (American Diabetes, 2013).   






HbA1c ≥ 6.5%. 
OR FPG ≥ 126mg/dL (7.0 mmol/L).  
OR 2h post-glucose load ≥ 200 mg/dL (11.1 mmol/L). 
OR in patients with classic symptoms of hyperglycemia 
or hyperglycemic crisis, a random plasma glucose ≥ 200 
mg/dL (11.1 mmol/L). 
Impaired glucose tolerance (IGT) 2h post-glucose load ≥ 140 mg/dL (7.8 mmol/L) and < 
199 mg/dL (11.0 mmol/L). 
Impaired fasting glucose (IFG) FPG ≥ 100 mg/dL (5.6 mmol/L) and ≤ 125 mg/dL (6.9 
mmol/L)  






1.1.3. Classification of Diabetes Mellitus 
Depending on the origin of hyperglycemia, diabetes mellitus can be divided into 
different types, which mainly involves type 1 diabetes, type 2 diabetes and the gestational 
diabetes. Hyperglycemia resulting from an absolute lack of insulin is characterized as 
type 1 diabetes, which is also known as insulin-dependent diabetes mellitus (IDDM) or 
juvenile-onset diabetes. In contrast, type 2 diabetes, also known as noninsulin-dependent 
diabetes mellitus (NIDDM) or adult-onset diabetes, is resulted from a relative 
insufficiency of insulin production in the face of insulin resistance.  
Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus, once known as the insulin-dependent diabetes mellitus 
(IDDM) or juvenile-onset diabetes, is a chronic condition in which the pancreas produces 
little or no insulin. Accounting for about 5-10% of cases in the US, type 1 diabetes is 
considered the result of a chronic, mainly T-cell mediated, autoimmune disease, which 
eventually leads to the virtually complete loss of pancreatic β-cells (Pugliese, 2013). 
Globally, the number of people with type 1 diabetes is unknown, although it is estimated 
that about 80,000 children develop the disease each year (WHO, 2013b). In the US, the 
number of type 1 diabetes patients is estimated to be around 3 million (JDRF). Although 
it has long been called “juvenile diabetes” due to the more frequent and relatively 
straightforward diagnosis in children, the majority of individuals living with the disease 
are adults. The increasing number of adult patients with type 1 diabetes is mainly due to 
two reasons: first, with increasing understanding of the disease and healthcare 





the rising number of new-onset cases of type 1 diabetes in adults, including those 
diagnosed with latent autoimmune diabetes in adults (LADA) (Andre et al., 1996). 
Patients of type 1 diabetes experience progressive β-cell destruction. In the absence 
of β-cells, there is neither production nor secretion of insulin, and circulating insulin 
concentrations are near zero. In the absence of insulin, insulin-responsive tissues fail to 
take up and store glucose, amino acids, and lipids, despite the high circulating plasma 
levels of these fuels. To make the situation worse, the unopposed action of the counter-
regulatory hormones, primarily glucagon, induces a starvation-like response. 
Glycogenolysis and gluconeogenesis proceed unchecked, further contributing to the high 
blood glucose concentration. Although blood glucose levels are elevated, a lack of insulin 
prevents glucose uptake into muscle and fat. This stimulates muscle proteolysis and 
adipose lipolysis, which provide additional precursors for gluconeogenesis, further 
exacerbating blood glucose levels. The process of fatty acids break down also generates 
ketones for export as ketone bodies that could be used as fuel by the brain. These ketones 
equilibrate into β-hydroxybutyrate and acetoacetate, and as the concentration of these 
metabolic acids increase, they deplete serum bicarbonate, leading to a state of metabolic 
acidosis called diabetic ketoacidosis (DKA). DKA is a serious, potentially life-
threatening medical emergency that requires immediate aggressive treatment and is often 
the precipitating event that leads to a diagnosis of type 1 diabetes. 
Type 1 diabetes has traditionally been diagnosed based on clinical catabolic 
symptoms suggestive of insulin deficiency: polyuria, polydipsia, weight loss, and marked 
hyperglycemia that is nonresponsive to oral agents. DKA may be present acutely or 





Tremendous variability exists in the initial presentation of type 1 diabetes in youth and 
adults: whereas children often present acutely, with severe symptoms of polyuria, 
polydipsia, and ketonemia; in adults, the disease presents with a more gradual onset, with 
a clinical presentation that may initially appear consistent with type 2 diabetes (Chiang, 
2014). 
Growing evidence suggests that impaired central tolerance to selected autoantigens is 
the earliest event in type 1 diabetes. Studies of the pathogenic mechanism of type 1 
diabetes have identified several islet autoantigens, including insulin/proinsulin, glutamic 
acid decarboxylase (GAD65), the tyrosine phosphatase-like protein IA-2, the islet-
specific glucose-6-phosphatase catalytic subunit-related protein (IGRP) and the cation 
efflux transporter ZnT8. Many of these autoantigens are diagnostic and predictive 
markers widely employed as screening tools (Vehik et al., 2011). Studies evaluating 
children at risk for developing type 1 diabetes have shown that the presence of more than 
two autoantibodies was associated with a nearly 70% risk for disease development within 
10 years and 84% within 15 years (Ziegler et al., 2013). One and usually more of these 
autoantigens are present in 85-90% of individuals when fasting hyperglycemia is initially 
detected (American Diabetes, 2013). Also, the disease has strong human leukocyte 
antigen (HLA) associations. Genetic variants in the highly polymorphic HLA on 
chromosome 6p21.3 can lead to functional differences in how fragments of proteins are 
presented to the immune system. In this regard, the HLA DR4-DQ8 and/or DR3-DQ2 
genes are positively linked to type 1 diabetes, while the DR2-DQB1*0602 allele is 
negatively associated. The HLA class II DQB*0302 on the DR4 haplotype and 





markers (Rubio-Cabezas and Argente, 2008). Type 1 diabetes has a family predilection 
and family members have higher risk of developing the disease compared to the general 
population, and the risk increases with the degree of genetic identity with the proband 
(Bonifacio and Ziegler, 2010). Despite the critical role of autoimmunity, growing 
evidence has shown that additional factors, including viruses (in particular enteroviruses) 
and environmental factors, can also contribute to the disease pathogenesis (Pugliese, 
2013). Experimental evidence suggests that enteroviruses can infect and damage β-cells 
and induce expression of HLA class I antigens and α-interferon, which could amplify 
inflammation and provide a link to the triggering of islet autoimmunity (Dotta et al., 2007; 
Foulis et al., 1987).  
Despite active research unveiling its pathogenesis, type 1 diabetes has no cure. 
However, it can be managed with proper treatment. The Diabetes Control and 
Complications Trail (DCCT) clearly showed that intensive insulin therapy, defined as 
three or more injections of insulin per day or continuous subcutaneous insulin infusion, 
was a key part of improved glycemia and better outcomes (1993a). A number of rapid-
acting and long-acting insulin analogs have been developed to avoid side effects 
associated with the use of human insulin, such as hypoglycemia, while offering 
considerable glycemia improving effects in people with type 1 diabetes (Rodbard et al., 
2014). In addition to intensive insulin supplementation, current experimental therapy 
trails also focus on the prevention of disease development, preservation of remaining β-
cells, and replacement of β-cells (Chiang, 2014). Whereas pancreas transplantation is 
now accepted as a proven therapy for patients that require both kidney and pancreas 





delay or prevent disease onset have been largely disappointing. A variety of different 
immuno-modulatory and immuno-suppressive agents have been evaluated in patients 
with recent-onset type 1 diabetes, but the results have been modest at best. Promising 
new agents and combinations of drugs or cell-based therapies are still being investigated 
in an effort to safely and effectively modulate the autoimmune response (Peters AL, 
2013).  
Type 2 Diabetes Mellitus 
Type 2 diabetes mellitus, also known as the noninsulin-dependent diabetes mellitus 
(NIDDM) or adult-onset diabetes, is now the most prevalent form of diabetes. The World 
Health Organization (WHO) estimates that 90-95% of people around the world suffer 
from type 2 diabetes (WHO, 2013b). More than 20 million adults in the US alone are 
reported to have type 2 diabetes (CDC, 2014), and the number is still on the rise. Unlike 
type 1 diabetes, the pathogenesis of type 2 diabetes does not involve autoimmune 
destruction of pancreatic β-cells. Thus, type 2 diabetes is not associated with direct lack 
of insulin. Rather, it is due to the body’s inability to respond properly to normal or even 
enhanced levels of insulin, creating a situation of relative insulin insufficiency, which is 
termed as insulin resistance.  
Type 2 diabetes has a multifactorial pathogenesis in which interactions between 
genetic and environmental factors result in the development of insulin resistance and β-
cell dysfunction (Figure 1.1-1) (Stumvoll et al., 2005). Insulin resistance, which is the 
hall mark of type 2 diabetes, is strongly associated with obesity and physical inactivity. 
Obesity is almost inevitably present in the majority of type 2 diabetes patients and 





teenagers (Engelgau et al., 2004). Several factors are proposed to link obesity to insulin 
resistance, which include free fatty acids (FFA) and tumor necrosis factor-α (TNF-α). In 
fact, it has been suggested that elevated levels of FFA and inflammatory cytokines 
released by expanded adipose tissue adversely affect the insulin signaling cascade (Boden 
and Shulman, 2002). FFA inhibit insulin-stimulated glucose uptake and glycogen 
synthesis in skeletal muscle and stimulate gluconeogenesis in liver (Boden and Shulman, 
2002), whereas TNF-α enhances adipocyte lipolysis, further increasing FFA, and at the 
same time elicits negative effects on insulin signaling itself (Hotamisligil, 2000). 
Abnormally activated cellular kinases, including atypical protein kinase C (PKC) 
isoforms also accompanies increases in the levels of FFA and cytokines. These events 
can activate the inflammatory kinases, inhibitor of κB kinase (IKK) and c-jun N-terminal 
kinase (JNK), which together decrease signaling through insulin receptor substrate-1 
(IRS-1) (Gao et al., 2004; Griffin et al., 1999; Itani et al., 2002). 
The second and equally important pathogenic factor is a decline in β-cell function, 
which is found in about 50% of patients at the time of diagnosis (DeFronzo, 2004; 
Stumvoll et al., 2005). Even before the onset of overt hyperglycemia, pancreatic β-cell 
dysfunction and secretory defects have been shown, for example in individuals with IGT 
and IFG (van Haeften et al., 2002). A number of different hypothesis have been proposed 
to explain the development of β-cell dysfunction in type 2 diabetes. Insulin insensitivity 
appears as an early phenomenon in the course of type 2 diabetes, and to compensate for 
the increase demand of insulin due to insulin resistance, increased insulin production and 
secretion by β-cells is required. Over a prolonged period of time, the increased demand 





addition, hyperglycemia itself can induce irreversible damages to cellular components of 
insulin production over time, which is referred to as “glucotoxicity” (Robertson et al., 
2003; Yki-Jarvinen, 1992). During oxidative glucose metabolism, reactive oxygen 
species (ROS) are produced as an inevitable byproduct of mitochondrial respiration. 
Whereas under normal conditions, the amount of ROS produced in β-cells can be 
effectively detoxified by catalase and superoxide dismutase, hyperglycemia leads to a 
substantial increase in the amounts of ROS and subsequent damage to cellular 
components (Robertson et al., 2003; Yki-Jarvinen, 1992). The “lipotoxicity” theory 
suggests that chronically elevated FFA may exert a direct toxic effect on pancreatic cells 
by increasing the rate of nitric oxide formation, yet providing another explanation for the 
development of β-cell dysfunction in type 2 diabetes (McGarry and Dobbins, 1999; 







Figure 1.1-1: Pathophysiology of hyperglycemia and increased circulating FFA in type 
2 diabetes.  
Under normal circumstance, insulin secretion from the pancreas reduces glucose output by 
the liver, enhances glucose uptake by skeletal muscle, and suppresses FFA release from fat tissue. 
The various factors shown that contribute to the pathogenesis of type 2 diabetes affect both 
insulin secretion (β-cell function) and insulin action. The onset of insulin resistance, together with 
the subsequent β-cell dysfunction will reduce insulin signaling in its target tissues, leading to 
increased circulating FFA and hyperglycemia. The raised level of plasma glucose and FFA 
further worsens the condition of insulin resistance, and β-cell destruction through glucotoxicity 
and lipotoxicity. (adapted from Stumvoll et al., 2005) 
Although the triggering pathogenic factors of type 2 diabetes comprise mainly 
environmental elements, genetic elements are also involved. Positive family history 
confers a 2-4 fold increased risk for type 2 diabetes, and 15-25% of the first-degree 
relatives of patients with type 2 diabetes develop IGT or diabetes (Pierce et al., 1995). 
Though there is little doubt that inherited factors predispose to an increased risk of 





polymorphisms in IRS-1 (Cocozza et al., 1992; O'Rahilly et al., 1991), the β3 adrenergic 
receptor (Lee et al., 2006), the insulin-sensitive glucose transporter (GLUT)-4 (Kusari et 
al., 1991) and a zinc transporter (SLC30A8 encoded) exclusively expressed on insulin 
secretory vesicles (Sladek et al., 2007) have been detected in certain sub-groups of type 2 
diabetes patients, but this initial association was not replicated in subsequent analysis. 
Currently, the most robust candidate variant is the highly prevalent Pro12A1a 
polymorphism in peroxisome proliferator-activated receptor ᵞ (PPARᵞ) (Lohmueller et al., 
2003). 
Type 2 diabetes frequently goes undiagnosed for many years as the disorder 
develops gradually and is often asymptomatic at earlier stages. It is frequently diagnosed 
either by elevated blood glucose levels in routine screening tests or after the disease has 
become severe enough to cause diabetic complications. Several risk factors have been 
identified, including age, sex, obesity and central obesity, low physical activity, smoking, 
low fiber and high saturated fat diet, ethnicity, family history, history of gestational 
diabetes mellitus, history of the nondiabetic elevation of fasting or 2h glucose, elevated 
blood pressure, dyslipidemia, and different drug treatments (diuretics, unselected β-
blockers, etc.) (Unwin et al., 2010). 
As insulin resistance plays a fundamental role in the disease pathogenesis, one 
intervention for type 2 diabetes is to use therapeutic agents that improve tissue insulin 
sensitivity. Drugs that enhance insulin sensitivity are primarily the thiazolidinediones, 
which are PPARᵞ agonists and can alter adipose metabolism and distribution (Hevener et 
al., 2001; Lebovitz and Banerji, 2001). The thiazolidinediones have been shown to not 





inflammatory milieu of type 2 diabetes (Yki-Jarvinen, 2004). Metformin has been shown 
effective in reducing glycemia as well as improving cardiovascular functions through 
reduction of hepatic glucose output (Bailey and Turner, 1996; Cusi et al., 1996; Mamputu 
et al., 2003), since it works independently of the pancreas it has less robust effects on 
insulin resistance. Sulfonylurea derivatives are insulin secretion enhancers, which work 
through closing the potassium channels in β-cells. These drugs have been shown effective 
in the control of blood glucose, as well as reducing the occurrence of microvascular and 
macrovascular complications of type 2 diabetes (1998b). Glucagon-like peptide-1 (GLP-1) 
is a gastrointestinal hormone, and has important effects on several of the 
pathophysiological features of type 2 diabetes, including potentiation of insulin secretion 
and suppression of glucagon secretion. Thus, GLP-1 agonists and mimetics serve as 
insulin secretagogues in the treatment of type 2 diabetes (Knudsen, 2004; Lund et al., 
2014). As some oral insulin sensitizers are ineffective without adequate amounts of 
insulin, exogenous insulin supplementation may also be necessary to achieve glycemic 
control in type 2 diabetes (Stumvoll et al., 2005).  
Gestational and Other Specific Types of Diabetes Mellitus 
Gestational diabetes mellitus is the third main form of diabetes and has been defined 
as any degree of glucose intolerance with onset or first recognition during pregnancy 
(American Diabetes, 2013). The International Diabetes Federation (IDF) estimates that 
21.4 million or 16.8% of live births to women in 2013 have hyperglycemia in pregnancy 
(Linnenkamp et al., 2014). According to a 2014 analysis by the CDC, the prevalence of 
gestational diabetes in the US is as high as 9.2%. The condition arises as the action of 





serious health risks to the mother and infants and increases the risk for developing type 2 
diabetes later in life. Gestational diabetes is usually asymptomatic, and formal systemic 
testing for gestational diabetes is normally performed between 24 and 48 weeks of 
pregnancy, with diagnostic criteria same as with other types of diabetes. Re-evaluation of 
blood glucose is required for women diagnosed with gestational diabetes six weeks or 
more after delivery. 
Other specific sub-types of diabetes are associated with genetic defects of β-cell 
function or insulin action. The former is referred to as maturity-onset diabetes of the 
young (MODY), and is characterized by impaired insulin secretion with minimal or no 
defects in insulin action. Common forms of MODY are due to mutations in the genes for 
hepatocyte nuclear transcription factor (HNF) 4-α (MODY-1), glucokinase (MODY-2), 
HNF1-α (MODY-3) and insulin promoter factor-1 (MODY-4). The latter one is mostly 
caused by mutations in the insulin receptor. Leprechaunism and Rabson-Mendenhall 
syndrome are two pediatric syndromes with mutations in the insulin receptor gene that 
cause subsequent alterations in insulin receptor function and extreme insulin resistance. 
Other specific causes of diabetes involve endocrinopathies, diseases of the exocrine 
pancreas and usage of drugs such as glucocorticoids (American Diabetes, 2013). 
1.1.4. Insulin Signaling in Diabetes Mellitus 
Insulin is the most potent physiological anabolic hormone known and is essential for 
appropriate tissue development, growth, and maintenance of glucose homeostasis. It 
serves as the primary regulator of blood glucose concentration by increasing glucose 
uptake in muscle and fat, and inhibiting hepatic glucose production. In addition, insulin 





stimulating lipogenesis, glycogen and protein synthesis and inhibiting lipolysis, 
glycogenolysis and protein breakdown (Chang et al., 2004; Saltiel and Kahn, 2001). 
Dysregulation of these processes due to insulin deficiency or resistance is a fundamental 
contributor to the pathogenesis of diabetes mellitus.  
Insulin Production and Secretion 
Insulin is exclusively produced by pancreatic β-cells, which are located in the 
pancreas in clusters known as the islets of Langerhans. The mature insulin molecule is a 
51-amino acid protein composed of two polypeptide chains designated as A and B that 
are linked by two disulfide bridges. There is an additional intramolecular disulfide bond 
in the A chain. Insulin is initially synthesized as preproinsulin on the ribosomes of the 
rough endoplasmic reticulum (ER), and is rapidly transferred to and sequestered within 
the ER. Following synthesis, the signal sequence on the N-terminus of preproinsulin is 
rapidly cleaved enzymatically to form proinsulin, which contains the insulin A and B 
chains linked by the connecting peptide or C-peptide (Dodson and Steiner, 1998). The C-
peptide ensures the efficient folding of the proinsulin molecule and the formation of its 
three intra-chain disulfide bonds in proinsulin. Once folding and disulfide bond formation 
has been accomplished, proinsulin is transferred in small vesicles to the Golgi apparatus, 
where it is packaged into secretory granules located close to the cell membrane. As the 
granules mature, proteases split proinsulin into equal amounts of insulin and C-peptide, 
allowing the insulin molecule to assume its active configuration (Steiner et al., 2009). 
Importantly, C-peptide remains intact and is stored and released during active secretion 
together with insulin, which makes it an independent indicator of insulin synthesis and 





Insulin secretion by β-cells is stimulated in response to increased circulating levels of 
glucose and amino acids after a meal. Type 2 glucose transporter (GLUT-2), which is an 
insulin-independent glucose transporter with low substrate affinity, mediates the entry of 
glucose into β-cells. Glucose is phosphorylated to glucose-6-phosphate (G6P) by the rate-
limiting enzyme glucokinase and thus started down the glycolytic pathway (Matschinsky 
et al., 1993). This modified glucose becomes effectively trapped within the β-cells and is 
further metabolized in the mitochondria to produce ATP. The increased ATP/ADP ratio 
causes the ATP-gated potassium (K+/ATP) channels in the plasma membrane to close, 
preventing K+ efflux. The ensuing rise in positive charge due to the increased 
concentration of K+ ions leads to depolarization of the cell. The net effect is the activation 
of voltage-gated calcium (Ca2+) channels, which transport Ca2+ into the cell. The brisk 
increase in intracellular Ca2+ concentrations triggers exocytosis of the insulin-storing 
granules. The ultimate result is the export of insulin from β-cells and its diffusion into 
nearby blood vessels (Koster et al., 2000). In contrast, under conditions of relatively low 
extracellular glucose concentrations, the β-cell has a low ATP/ADP ratio. In this case, the 
K+/ATP channels remain open, which prevents Ca2+ influx and subsequent insulin 
secretion. 
Insulin Signaling through the Insulin Receptor 
Insulin elicits its effects by binding to the receptors on the surface of target cells 
(Figure 1.1-2). Although virtually all tissues express insulin receptors, the energy-storing 
tissues (liver, muscle, and adipose) express much higher levels of insulin receptor and 
thus constitute the main insulin target tissues. The insulin receptor is a tetrameric protein 





subunits and two β subunits. The β subunits function as allosteric enzymes whose 
intrinsic tyrosine kinase activity is inhibited by the α subunits. The binding of insulin to 
the α subunit leads to derepression of the kinase activity in the β subunit, resulting in 
“autophosphorylation” of tyrosine on the nearby β subunit and a conformational change 
that further increases kinase activity (Patti and Kahn, 1998). Activation of the tyrosine 
kinase of the insulin receptor results in phosphorylation of several other intracellular 
proteins, most importantly, four members of the insulin receptor substrates (IRS) family 
(White, 1998). Other substrates include Gab-1, p60dok, Cbl, APS and isoforms of Shc 
(Pessin and Saltiel, 2000). In response to insulin, these substrate proteins are recruited to 
the phosphorylated insulin receptor through the phosphotyrosine binding (PTB) domains, 
and are phosphorylated at tyrosine residues (Gual et al., 2005; Sasaoka and Kobayashi, 
2000). The phosphorylated tyrosine in these substrates then act as docking sites to recruit 
a series of Src-homology-2 (SH2) domain containing signal transducers, including the 
phosphatidylinositol 3-kinase (PI3-K) (White, 2002). 
The first step by which insulin increases energy storage or utilization is through 
regulating transport of glucose into the cell, mediated by the type 4 glucose transporter 
(GLUT-4). GLUT-4 is found in vesicles that slowly cycle between the plasma membrane 
and intracellular stores within the cell. Insulin increases glucose uptake in fat and muscle 
cells by stimulating GLUT-4 vesicle exocytosis, and by slightly attenuating the rate of its 
internalization (Chang et al., 2004). PI3-K plays a pivotal role in insulin-stimulated 
glucose uptake and GLUT-4 translocation (Shepherd et al., 1995). PI3-K interacts with 
tyrosine-phosphorylated IRS through the SH2 domains on its p85 regulatory subunit, 





it catalyzes the phosphorylation of phosphatidylinositols at 3’ position of the sugar 
alcohol, typically generating phosphatidylinositol 3,4 bis-phosphate (PIP2) and 
phosphatidylinositol 3,4,5-tris-phosphate (PIP3) (Lietzke et al., 2000). Inhibition of PI3-K 
with pharmacological inhibitors or overexpression of dominant interfering forms of PI3-
K blocks insulin-stimulated GLUT-4 translocation and glucose uptake. Conversely, 
overexpression of constitutively active forms of PI3-K partially mimics insulin action 
(Martin et al., 1996; Okada et al., 1994; Sharma et al., 1998). Insulin-stimulated increase 
in PIP3 leads to the recruitment and/or activation of a variety of pleckstrin homology (PH) 
domain-containing signaling molecules, enzymes, as well as cytoskeletal proteins 
(Lietzke et al., 2000). PIP3 plays a direct role in the recruitment of the Ser/Thr kinases 
PDK1 and Akt to the plasma membrane via their PH domain (Corvera and Czech, 1998). 
PDK1 then phosphorylates and activates Akt and other downstream kinases including 
atypical protein kinases C (PKC) λ and ζ (Mora et al., 2004). PKC λ and PKCζ activity 
seems to be essential for insulin-stimulated glucose transport (Kohn et al., 1998; Kohn et 
al., 1996).  
Despite the important role for the PI3-K pathway, activation of this pathway alone is 
not sufficient for insulin-stimulated glucose uptake. For example, platelet-derived growth 
factor (PDGF) and interleukin-4 also stimulate PI3-K activity but have no effect on either 
GLUT-4 translocation or glucose uptake (Isakoff et al., 1995; Wiese et al., 1995). Thus, 
other signaling pathways seem to be required for insulin-stimulated glucose uptake in 
addition to the PI3-K pathway (Figure 1.1-2) (Saltiel and Kahn, 2001). Studies suggest 
that this second pathway is localized in lipid raft domains, and seems to involve tyrosine 





insulin receptor located in the lipid raft domain recruits Cbl to the phosphorylated insulin 
receptor adapter protein APS (Hu et al., 2003), and subsequently stimulates the tyrosine 
phosphorylation of Cbl (Liu et al., 2002). The Cbl associated protein (CAP) is an adapter 
protein containing three SH3 domains in its C-terminus and a sorbin homology (SoHo) 
domain (Kimura et al., 2001). CAP binds to the proline-rich sequences in Cbl through the 
SH3 domains (Ribon et al., 1998), and is recruited to the insulin receptor-APS complex 
together with Cbl. Upon recruitment to the insulin receptor, CAP interacts with the lipid 
raft domain protein flotillin via its SoHo domain, which is required for insulin-stimulated 
glucose uptake and GLUT-4 translocation (Baumann et al., 2000; Kimura et al., 2001). 
Tyrosine-phosphorylated Cbl interacts with the SH2/SH3-containing adapter protein 
CrkII, recruiting CrkII together with the nuclear exchange factor C3G to the lipid raft 
domain (Knudsen et al., 1994; Ribon et al., 1996). C3G can catalyze the activation of the 
small G protein TC10 in the lipid rafts, which provides a second signal to GLUT-4 
translocation that functions in parallel with the PI3-K pathway (Chiang et al., 2001).   
Once glucose is transported into the cells, insulin stimulates glycogenesis, 
lipogenesis and protein synthesis, and inhibits glycogenolysis, lipolysis and protein 
breakdown primarily through the PI3-K/Akt pathway. In muscle tissues, insulin 
stimulates glycogen synthesis by dephosphorylation and activation of glycogen synthase, 
which is done through inhibition of kinases such as PKA or glycogen synthase kinase 
(GSK)-3β (Cross et al., 1995) and activation of protein phosphatase 1 (PP1) (Brady et al., 
1997). In adipose tissues, insulin promotes lipid synthesis and inhibits lipolysis through 
increased expression of the transcription factor steroid regulatory element-binding protein 





Insulin activates protein synthesis by activating components of the translational 
machinery including eukaryotic initiation factors (eIFs) and eukaryotic elongation factors 
(eEFs) (Proud, 2006). In the liver, insulin inhibits gluconeogenesis and glycogenolysis, 
primarily through a direct effect on the activities of metabolic enzymes via 
phosphorylation and dephosphorylation and also regulation of gene expression of hepatic 
enzymes (Pilkis and Granner, 1992).   
 
Figure 1.1-2: Signaling transduction in insulin action.  
The insulin receptor is a tyrosine kinase that undergoes autophosphorylation, and catalyzes 
the phosphorylation of cellular proteins such as members of the IRS family, Shc and Cbl. Upon 
tyrosine phosphorylation, these proteins interact with signaling molecules through their SH2 
domains, resulting in a diverse series of signaling pathways, including activation of PI3-K and 
downstream PIP3-dependent protein kinases, Ras and the MAP kinase cascade, Cbl/CAP and the 
activation of TC10. These pathways act in a concerted fashion to coordinate vesicle trafficking, 
protein synthesis, enzyme activation and inactivation, and gene expression, which together 
regulate cellular glucose, lipid and protein metabolism. (adapted from Saltiel and Kahn, 2001) 
In addition to its anabolic actions, insulin also promotes mitogenesis by stimulating 





regulated kinase (ERK). This pathway initiates with the tyrosine phosphorylation of IRS 
proteins and/or Shc, which in turn interact with Grb2, recruiting the Son-of-sevenless 
(SOS) exchange protein to the plasma membrane for the activation of Ras. Stimulation of 
the tyrosine phosphatase SHP2 through its interaction with receptor substrates such as 
Gab-1 or IRS-1/2 is also required for the activation of Ras. Upon activation, Ras 
stimulates a serine kinase cascade through the stepwise activation of Raf, MEK and ERK, 
which is essential for cellular proliferation and differentiation (Boulton et al., 1991) 
(Figure 1.1-2).  
Upon dissociation of insulin, both the insulin receptor and its substrates undergo a 
rapid dephosphorylation mediated by protein tyrosine phosphatases (PTPase). A number 
of PTPase have been identified to dephosphorylate the insulin receptor in vitro, some of 
which are expressed in insulin-responsive cells or upregulated under states of insulin 
resistance (Drake and Posner, 1998). The cytoplasmic phosphatase PTP1B is important in 
dampening insulin signaling since its genetic deletion leads to increased tyrosine 
phosphorylation of the insulin receptor and IRS proteins and enhanced insulin sensitivity 
(Elchebly et al., 1999). Lipid phosphatases, such as PTEN (Maehama and Dixon, 1999) 
and SHIP2 (Vollenweider et al., 1999) may also attenuate insulin signaling through 
dephosphorylation of phosphatidylinositol polyphosphates. Substantial evidence has 
revealed a reduction in the autophosphorylation of insulin receptor as well as the tyrosine 
phosphorylation of its substrates in patients with type 2 diabetes, which subsequently 
leads to reduced PI3-K activity (Morino et al., 2006; Pessin and Saltiel, 2000). Other 
negative regulators of insulin signaling include serine phosphorylation of the insulin 





insulin-stimulated tyrosine phosphorylation (Hotamisligil et al., 1996) and promoting 
interaction with 14-3-3 proteins (Craparo et al., 1997). Several kinases have been 
implicated in this process, including PI3-K, Akt, GSK-3 and mammalian target of 
rapamycin (mTOR) (Saltiel and Kahn, 2001). For example, Ser312, a residue located 
close to the IRS-1 PTB domain, has been shown to be phosphorylated by JNK, IKKβ and 
mTOR. Phosphorylation of this serine residue impairs IRS-1 binding to the activated 
insulin receptor, and contributes to onset of insulin resistance (Aguirre et al., 2002; 
Carlson et al., 2004; Gao et al., 2002). In addition, phosphorylation of IRS-1 serine 
residues that locate in proximity to the SH2 domain binding motif, for example Ser636, 
negatively modulates the binding of PI3-K to IRS-1, further abolishing the downstream 
signaling (Ozes et al., 2001).  
As discussed above, the insulin signaling system plays an important role in many 
physiological processes, including carbohydrate, lipid and protein metabolism, cellular 
growth, differentiation and survival. Systematic interactions between the insulin receptor 
and its substrates, as well as interactions between downstream signaling molecules are 
crucial for the maintenance of insulin-stimulated signal transduction. Dysregulation of 
insulin signaling, either due to a lack of insulin production or insulin resistance, leads to 
onset of a cohort of systemic disorders including impaired glucose tolerance, 
dyslipidemia and overt diabetes. Thus, halting the loss of insulin-producing β cells and/or 
increasing insulin sensitivity is a key tactic for contending with these metabolic disorders 





1.1.5. Complications of Diabetes Mellitus 
Long-term diabetes increases the likelihood of developing secondary damage to 
numerous systems, which are the major sources of morbidity and mortality in both type 1 
and type 2 diabetes. It is recognized that until a cure for the worldwide diabetes epidemic 
is realized, it is also necessary to address approaches that delay the onset of diabetic 
complications. Generally, the injurious effects of hyperglycemia are separated into 
macrovascular complications (due to damage to larger blood vessels) and microvascular 
complications (due to damage to small blood vessels). Macrovascular complications 
include atherosclerosis, coronary artery disease and cerebrovascular disease, such as 
stroke. Microvascular complications include diabetic retinopathy, diabetic nephropathy 
and diabetic neuropathy (Mattila and de Boer, 2010).  
Macrovascular Complications 
Both type 1 and type 2 diabetes have a largely irreversible and devastating effect on 
small and large blood vessels, leading to vascular injuries and subsequently, 
macrovascular complications of diabetes (Holman et al., 2008; Nathan et al., 2005). 
Common consequences of vascular injury, such as hypertension, altered vascular 
permeability and ischemia, can also contribute to other diabetic complications. 
Macrovascular complications of diabetes affect many organs, and can cause substantial 
morbidity and early mortality, with cardiovascular disease and stroke being the leading 
causes of mortality in diabetic patients (Dale et al., 2008; Nathan et al., 2005). 
Approximately 71% of adults with diabetes also have hypertension and 65% have high 
cholesterol. The risk of having a stroke is 1.5 times higher in diabetic patients and the 





Hyperglycemia and dyslipidemia, along with many glucose-driven pathways, have 
been shown as key players in contributing to these vascular co-morbidities. Oxidative 
stress and inflammation have been heightened as central pathogenic mechanisms for 
these marcovascular complications, as they markedly alter gene expression patterns in the 
vasculature, shifting the balance towards an increased pro-inflammatory and 
thrombogenic potential (Calcutt et al., 2009). Studies in type 1 diabetes have shown that 
intensive glucose control is associated with a 42% risk reduction in all cardiovascular 
events and a 57% reduction in the risk of nonfatal myocardial infarction (MI), stroke, or 
death from cardiovascular diseases (CVD) (Nathan et al., 2005). Though there has not 
been a large, controlled study showing decreases in macrovascular disease from 
improved glycemic control in type 2 diabetes, modification of other elements of the 
metabolic syndrome, such as lowering blood pressure, has been shown to significantly 
decrease the risk of cardiovascular events (1998a). The increased understanding towards 
mechanisms underlying these diabetes-induced complications have led to clinical trials 
investigating antagonism of various glucose-driven pathways, including the polyol 
pathway, activation of PKC isoforms, accumulation of advanced glycation endproducts 
(AGEs) and oxidative stress (Joy et al., 2005; Kass et al., 2001; Stirban et al., 2006; 
Suzen and Buyukbingol, 2003). Agents that suppress inflammation and adaptive immune 
mechanisms, such as statins and PPAR agonists, have also been considered relevant to 
the treatment of vascular diseases in diabetes (Ludwig and Shen, 2006; Panunti and 
Fonseca, 2006). As many mechanisms may synergize to cause vascular injuries in 







Diabetic retinopathy is the leading cause of blindness in persons 25-74 years old in 
the US. The progression of diabetic retinopathy can be divided into two stages: non-
proliferative diabetic retinopathy (NPDR) and proliferative diabetic neuropathy (PDR). In 
the initial stages of diabetic retinopathy, patients are generally asymptomatic. In the more 
advanced stages of the disease patients may experience symptoms that include floaters, 
blurred vision, distortion and progressive visual acuity loss (Bhavsar, 2014). The clinical 
signs of diabetic retinopathy include a range of retinal lesions and abnormalities that 
indicate vascular damage (capillary microaneurysms, capillary degeneration, increased 
vascular permeability and new vessel formation) and death or dysfunction of the neural 
retina (‘cotton wool spots’, alterations in retinal electrophysiology and loss of color or 
hue discrimination) (Frank, 2004). 
Approximately 700,000 people in the US have proliferative diabetic retinopathy 
(PDR), with an annual incidence of 65,000 (Bhavsar, 2014; Zhang et al., 2010b). 
Diabetic retinopathy occurs in all forms of diabetes, and its development depends on the 
duration and severity of diabetes, as is the case with all diabetes-specific complications. 
Other risk factors for diabetic retinopathy include hypertension, hyperlipidemia, and most 
importantly, hyperglycemia (Crawford et al., 2009). The disease takes years to develop, 
and almost all patients with type 1 and type 2 diabetes will to some extent develop 
retinopathy after 20 years of disease (Kempen et al., 2004; Roy et al., 2004). In patients 
with type 1 diabetes, no clinically significant signs of retinopathy can be seen in the first 
5 years after the initial diagnosis of diabetes. After 10-15 years, 25-50% of patients show 





approaches 100% after 30 years of diabetes. PDR is rare within the first decade of type 1 
diabetes diagnosis but increases to 14-17% by 15 years, rising steadily thereafter. In 
patients with type 2 diabetes, the incidence of diabetic retinopathy increases with the 
disease duration; 23% have non-proliferative diabetic retinopathy (NPDR) after 11-13 
years, 41% have NPDR after 14-16 years, and 60% have NPDR after 16 years (Bhavsar, 
2014).  
Although studies have clearly shown that the development of diabetic retinopathy is 
tightly associated with poor glycemic control, achievement of better glycemic control 
does not promise reversion or immediately halt disease progression (1993a; Engerman 
and Kern, 1987). Indeed, co-morbidities that commonly parallel with hyperglycemia, 
such as hypertension and dyslipidemia, can influence the progression rate of retinopathy 
(1998a; Barile et al., 2005). Thus, tight control of blood glucose, blood pressure and 
cholesterol levels are essential for the prevention of diabetic retinopathy. Treatment for 
diabetic retinopathy varies with the stage of the disease and is directed towards slowing 
or halting the progression of the disease. In the early stages of NPDR, treatment other 
than regular monitoring may not be required. With progression of the disease, leakage of 
fluid from blood vessels can lead to macular edema, under which condition laser 
treatment (photocoagulation) is used to stop the leakage of blood and fluid into the retina. 
When blood vessel growth is more widespread throughout the retina, as in PDR, a pattern 
of scattered laser burns is conducted to help shrink the abnormal blood vessels (Institute, 
2014). In addition to laser surgeries, a number of potential therapies, ranging from pan-
complication therapies (aldose reductase inhibitors and PKC-β inhibitors) to retinopathy-





degeneration of retinal capillaries and neurons and increase in retinal vascular 
permeability in animals (Dorrell et al., 2007; Kern, 2007). However, approved 
pharmacologic treatments in humans are limited to several anti-VEGF agents.  
Diabetic Nephropathy 
Diabetic nephropathy is the leading cause of renal failure, and it has become the 
most common single cause of end-stage renal disease (ESRD) in the Western world 
(Gilbertson et al., 2005). In the US, diabetic nephropathy accounts for about 40% of new 
cases of ESRD. About 20-30% of patients with type 1 and type 2 diabetes develop 
evidence of nephropathy. Whereas diabetic nephropathy rarely develops in the first 
decade of type 1 diabetes, approximately 3% of newly diagnosed patients with type 2 
diabetes have overt nephropathy. The peak incidence of nephropathy is usually found in 
people who have had diabetes for 10-20 years, after which the rate progressively declines. 
Though in type 2 diabetes, a considerably smaller fraction of nephropathy cases would 
progress to ESRD, such patients constitute over half of the diabetic patients currently 
requiring dialysis because of the greater prevalence of type 2 diabetes (Batuman, 2014; 
Molitch et al., 2004). 
Diabetic nephropathy is defined by proteinuria > 300 mg in 24 hours in the setting of 
diabetes, followed by a subsequent decline in glomerular filtration rate and ultimate 
progression to azotemia and uremia, which is fatal if left untreated (Mogensen et al., 
1983). The onset of overt proteinuria is preceded by microalbuminuria, which is 
characterized by the appearance of low but abnormal levels (30-299 mg / 24 hours) of 





incipient nephropathy. Without intervention, patients of both type 1 and type 2 diabetes 
with microalbuminuria typically progress to overt diabetic nephropathy.  
Like the other microvascular diabetic complications, there is strong association 
between glycemic control and the risk of developing nephropathy, which makes tight 
glycemic control the initial prevention and treatment of diabetic nephropathy (1993a). 
Another main risk factor for nephropathy is hypertension. Hypertension has an 
interdependent relationship with nephropathy since the onset of nephropathy often leads 
to a further increase in the blood pressure of diabetic patients (1993b). Insight into the 
molecular and biochemical mechanisms for diabetes-induced renal lesions revealed 
several potential therapeutic targets for treating diabetic nephropathy. Glucose-dependent 
pathways, such as advanced glycation, have been shown to be involved in disease 
pathogenesis both through the disruption of vasoactive hormone pathways, and through 
activation of the receptor for AGEs (RAGE), PKC, MAPK and angiotensin II (AT2) 
(1993b; Wendt et al., 2003). Despite ongoing research on disease mechanisms and 
potential therapies, the drugs currently used to treat diabetic nephropathy are mainly anti-
hypertensive agents. Drugs that interrupt the renin-angiotensin system (RAS), including 
angiotensin-converting enzyme (ACE) inhibitors and AT2 receptor antagonists, have 
been incorporated into most national and international treatment guidelines and are 
currently the first-line treatments for diabetic nephropathy (Molitch et al., 2004).  
1.2. Diabetic Neuropathy 
Diabetic neuropathy is the most common and intractable complication of diabetes, 
affecting about 60-70% of patients with type 1 and type 2 diabetes (Veves et al., 2008). 





forms of neuropathy (Singleton et al., 2003). Recognized by the ADA as “the presence of 
signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other 
causes” (American Diabetes, 2007), diabetic neuropathy has become the most prevalent 
neuropathy in the western world. Diabetic neuropathy can result in pain, decreased 
motility, and foot ulceration and is the leading cause of non-traumatic lower-limb 
amputations in the US, accounting for about 60% cases among people aged 20 years or 
older. Economically, diabetic neuropathy constitutes a huge burden on the healthcare 
system, with an estimate annual cost of up to $13.7 billion (Gordois et al., 2003). Also 
about one-third of the direct medical cost of diabetes may be attributed to diabetic 
neuropathy and its complications (e.g. foot ulceration) (Carls et al., 2011). 
1.2.1. Classification and Clinical Manifestations 
Diabetic neuropathy is a descriptive term that encompasses a spectrum of clinical 
and subclinical syndromes that affect different parts of the nervous system and present 
with diverse clinical manifestations. Diabetic patients may have only one type of 
neuropathy or develop different combinations of neuropathies. Different forms of 
diabetic neuropathy can be classified in terms of their anatomical distribution (e.g., 
proximal or distal, symmetric or asymmetric, focal or diffuse), clinical course (e.g., acute 
or chronic) and characteristic features (e.g., painful or insensate, sensory, motor, or 
autonomic). Table 1.2-1 lists the major types of diabetic neuropathy which are classified 
into diffuse and focal neuropathies (Boulton et al., 2005; Edwards et al., 2008). The 
diffuse neuropathies are common, usually chronic and progressive. In contrast, the focal 





of nerve injuries in diabetic neuropathy are illustrated in figure 1.2-1 (Callaghan et al., 
2012a). 
Table 1.2-1: Classification of Diabetic Neuropathy 
Diffuse neuropathy  Focal neuropathy 
Distal symmetrical sensorimotor polyneuropathy 
(DPN) 
Mononeuropathy 
    -Small fiber Mononeuropathy multiplex 
    -Large fiber  Plexopathy 
    -Mixed  Radiculopathy 
Diabetic autonomic neuropathy (DAN) Cranial neuropathy 
    -Abnormal pupillary function  
    -Sudomotor dysfunction  
    -Genitourinary  
    -Gastrointestinal  
    -Cardiovascular  
    -Hypoglycemia unawareness  
(modified from Boulton et al., 2005; Edwards et al., 2008) 
  
 
Figure 1.2-1: Patterns of Nerve Injuries in Diabetic Neuropathy. 
The patterns of nerve injuries are illustrated as follow. The affected areas in different 
categories are indicated with red shading. (A) Distal symmetrical sensorimotor polyneuropathy 
(DPN) and small-fiber predominant neuropathy; (B) plexopathy and radiculopathy; (C) 





them, DPN (A) and DAN (D) are diffuse neuropathies, and they normally progress with 
increasing duration and severity of diabetes. Plexopathy, radiculopathy (B), mononeuropathy and 
mononeuropathy multiplex (C) are focal neuropathies. Diabetic plexopathy can be responsive to 
immunotherapy and, in contrast to most nerve injury in patients with diabetes, usually improves 
with time. (adapted from Callaghan et al., 2012a) 
Distal Symmetrical Sensorimotor Polyneuropathy  
Distal symmetrical sensorimotor polyneuropathy (DPN) is the most common subtype 
of diabetic neuropathy, with up to 50% of patients experiencing symptoms such as 
numbness, tingling, pain, or weakness. These symptoms appear first in the distal portions 
of the extremities and progress gradually to the more proximal part of the body in a 
“stocking-glove” distribution with increasing duration and severity of diabetes. The 
prevalence of DPN increases with age in both type 1 and type 2 diabetes, and tends to be 
more common in patients with type 2 diabetes. Height is another risk factor for DPN, 
implicating the distant-dependent pathology of DPN. Other suggested risk factors for 
DPN include hypertension, low plasma insulin levels, other microvascular diabetic 
complications, smoking and excessive alcohol use (Edwards et al., 2008). 
The symptoms of DPN are associated with many downstream effects that greatly 
affect quality of life for patients. One determinant factor of the signs and symptoms of 
DPN is the fiber type involved. Large-fiber involvement results in impaired 
proprioception and light touch, while small-fiber involvement results in impaired pain 
and temperature perception (Edwards et al., 2008). Neuropathic pain is one of the most 
disabling symptoms in patients with DPN. Patients experience frequent burning pain, 
electrical or stabbing sensations, paresthesia, hyperesthesia, and deep aching pain, which 
typically worsen at night. Allodynia (painful sensations to innocuous stimuli) and 





DPN (Boulton et al., 2005). DPN-associated numbness often causes balance problems, 
which makes it one of three main risk factors for falls in patients with diabetes (Agrawal 
et al., 2010). Additionally, patients with severe DPN are at risk of ulcerations, 
neuroarthropathy (Charcot's joints) and lower-extremity amputations, with 15% 
developing an ulcer during the course of their disease (Gordois et al., 2003). With disease 
progression, distal weakness might occur in the most severe cases (Edwards et al., 2008).  
As up to half of the patients may be asymptomatic, the diagnosis of DPN can only be 
made after a careful clinical examination. All patients with diabetes should be screened 
annually for DPN by examining pinprick, temperature, and vibration perception (using a 
128-Hz tuning fork), 10-g monofilament pressure sensation at the distal halluces, and 
ankle reflexes. Combinations of more than one test have >87% sensitivity for the 
detection of DPN. Loss of 10-g monofilament perception and reduced vibration 
perception provide good prediction for foot ulcers. The feet should be examined for 
ulcers, calluses and deformities, and footwear should be inspected. Different scoring 
systems have been developed for monitoring progression or response to intervention in 
clinical trials. As the definition of diabetic neuropathy is defined by “the presence of 
signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other 
causes”, the diagnosis of DPN should involve the exclusion of other non-diabetic causes, 
which include chronic inflammatory demyelinating polyneuropathy (CIDP), B12 
deficiency, hypothyroidism, and uremia. A combination of typical symptomatology and 
distal sensory loss with absent reflexes, or the signs in the absence of symptoms, is highly 





Nerve conduction (NC) studies, which include motor nerve conduction, F response 
and sensory nerve conduction, can be used to quantify the degree of nerve injury in DPN. 
Though the electrodiagnostic studies are not required for the diagnosis of DPN, they are 
recommended to monitor disease progression in clinical research protocols. Abnormal 
nerve conduction velocities appears to be the first objective quantitative indication of the 
condition (Tesfaye et al., 2010). Table 1.2-2 lists the stages of DPN severity, using NC as 






Table 1.2-2: Stages of severity of DPN. 
Grade 0 No abnormality of NC, e.g., Σ 5 NC normal deviates < 95th percentile or 
another suitable NC criterion. 
Grade 1a Abnormality of NC, e.g., Σ 5 NC normal deviates ≥ 95th percentile without 
symptoms or signs. 
Grade 1b NC abnormality of stage 1a plus neurologic signs typical of DPN but without 
neuropathy symptoms. 
Grade 2a NC abnormality of stage 1a with or without signs (but if present, < 2b) and 
with typical neuropathic symptoms. 
Grade 2b NC abnormality of stage 1a, a moderate degree of weakness (i.e., 50%) of 
ankle dorsiflexion with or without neuropathy symptoms. 
(modified from Dyck, 1988) 
Diabetic Autonomic Neuropathy  
Diabetic autonomic neuropathy (DAN) is the other form of diffuse diabetic 
neuropathy, and it often accompanies DPN. DAN can impair any sympathetic or 
parasympathetic autonomic function, resulting in significant morbidity and mortality in 
patients with diabetes, in fact, the mortality rate in patients with DAN is twice of the rate 
in patients without DAN (Soedamah-Muthu et al., 2008). The clinical manifestations of 
DAN is listed in table 1.2-3, which mainly include resting tachycardia, exercise 
intolerance, orthostatic hypotension, constipation, gastroparesis, erectile dysfunction, 
sudomotor dysfunction, impaired neurovascular function and hypoglycemic autonomic 
failure (Boulton et al., 2005; Edwards et al., 2008). Many of the clinical symptoms of 
DAN are common and may be associated with causes other than diabetic neuropathy. 
Thus, a non-diabetes related etiology for the specific symptoms presented by a diabetic 






Table 1.2-3: Clinical manifestation of diabetic autonomic neuropathy. 
Cardiovascular  Sudomotor 
 -Resting tachycardia  -Anhidrosis 
 -Exercise intolerance  -Heat intolerance 
 -Orthostatic hypotension  -Gustatory sweating  
 -Silent myocardial ischemia   -Dry skin 
Gastrointestinal  Genitourinary  
 -Esophageal dysmotility  -Neurogenic bladder 
 -Gastroparesis  -Erectile dysfunction 
 -Constipation  -Retrograde ejaculation 
 -Diarrhea, fecal incontinence  -Female sexual dysfunction 
Pupillary   
 -Decreased dark-adapted pupil diameter   
(modified from Boulton et al., 2005; Edwards et al., 2008) 
Other Types of Neuropathies 
A focal neuropathy reflects damage to single (mononeuropathy) or multiple 
peripheral nerves (mononeuropathy multiplex), cranial nerves, regions of the brachial or 
lumbosacral plexuses (plexopathy), or the nerve roots (radiculopathy). The occurrence of 
focal neuropathy is far less common than DPN and DAN, and it affects mostly older 
diabetic patients. Focal neuropathies may have a sudden onset and sometimes improve on 
their own within 6 to 8 weeks (Edwards et al., 2008). 
Although poor glucose control is associated with an increased risk of neuropathy, 
intensive treatment of diabetes can also cause neuropathy. Treatment-induced neuropathy 
can occur after any quick establishment of glucose control, with insulin treatment being 
the most common trigger. It often presents as acute pain, and may have autonomic 
involvement, which can improve significantly with time (Gibbons and Freeman, 2010). 
1.2.2. Animal Models of Diabetic Peripheral Neuropathy  
Animal models provide a valuable resource to study the pathogenesis as well as 





rodent models available to study DPN in both type 1 and type 2 diabetes. Though in early 
studies of diabetes it was difficult to establish neuropathic changes in animal models, 
technical advances have enabled the identification of biochemical, electrophysiological, 
and morphological changes that contribute to the etiology of DPN and its progression. In 
rat models, DPN initially presents with an acute metabolic phase featuring nerve 
conduction velocity (NCV) slowing and hyperalgesia that are usually reversible. With 
increasing duration of diabetes, more severe functional abnormalities develop in concert 
with progressive structural changes in the nerve, which is less amenable to metabolic 
interventions. 
Type 1 Diabetes Models 
Streptozotocin (STZ), a glucosamine-nitrosourea compound that is particularly toxic 
to the insulin producing pancreatic β-cells, is widely used to induce type 1 diabetes in 
experimental animals. There are clear advantages to using STZ diabetic animal models, 
with its relative inexpensiveness and the availability of a considerable body of published 
data. To date, the STZ diabetic rat has been the most commonly used model to study 
DPN. Diabetes is induced by a single dose of 40-80 mg STZ/kg body weight through 
intraperitoneal (IP) or intravenous (IV) injection. Fasting plasma glucose is measured one 
week after injection, and diabetes is usually defined by blood glucose concentrations of 
15 mM (270 mg/dL) or greater. Depending on the aspect of neuropathy under 
investigation, the duration of diabetes can be as little as 2-4 weeks for symptoms of 
allodynia and NCV slowing, while longer durations (at least 8-16 weeks) are required for 





STZ can also be used to induce diabetes in both inbred (C57/Bl6 and CD1) and 
outbred (Swiss Webster) mouse strains, administered either at a single high dose in the 
150-200 mg/kg range, or at lower doses given over consecutive days such as 90+90, 
85+70+55, or 100+40+40 mg/kg. Mouse models are limited in studies of neuropathy due 
to size constrains, which can preclude certain examination techniques. However, one 
advantage for phenotyping neuropathy in the mouse is that diabetes can be induced in a 
wide range of genetically modified strains to highlight specific pathogenic mechanisms 
and treatments. In these diabetic mice, NCV slowing, impaired responses to sensory 
stimuli, and intraepidermal nerve fiber (IENF) loss occur within 2-8weeks of diabetes, 
whereas distal nerve fiber loss, axonal atrophy and myelin thinning have been reported to 
occur after many months of diabetes (Biessels et al., 2014). 
Genetic models of type 1 diabetes include the BB/Wor-rat, the non-obese diabetic 
(NOD) mouse and the Akita mouse. The diabetes prone BB/Wor rats, which lack T 
lymphocytes that express the RT6 alloantigen, spontaneously develop type 1 diabetes, 
whereas the diabetes resistant BB/Wor rats serve as controls (Nakhooda et al., 1978). 
These diabetic rats develop NCV deficits after 2 weeks of diabetes, and sural nerve fiber 
loss and structural pathology have been reported by 4 months. Though this model has a 
clear advantage for its close resemblance to human type 1 diabetes, extensive application 
of this model has been limited due to the high cost and maintenance need. There is 
currently little consistent information on the development of neuropathy in NOD and 
Akita mice, which also spontaneously develop type 1 diabetes. Similar to the BB/Wor 
rats, these mice are expensive to maintain since daily insulin supplementation are 





Type 2 Diabetes Models 
Genetic rat models of impaired glucose tolerance and type 2 diabetes include the 
Zucker fatty (ZF) and Zucker Diabetic Fatty (ZDF) rat, which exhibit leptin receptor 
deficiency. Whereas the ZF rat harboring a missense mutation in the leptin receptor (Lepr) 
gene develops obesity without diabetes, the ZDF rat derived from the ZF strain exhibit 
obesity which progress to overt diabetes at 8-10 weeks of age. Increases in 
hyperinsulinemia and hyperlipidemia parallel the progression through pre-diabetes (ZF) 
to overt diabetes (ZDF) in these animals, with the appearance of hypertension later in the 
disease course. These animals develop neuropathic symptoms including NCV slowing, 
mechanical allodynia and IENF loss. Similar to genetic rat models of type 1 diabetes, the 
primary disadvantages of the ZDF rats are the high cost, the need for close attention and 
maintenance, and high mortality after 4-6 months of diabetes. 
Mouse models for type 2 diabetes used in the study of DPN include the db/db mouse 
(lepr mutation) and the ob/ob mouse (leptin mutation). Both models develop diabetes at 
4-6 weeks of age with concurrent onset of hyperinsulinmia and hyperlipidemia. NCV 
slowing and behavioral deficits are established with 4–8 weeks of diabetes, IENF loss 
and structural abnormalities of the sural nerve are also reported at late stages of the 
disease. Whereas both db/db and ob/ob mice are available on the C57 BKLS and Bl/6 J 
backgrounds and develop symptoms of type 2 diabetes similarly, there is growing 
recognition that the development of neuropathic symptoms might be background specific 
(Biessels et al., 2014).   
In addition to the genetic models of type 2 diabetes, feeding a high fat diet (HFD) 





diabetic state and metabolic syndromes that may contribute to DPN in the absence of 
overt diabetes due to insulin resistance and dyslipidemia. Rodents fed with a HFD have 
been reported to develop symptoms of neuropathy such as NCV deficits, altered response 
to sensory stimuli and IENF loss (Guilford et al., 2011; Xu et al., 2014).  
1.2.3. Pathogenesis of Diabetic Peripheral Neuropathy  
Despite the high prevalence of DPN in both type 1 and type 2 diabetic patients, the 
disease etiology remains largely unknown. Hyperglycemia, as the fundamental cause for 
diabetic mellitus, clearly plays a critical role in the pathogenesis of DPN. Various 
glucose-driven metabolic pathways, including the polyol pathway, formation of advanced 
glycation end-products (AGEs), abnormal activation of PKC isoforms, oxidative stress 
and mitochondrial dysfunction have all been shown to be involved in peripheral nerve 
dysfunction in diabetic patients. In addition, factors other than hyperglycemia also seem 
to be involved in the development of DPN, especially in type 2 diabetes, since tight 
glycemic control is more effective in risk reduction of DPN in patients with type 1 rather 
than type 2 diabetes. In this regard, recent findings suggest that obesity, hypertension, 
dyslipidemia, inflammation and insulin resistance contribute to DPN in type 2 diabetes to 
an equal, if not greater degree compared with hyperglycemia (Callaghan et al., 2012b). 
The Polyol Pathway 
The polyol pathway of glucose metabolism consists of two tandem reactions. First, 
aldose reductase (AR) utilizes NADPH to reduce glucose to sorbitol and NADP+. 
Sorbitol dehydrogenase (SDH) then utilizes NAD+ to oxidize sorbitol into fructose and 
NADH (Oates, 2008). Under diabetic conditions, the polyol pathway is activated by 





excess glucose is then available for shunting into the polyol pathway resulting in an 
increase in intracellular sorbitol. An increase in sorbitol contributes to a relative 
intracellular hypertonic state and a compensatory efflux of other osmolytes such as myo-
inositol and taurine (Edwards et al., 2008). Though this increase in intracellular 
osmolarity has been proposed as one of the mechanisms involved in the pathogenesis of 
diabetic complications, this may not be the case for diabetic neuropathy (Oates, 2002; 
Oates, 2008), since sorbitol levels have been reported to be comparatively modest in 
diabetic nerves (Clements, 1986). Also, certain pharmacological agents robustly raise 
peripheral nerve sorbitol, fructose, and myo-inositol, yet do not cause detectable 
impairment of peripheral nerve function (Oates, 2002).  
Ironically, evidence that AR plays a key pathogenic role in diabetic neuropathy has 
continued to mount. Diabetic mice overexpressing AR have accelerated nerve 
dysfunction and damage, which could be prevented by the treatment with the AR 
inhibitor WAY121-509 (Yagihashi et al., 2001). In contrast, AR-deficient mice exhibit 
strong protection of nerve function under diabetic conditions (Ho et al., 2006). Human 
diabetics with "high AR expression" alleles show a faster loss of maximum pupillary 
constriction velocity, an indicator of autonomic neuropathy, while those with "low AR 
expression" alleles have a slower loss in plantar heat sensitivity, an indicator of sensory 
neuropathy (Oates, 2008). This suggests that there must be other mechanisms linking the 
polyol pathway to the pathogenesis of diabetic neuropathy, and numerous studies suggest 
this alternative mechanism to be oxidative stress. The polyol pathway contributes to 
oxidative stress through the interdependence of many key biochemical pathways involved 





NADH/NAD+ cofactor systems (Oates, 2008). Increased flux through the polyol pathway 
consumes NADPH, which is needed for the regeneration of a major cellular antioxidant, 
reduced glutathione (GSH), thus weakening the cell’s capacity to defend against oxidants. 
Chronic elevation of the NADH/NAD+ ratio can lead to the synthesis of diacylglycerol 
(DAG), a well-known activator of PKC. PKC activation can increase superoxide 
production and oxidative stress via elevated NAD(P)H oxidase activity and mitochondrial 
metabolism. Furthermore, the polyol pathway generates fructose, a 10-times more potent 
glycation agent than glucose, contributing to the formation of advanced glycation end-
products. Similar to PKC, AGE production can also generate oxidative stress through 
interacting with the receptor for AGEs (RAGE) (Obrosova, 2005).  
The Advanced Glycation Endproducts Pathway 
The formation of early glycation adducts and AGEs results from the non-enzymatic 
reactions of glucose, oxaldehydes and other saccharide derivatives with proteins, 
nucleotides and lipids. However, other reducing sugars such as fructose and fructose-3-
phosphate, which are also formed under hyperglycemia conditions, undergo non-
enzymatic glycation at a faster rate compared with glucose (Ahmed, 2005; Szwergold et 
al., 1990). Emerging data from animal and clinical studies suggest the role of AGEs in 
the pathogenesis of diabetic neuropathy. The accumulation of AGEs is considered 
detrimental mainly in two ways. Firstly, the glycation of proteins alters their function and 
cellular transport and causes abnormal interactions with other matrix proteins, eventually 
leading to functional and structural abnormalities in diabetic peripheral nerves. Secondly, 
accumulation of extracellular protein AGEs can activate RAGE (Ramasamy et al., 2007), 





(Ramasamy et al., 2005) and induces oxidative stress through NAD(P)H oxidase activity 
(Vincent et al., 2007).  
Evidence for accumulation of fructosyl-lysine and AGEs in peripheral nerve of STZ-
diabetic rats has been provided using liquid chromatography with tandem MS detection 
(Karachalias et al., 2003). Furthermore, myelin components in the peripheral nervous 
system have been shown to be subject to non-enzymatic glycation in diabetic rodent 
studies (Vlassara et al., 1983). It has been suggested that AGE-modified peripheral nerve 
myelin is susceptible to phagocytosis by macrophages and that this stimulates 
macrophages to secrete proteases, which may contribute to demyelination in diabetic 
neuropathy (Vlassara et al., 1985). Also likely to undergo glycation during diabetes are 
major axonal cytoskeletal proteins such as tubulin, neurofilament, and actin, which are 
central to the maintenance of axonal function and structure (Cullum et al., 1991; Pekiner 
et al., 1993; Ryle et al., 1997; Williams et al., 1982). The glycation of these cytoskeletal 
proteins may alter the structural and functional properties of the axon, thereby leading to 
axonal atrophy and degeneration, as well as slowing axonal transport (Sugimoto et al., 
2008). The ability of peripheral nerve to regenerate might also be impaired by glycation 
of extracellular matrix proteins. The glycation of two major components of basal lamina, 
collagen type IV and laminin, has been shown to reduce neurite outgrowth in dorsal root 
ganglion (DRG) neurons obtained from neonatal rats (Luo et al., 2002) and young adult 
mice (Ozturk et al., 2006). These data suggest that the accumulation of AGEs in 
peripheral nerves contributes to segmental demyelination, axonal degeneration, and 
diminished regeneration of neurons, which are important pathophysiological features of 





RAGE, a multi-ligand member of the immunoglobulin superfamily of cell surface 
molecules (Stern et al., 2002), has also been implicated in the pathogenesis of diabetic 
neuropathy. Ligation of RAGE by its ligands can upregulate receptor expression and 
trigger a spiral of cellular perturbations due to sustained RAGE-mediated signaling (Stern 
et al., 2002). In support of this view, a dramatic and cumulative rise in RAGE mRNA and 
protein expression has been found in peripheral epidermal axons, sural axons, Schwann 
cells, and sensory neurons within DRG, which correlates with progressive 
electrophysiological and structural abnormalities in STZ-diabetic mice with neuropathy 
(Toth et al., 2008). The activation of RAGE can result in a burst of ROS, caspase-3 
activation, and nuclear DNA degradation in the DRG neurons from embryonic rat. All of 
these abnormalities were prevented by treatment with the antioxidant α-lipoic acid 
(Vincent et al., 2007), suggesting a role for RAGE activation in the generation of 
oxidative stress. Human sural nerve biopsy studies have revealed the co-localization of 
RAGE ligands, RAGE and NF-κB in the perineurium, as well as in the endoneurial and 
epineurial vessels of patients with diabetic neuropathy (Haslbeck et al., 2007). A similar 
localization is also found in patients with IGT-related peripheral neuropathy (Haslbeck et 
al., 2005), implicating the involvement of AGE/RAGE/NF-κB signaling pathway in the 
etiology of DPN. This relationship is further consolidated by the recently generated 
RAGE-/- mice which displayed diminished upregulation of peripheral nerve NF-κB and 
NF-κB-dependent proinflammatory gene expression. The absence of NF-κB activation 
partially protected the mice from a diabetes-associated loss of pain perception (Bierhaus 





cell survival through NF-κB (Huttunen et al., 2000), but whether this has any 
physiological significance for slowing the onset of DPN is unclear. 
The Protein Kinase C Pathway 
Protein kinase C (PKC) comprises a superfamily of isoenzymes that play a key role 
in many cellular functions, and is involved in numerous signal transduction pathways 
(Newton, 2003). Increased production of PKC, especially the PKCβ isoform, has been 
implicated in the pathogenesis of diabetic complications, as it is associated with 
overexpression of vascular endothelial growth factor (VEGF), plasminogen activator 
inhibitor-1 (PAI-1), NF-κB, and transforming growth factor-β (TGF-β) (Das Evcimen 
and King, 2007).  
The activation of PKC in hyperglycemic or diabetic environment has been suggested 
to associate with elevated levels of the well-known PKC activator diacylglycerol (DAG). 
Chronic hyperglycemia leads to an increase in the glycolytic intermediate 
dihydroxyacetone phosphate, which when reduced to glycerol-3-phosphate, contributes to 
the enhanced de novo synthesis of DAG (Xia et al., 1994). An increase in NADH level 
due to activation of polyol synthesis also leads to DAG synthesis from dihydroxyacetone 
phosphate (Thomas et al., 1994). Steadily accumulating evidence has strongly linked 
retinal, renal, and cardiovascular complications of diabetes with elevations in DAG levels 
as well as an increase in both PKC activation and activity (Idris et al., 2001; Ways and 
Sheetz, 2000). However, the exact role of PKC activity in diabetic neuropathy is yet to be 
established. Despite the beneficial effects of various PKC inhibitors in ameliorating 
diabetes-induced deficits in the peripheral nerves (Cameron et al., 1999; Nakamura et al., 





1991), unchanged (Cameron et al., 1999), or increased (Kishi et al., 1999), with no 
consistent change in DAG levels (Ido et al., 1994) in diabetic rat nerve. Considering the 
role of PKC in altering vasoconstriction and capillary permeability, causing angiogenesis, 
basement membrane thickening, and endothelial proliferation, the contribution of this 
pathway to diabetic neuropathy is likely through its effects on vascular blood flow and 
microvascular disease rather than directly on neuronal cells. Other studies suggest that 
the deleterious role of PKC activation in the nerves might be isoform-specific: in diabetic 
rats, there is a trend towards decreased expression of PKCα, an isoform that is primarily 
expressed in the Schwann cells, and intensified expression of  PKCβII, an isoform that 
localizes in the axons of nerve fibers, macrophages and the wall of endoneurial 
microvessels (Mizukami et al., 2011). Whereas increased PKCβII expression and activity 
is consistent with other diabetic complications, the unique decrease in PKCα level might 
be related to the decrease of Schwann cell proliferation under hyperglycemic conditions. 
Decreased proliferative potential of Schwann cells might be an underlying mechanism for 
the slowing of Schwann cell regeneration in glucose stressed cells, which likely 
contributes to segmental demyelination manifested in human diabetic 
neuropathy(Kamiya et al., 2003). 
Oxidative Stress  
Oxidative stress occurs in a cellular system when the production of free radicals 
exceeds the antioxidant capacity of the system. An imbalance between the production and 
neutralization of reactive oxygen species (ROS) is a well-recognized mechanism in the 
pathogenesis of diabetic neuropathy and may be a central biochemical mechanism in 





Several free radical species, including superoxide (O2
-) and nitric oxide (NO), are 
produced in the body under normal conditions to perform specific functions. While the 
presence of these free radicals is essential for normal physiology, their overproduction 
during metabolic dysfunction leads to cellular injury. In addition to their distinct roles in 
inhibiting protein/enzyme activity, the combination of the relatively inert O2
-
 and NO 
forms peroxynitrite, a highly reactive ROS which attacks proteins, DNA and lipids 
(Vincent et al., 2004b).  
The presence of oxidative stress in diabetic peripheral nerves has been demonstrated 
by the identification of various biomarkers of ROS-induced injury, including 
accumulation of free lipid peroxidation products, increased GSSH/GSH ratio, GSH 
depletion, downregulated superoxide dismutase (SOD) activity, decreased catalase, 
decreased total quinone reductase activities, depletion of ascorbate and taurine, and an 
increase in the dehydroascorbate/ascorbate ratio (Cheng and Zochodne, 2003; Obrosova 
et al., 2001; Stevens et al., 2000). Accumulation of nitrotyrosine, which is the marker of 
peroxynitrite-induced protein nitration, has been documented in peripheral nerve, spinal 
cord, vasa nervorum and DRG in both type 1 and type 2 diabetes rodent models (Cheng 
and Zochodne, 2003; Drel et al., 2007; Obrosova et al., 2007a; Obrosova et al., 2005b; 
Vareniuk et al., 2007).  
Oxidative stress can be deleterious in several ways and oxidative damage of DNA is 
known to promote apoptosis (Harrison et al., 2005). Lipid peroxides are the end products 
of lipid peroxidation that can be toxic to a cell and require removal by GSH (Mylonas 
and Kouretas, 1999).  Lastly, accumulation of proteins that have undergone peroxidation 





dysfunction (Berlett and Stadtman, 1997). Combined with the efficacy of various 
antioxidants in improving NCV and ameliorating deficits in nerve blood flow (Obrosova 
et al., 2001; Stevens et al., 2000), these data clearly support a role of oxidative damage in 
the peripheral nerve as a major contributor to diabetic neuropathy.  
The generation of oxidative stress not only causes damage to the cells through free 
radical attack, but also through induction of other cellular pathways. Poly(ADP-ribose) 
polymerase (PARP) is one of the downstream effectors of enhanced oxidative stress in 
diabetic neuropathy. The nuclear and mitochondrial poly(ADP-ribose) polymerases are 
closely associated with oxidative-nitrosative stress. Free radicals and peroxynitrite can 
induce DNA strand breakage, activating PARP, which in turn further intensifies oxidative 
stress (Obrosova et al., 2005a). Activated PARP cleaves NAD+ to nicotinamide and 
ADP-ribose, which can ADP-ribosylate nuclear proteins and PARP itself. Formation of 
poly(ADP-ribosyl)ated protein polymers plays an important role in the pathogenesis of 
DPN (Jagtap and Szabo, 2005). For example, poly(ADP-ribosyl)ation of glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) diverts glycolytic flux towards the polyol pathway, 
contributing to diabetic complications (Obrosova et al., 2004). The PARP activation has 
been shown in the peripheral nerve, vasa nervorum, and DRG neuron of STZ diabetic rats 
(Li et al., 2004; Obrosova et al., 2007a; Obrosova et al., 2004), STZ-diabetic mice (Drel 
et al., 2007), ob/ob mice (Vareniuk et al., 2007), and HFD-fed mice (Obrosova et al., 
2007b). Furthermore, activation of the PARP pathway depletes NAD+, a factor for 
glycolysis and the tricarboxylic acid (TCA) cycle, which could ultimately lead to an 
energy failure in the cells (Obrosova et al., 2004). Also, PARP activation affects gene 





inflammatory genes (Ha et al., 2002). In support of the important role of PARP, PARP-
deficient mice were protected from both diabetes- and galactose-induced motor and 
sensory nerve conduction slowing and nerve energy failure. In addition, two structurally 
unrelated PARP inhibitors, 3-aminobenzamide and 1, 5-isoquinolinediol have been 
shown to reverse established nerve blood flow and conduction deficits and energy failure 
in STZ-induced diabetic rats (Obrosova et al., 2004).  
Another pathway that is indicated as a downstream effector of oxidative stress is the 
activation of MAPK (Torres and Forman, 2003). High glucose has been shown to 
activate JNK and p38 MAPK in cultured adult DRG neurons, whereas oxidative stress 
has been shown to activate ERK and p38 MAPK and cause damage to the cells (Purves et 
al., 2001). In addition, ERK, p38 MAPK and JNK are found activated in DRG neurons of 
STZ-diabetic rats. JNK activation and increases in total levels of p38 and JNK are also 
observed in sural nerve of type 1 and 2 diabetes patients (Purves et al., 2001; Tomlinson 
and Gardiner, 2008). It is proposed that elevated MAPK activity in diabetic nerves is 
associated with increased neurofilament phosphorylation, which is a contributor to the 
distal sensory axonopathy in diabetes (Fernyhough et al., 1999). Furthermore, the 
potency of a p38 MAPK inhibitor to correct motor and sensory nerve conduction velocity 
(MNCV and SNCV) deficits in STZ-diabetic rats also implicates a role of MAPK 
activation in motor and sensory nerve dysfunction (Price et al., 2004). 
Mitochondrial Dysfunction 
As the most important organelle in controlling the bioenergetic status of cells, 
mitochondria have been shown to play a crucial role in the development of diabetic 





ATP for high energy requiring axonal functions such as excitation, axonal transport and 
growth cone motility is suggested to be one prime trigger of peripheral nerve 
degeneration.  
In eukaryotes, mitochondrial oxidative phosphorylation is the major ATP synthetic 
pathway. Upon uptake into cells, glucose is metabolized through the TCA cycle, 
generating electron donors such as NADH and FADH2. The electrons then travel through 
the electron transport chain (complex I-IV) located in the inner mitochondria membrane 
for the reduction of molecular oxygen (O2) to water. While the majority of O2 is reduced 
to water at complex IV, 1-4% of the O2 is incompletely reduced to O2
- mainly at 
complexes I and III. The O2
- produced is trapped in the intermembrane space or matrix of 
the mitochondria as it cannot readily diffuse across mitochondrial membranes (Figueroa-
Romero et al., 2008). The conversion of O2
- to H2O2 by the mitochondrial isoform of the 
enzyme superoxide dismutase (SOD) facilitates the permeation of ROS across the 
mitochondrial membrane. H2O2 could then be reduced enzymatically to water and O2 by 
other enzymes both inside and outside the mitochondria (Brownlee, 2005).  
In normal cells, ROS accounts for a tiny proportion of the products of the electron 
transport chain, and can be scavenged efficiently by innate antioxidants. However, as 
proposed by Brownlee et al., under diabetic conditions, high glucose in tissues 
susceptible to diabetic complications leads to an increased supply of NADH in the 
mitochondria, the subsequent increase in electron availability and/or saturation may cause 
enhanced production of superoxide radicals in the proximal part of the electron transport 
chain (Nishikawa et al., 2000a). Though this mechanism might be true in cultured 





transport chain in mitochondria resulting in the hyperpolarization of mitochondrial inner 
membrane and elevated production of ROS (Nishikawa et al., 2000a; Nishikawa et al., 
2000b), its validity remains unclear for sensory neurons. The work from many distinct 
research groups have shown depolarized mitochondrial inner membrane potential in adult 
sensory neurons from STZ-diabetic rats (Huang et al., 2003; Huang et al., 2005; 
Srinivasan et al., 2000), as well as high glucose-treated embryonic sensory neurons 
(Russell et al., 2002), which is contradictory to the mechanism proposed by Brownlee et 
al. (Brownlee, 2005). In cultured embryonic DRG neurons, high glucose treatment 
induced a rapid increase in mitochondrial membrane potential that peaked at 3h, followed 
by a subsequent decrease. After 24h of hyperglycemia, the mitochondrial membrane 
potential of hyperglycemically stressed neurons was lower than control neurons (Russell 
et al., 2002; Vincent et al., 2004a). Thus, one plausible illustration for the depolarization 
of mitochondrial membrane potential is that the DRG neurons might have undergone a 
state of hyperpolarization in membrane potential at the initial stage of diabetes, which 
initiates the serial oxidative damage, resulting in mitochondrial depolarization at later 
stages. Hence, as a contributor rather than a consequence of peripheral neuropathy, the 
mitochondrial hyperpolarization is beyond detection in animals that already have 
significant signs of diabetic neuropathy. 
DRG neurons are uniquely susceptible to damage by hyperglycemia because they 
have long, mitochondria-rich axons that directly access the nerve blood supply 
(Leinninger et al., 2006b). Consequently, axonal mitochondrial are acutely exposed to the 
hyperglycemic environment in diabetic conditions, and as the sites of increased ROS 





swollen, structurally disrupted or, in some cases, as an abundant population of smaller-
than-normal organelles (Bach et al., 2005; Bach et al., 2003). It has also been shown that 
in cultured primary DRG neurons, high glucose treatment induced a rise in ROS 
production, and corresponding mitochondrial swelling, loss of mitochondrial membrane 
potential, depletion of ATP and apoptosis (Russell et al., 2002; Vincent et al., 2005).  
Mitochondrial DNA (mtDNA), which encodes genes that are involved in local 
mitochondrial protein synthesis, is also susceptible to oxidative damage (Leinninger et al., 
2006b). Increased ROS destabilizes mtDNA and prevents cAMP responsive element 
binding protein (CREB)-mediated transcription in mitochondria, thereby inhibiting 
production of proteins that are critical to mitochondrial function (Ryu et al., 2005). Many 
proteins involved in mitochondrial function, including complexes I-III, are exquisitely 
sensitive to ROS-induced inhibition of activity (Brown, 1999). In addition, oxidative 
stress has been implicated in the inhibition of mitochondrial import of preproteins 
(Wright et al., 2001), the presence of which are essential for normal mitochondrial 
function.  
Other signaling pathways that result in localized mitochondrial destruction have also 
been proposed as underlying mechanisms for mitochondrial dysfunction in DPN. For 
example, in times of stress, ATP depletion stimulates dynamin-related protein 1 (Drp1) 
translocation from cytosol to the mitochondria to increase mitochondrial fission, 
presumably to increase mitochondrial number and distribute energy throughout the cell. 
Though increased fission might provide an immediate relief for the cellular energy crisis, 
long-term imbalance between mitochondrial fission and fusion leads to the production of 





Drp1 have been found in in vitro and in vivo models of diabetic neuropathy (Leinninger 
et al., 2006a). Through gene array and proteomic studies, reduced expression of oxidative 
phosphorylation genes have been found in type 2 diabetes (Mootha et al., 2003), 
decreased expression of the transcriptional regulator nuclear respiratory factor 1 (NRF-1) 
and peroxisome proliferator-activated receptor- γ coactivator 1α (PGC-1α) has also been 
observed in pre-diabetic and diabetic tissues (Patti et al., 2003).  Some groups discovered 
significantly decreased phosphorylation of AMP-activated protein kinase (AMPK) and 
decreased expression of PGC-1α in DRG neurons from STZ-diabetic Swiss Webster mice 
(Chowdhury et al., 2011), suggesting the role of these upstream regulators of 
mitochondrial biogenesis in mitochondrial dysfunction and subsequent deficits in nerve 
function.  
Impaired Neurotrophic Support  
Neurotrophic/growth factors are essential for the growth and survival of neurons. A 
variety of neurotrophic and growth factors secreted by target tissues, Schwann cells, and 
neurons themselves support nerve regeneration after injury. Dysregulation of 
neurotrophic factors, including insulin, insulin-like growth factor (IGF), nerve growth 
factor (NGF) and neurotrophin 3 (NT-3), have been implicated to contribute to segmental 
demyelination, axon atrophy or loss, slowed NCV, and impaired retrograde transport in 
DPN (Apfel, 1999). In fact, the expression levels of multiple neurotrophins have been 
found to be decreased in diabetic animals. In addition, many of the neuronal 
abnormalities of DPN can be duplicated by genetic depletion of specific neurotrophins, 





dysregulated neurotrophic support in the pathogenesis of DPN (Pittenger and Vinik, 
2003).  
The impact of neurotrophic factors is often selective. The relationship of different 
nerve fiber types, the modalities served, and the neurotrophins targeting them is 
illustrated in Figure 1.2-2 (Pittenger and Vinik, 2003). Neurotrophins exert their effects 
through binding to two classes of receptors: the trk family of receptor tyrosine kinases 
(trk A, trk B, trk C) and the low-affinity receptor p75. Functional binding of 
neurotrophins to trks largely mediates the signal transduction and biological functions of 
neurotrophins, including neuronal survival and differentiation, cytoskeletal changes, and 
synaptic plasticity. In contrast, p75 has been shown to act as a modifier for trks. It has 
also been shown that p75 is widely expressed in non-neuronal tissues, such as Schwann 
cells, where its expression increases following nerve injury. NGF activity is specifically 
associated with activation of p75 and/or trk A, with concomitant effects on small sensory 
and autonomic nerve fibers. In contrast, the activity of trk C mediated NT-3 signaling is 
essential for large nerve fiber function, whereas BDNF, NT-4 and NT-5 exert their 







Figure 1.2-2: Schematic illustration of the peripheral nervous system, nerve fiber types, 
and the potential growth factors responsible for the integrity of the different fiber types. 
A nerve fiber is a threadlike extension of a nerve cell and consists of an axon and myelin 
sheath (if present). In the peripheral nervous system, myelin is formed by Schwann cells, which 
can also make a thin covering for an axon without formation of myelin. There are three types of 
nerve fibers in a mixed nerve which include motor nerve fibers, sensory nerve fibers, and 
autonomic nerve fibers. Individual nerve fibers vary widely in diameter and also may be 
myelinated or unmyelinated, which enable them to carry out different functions: the Aα nerve 
fibers are large in diameter and involved in muscle control; the Aβ fibers mainly carry sensory 
information related to touch, pressure, vibration and joint position; the Aδ fibers carry 
information related to sharp pain, very light touch and cold sensation; and the unmyelinated C 
fibers are mainly involved in sensations of dull, aching, burning pain and temperature. (adapted 
from Pittenger and Vinik, 2003) 
Nerve growth factor (NGF) is the most extensively investigated neurotrophin as a 
possible contributor to the development of DPN. Both sensory neurons and sympathetic 
neurons are dependent on NGF for development, maintenance and survival (Calcutt et al., 
1990; Rich et al., 1987). NGF levels, as well as its retrograde transport which is required 
for its neurotrophic effects, have been shown diminished in multiple diabetic models 





restored by allogenic islet transplantation, implicating the effect of hyperglycemia and/or 
insulin deficiency on growth factor levels (Hellweg et al., 1991). The expression of the 
low-affinity receptor for NGF, p75, has also been found reduced in STZ-diabetic rats, 
leading to impaired NGF signaling in the neurons (Schmidt et al., 2000). Knockout of 
p75 was found to result in loss of small sensory ganglia, with decreased pain perception 
and cutaneous innervation. NGF treatment prevented diabetes-related reduction in pain 
sensation, as well as the levels of calcitonin gene related peptide (CGRP) and substance P 
(SP) in sensory ganglia of diabetic animals (Apfel et al., 1998; Diemel et al., 1994). 
Similar to NGF, the expression of IGF-I and II are also down-regulated under diabetic 
conditions and could be reversed by insulin treatment (Migdalis et al., 1995; Wuarin et al., 
1994). Intrathecal delivery of low doses of insulin (at levels insufficient to reduce 
hyperglycemia) and IGF-I were associated with reversal of motor and sensory nerve 
conduction deficits in diabetic rats. In addition, insulin and IGF-I both reversed atrophy 
in myelinated sensory axons within the sural nerve (Brussee et al., 2004). Though NGF 
and IGF both yielded encouraging results in animal studies, only recombinant NGF has 
been tested in phase III clinical trials in humans, and it did not demonstrate major 
benefits. 
Inflammation 
Recent studies have shown that inflammation also plays a determinant role in the 
development of microvascular diabetic complications (Navarro and Mora, 2005). Higher 
levels of inflammatory agents, including C-reactive protein and TNF-α have been found 
in the blood of diabetic patients, which correlate with the incidence of neuropathy 





including AGE/RAGE, PKC, PARP and oxidative stress, have been shown to activate 
NF-κB and transcription of a series of inflammatory and immune mediators. Activated 
NF-κB has been identified in perineurium, epineurial vessels and endoneurium of sural 
nerve biopsies of diabetic patients (Bierhaus et al., 2004b). Secondary effectors of the 
NF-κB pathway, including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 
(COX-2), TNF-α, endothelin-1 and cell adhesion molecules, have been shown to be 
upregulated under diabetic conditions, which also contribute to the pathogenesis of DPN 
(Ha et al., 2002). In addition, enhanced NF-κB activation downregulates the NRF-2 
pathway, thus indirectly weakens the antioxidant defense through suppressing the 
expression of antioxidant genes (Ganesh Yerra et al., 2013). The upregulated 
inflammatory response drives a feed-forward loop since enhanced NF-κB activity 
increases TNF-α and COX-2 production, which can stimulate ROS and prostaglandin E2 
(PGE2) production and further activate NF-κB (Williams and Nadler, 2007). Chronic 
hyperglycemia-induced inflammation also affects peripheral nerve function through 
extensive infiltration of monocyte, macrophages and modest infiltration of granulocytes 
from the blood circulation (Wang et al., 2006). Cytokines induced by NF-κB activation in 
endothelial cells, Schwann cells and neurons leads to macrophage recruitment to the 
diabetic nerves, which results in damaged myelin sheath, increased nerve excitability, 
impaired nerve regeneration and the onset of DPN (Conti et al., 2002; Yamagishi et al., 
2008).  
Given the important role of neuroinflammation in the pathogenesis of DPN, it is not 
surprising that inhibition of NF-κB with an IκB protease inhibitor is effective at 





(Cameron and Cotter, 2008). The various downstream effectors of NF-κB have also been 
extensively studied in experimental diabetics. Chemical and genetic inhibition of COX-2 
has shown effectiveness in preventing nerve conduction and endoneurial nutritive blood 
flow deficits, peripheral nerve oxidative damage and inflammation in diabetic animals 
(Kellogg et al., 2007; Pop-Busui et al., 2002). Blockade of receptors for endothelin-1, 
which is a powerful vasoconstrictor that is upregulated in diabetes, normalized nerve 
blood flow, motor and sensory NCV, and mechanical hyperalgesia in diabetic rats 
(Cameron and Cotter, 1996). 12/15-lipoxygenase (12/15-LO) is an important member of 
the lipoxygenase family that produces pro-inflammatory substances such as the 
hydroxyeicosatetraenoic acids (HETEs). In diabetic mice, 12/15-LO inhibition reversed 
motor and sensory NCV deficits and mechanical allodynia, but had no effects on thermal 
hypoalgesia. 12/15-LO-/- mice were more resistant to the development of DPN in both 
type 1 (STZ-induced) and type 2 (HFD-induced) diabetic models (Obrosova, 2009). 
1.2.4. Current Therapeutic Strategies for Diabetic Peripheral Neuropathy 
Treatment of DPN has been largely directed at control of symptoms rather than 
targeting the underlying pathogenic mechanisms with the exception of glycemic control. 
Despite increasing understanding towards the etiology of DPN, to date, tight and stable 
glycemic control remains to be the only proven effective pathogenic treatment for DPN. 
The DCCT and the Epidemiology of Diabetes Interventions and Complications (EDIC) 
follow-up study clearly demonstrate that intensive glycemic control implemented early in 
the course of diabetes effectively delays development of DPN in patients with type 1 
diabetes (Albers et al., 2010; Wolffenbuttel, 1993). Compared with type 1 diabetes, the 





definitive. In several randomized controlled trials of patients with type 2 diabetes, only a 
modest reduction in neuropathy was observed in patients receiving intensive glucose 
control (Callaghan et al., 2012a). Whereas some studies suggest that intensive glycemic 
control in type 2 diabetes patients is most beneficial if implemented early in the disease 
when patients have fewer microvascular complications (Ismail-Beigi et al., 2010; Ohkubo 
et al., 1995), other studies failed to confirm this finding (Azad et al., 1999). Interestingly, 
the Bypass Angioplasty Revascularization Intervention 2 Diabetes trial reported that 
specific glucose-lowering strategies and medications have different effects on DPN 
prevention in type 2 diabetes (Pop-Busui et al., 2013). In addition to tight glycemic 
control, diet and exercise lifestyle interventions, have also shown some promise in 
reversing neuropathic symptoms in patients with IGT (Smith et al., 2006) and type 2 
diabetes (Kluding et al., 2012). 
Attempts to treat DPN through targeting other proposed pathogenic mechanisms 
include aldose reductase inhibitors, antioxidants, recombinant nerve growth factor, and 
acetylcarnitine, all of which have shown efficacy in animal models but failed in clinical 
trials. Some mechanistic treatments are currently undergoing evaluation, the most 
promising one among which is the ROS scavenger α-lipoic acid. Several trials have 
associated α-lipoic acid with reduced neuropathic symptoms of DPN, although no 
significant differences were identified for primary end points, NCV results, or 
quantitative sensory testing (Ziegler et al., 2006; Ziegler et al., 2004). Other agents 
currently under investigation include C-peptide and Actovegin. Beneficial effects of C-
peptide on measures of DPN in patients with type 1 diabetes have been reported by 





PEGylated C-peptide in type 1 diabetes patients with mild to moderate DPN is ongoing 
(Ekberg et al., 2003; Ekberg et al., 2007). Actovegin is a deproteinized hemoderivative 
mixture of low molecular weight compounds produced from calf blood that is thought to 
stimulate oxygen utilization, cellular energy metabolism, glucose transport, and glucose 
oxidation. A randomized trial of patients with DPN in type 2 diabetes has shown that 
Actovegin improved neuropathic symptoms, vibration perception threshold, and sensory 
function (Ziegler et al., 2009), but it has not received broad medical acceptance.   
One confounding factor in identifying effective treatments for DPN is that the 
contribution of various pathogenic pathways differs between individuals and does not 
occur with temporal and/or biochemical uniformity. Thus, before the identification of a 
uniform target in the disease pathogenesis, combinatorial therapies targeting multiple 
glucose-driven insults may be the best approach to control DPN in addition to good 
glycemic control. On the other hand, reinforcing endogenous cytoprotective mechanisms 
has appeared as an innovative strategy to help counteract glucotoxicity and manage DPN. 
Pharmacological modulation of heat shock proteins (HSPs) has shown great benefits in 
ameliorating peripheral nerve dysfunction, iENF loss and mitochondrial dysfunction in 
STZ-diabetic mice (Urban et al., 2010; Urban et al., 2012b).  
1.3. Heat Shock Proteins 
1.3.1. Overview of Heat Shock Proteins  
The heat shock proteins (HSPs) were initially identified as gene products whose 
expression is induced by heat or other stresses. However, research over the past several 
decades has gradually revealed their roles as molecular chaperones which are involved in 





relatives and molecular partners, play essential roles in protein folding, assembly, 
intracellular localization, secretion, regulation, and degradation. Dysregulation of these 
activities have been implicated in numerous human diseases (Feder and Hofmann, 1999; 
Thomas et al., 1995).  
HSPs are among the most highly conserved proteins in existence, and function as 
heavy duty molecular machines that operate on a wide range of substrates found in all 
cellular compartments. Through interaction with other proteins, they minimize 
inappropriate protein interactions, and thus reduce the probability of protein aggregation. 
Though not all HSPs are stress-inducible, the stress-inducible HSPs respond to a wide 
variety of stresses, including temperature, cellular energy depletion, extreme 
concentrations of ions, osmolytes, gases, and various toxic substances. A common feature 
of these stresses is that they result in the accumulation of non-native proteins, which is 
consistent with the role of HSPs as molecular chaperones to help folding, unfolding or 
disposing denatured proteins. HSPs preferentially bind to proteins that are in their non-
native conformations, either because the peptides have not yet been fully synthesized, 
folded, assembled, localized to the proper cellular compartment, or have undergone some 
level of  protein-denaturation. HSPs normally function as complexes of several different 
chaperones, co-chaperones, and/or nucleotide exchange factors. Many chaperones are 
ATP-dependent, and utilize cycles of ATP binding and hydrolysis to assist the folding or 






Heat Shock Response and the Heat Shock Factors 
Cells respond to protein-denaturing stresses by induction of HSPs, and this process is 
termed as heat shock response (HSR). This response is universal, as it has been observed 
in organisms from eubacteria to archebacteria, from plants to mammals. Despite the 
existence of several mechanisms to regulate the abundance of cytosolic and nuclear 
chaperones, the induction of HSPs is largely mediated by transcription factors termed 
“heat shock factors” (HSFs). In response to various proteotoxic stresses, HSFs bind to a 
highly conserved short DNA sequence known as the heat shock element (HSE) to 
mediate the transcription of heat shock genes (Sorger, 1991).  
Several members of the HSF family (i.e., murine and human HSF1, 2, and 4 and a 
unique avian HSF3) have been identified (Pirkkala et al., 2001). HSF1 functions as the 
major transcription factor that can be activated by a diverse range of stresses in most 
vertebrates, whereas HSF3, has been shown to be a heat responsive transcription factor. 
In contrast, HSF2 is only activated under developmentally related stress conditions; and 
the most recently identified mammalian HSF, HSF4, is expressed in a tissue-specific 
manner and required for proper eye development (Anckar and Sistonen, 2007).  
Although different HSFs play distinct biological roles, they share a highly conserved 
structure, with the N-terminal helix-turn-helix DNA binding domain (DBD) being the 
most conserved functional domain. HSFs bind to DNA as trimers, in which the 
concurrent binding of all DBDs to the pentameric nGAAn sequences (n denotes less 
strongly conserved nucleotides that nevertheless may be involved in important DNA-
protein interactions) within the HSEs on the promoter region of HSP genes is required for 





that is situated adjacent to the DBD is required for activation-induced trimerization of 
HSFs. In contrast, an additional hydrophobic repeat sequence (HR-C) which locates near 
the C-terminus of the protein has been suggested to negatively regulate HSF trimerization 
(Pirkkala et al., 2001; Voellmy and Boellmann, 2007). Human HSF4 lacks the HR-C, 
which explains its constitutive trimerization and DNA binding activity. The 
transactivation domain is positioned at the extreme C-terminus of most HSFs, and is 
responsible for the responsiveness to stress stimuli (Akerfelt et al., 2010).  
In vertebrates, HSF1 has been identified as the HSF that mediates stress-induced heat 
shock gene expression in response to environmental, as well as physiological stressors. 
HSF1 mainly exists as transcriptionally inactive monomers in the nucleoplasm or the 
cytosol under normal growth conditions, and its activity is largely mediated post-
translationally (Figure 1.3-1). One common feature of the diverse signals that regulate 
HSF1 activity is that it responds to the accumulation of non-native proteins. This has led 
to a widely accepted model in which the elevated level of mis-folded protein liberates 
HSF1 from HSPs to allow HSF1 to be converted into its active state. HSF1 interacts with 
multiple HSPs at different phases of its activation cycle, and Hsp90 is a key negative 
regulator of HSF1 activity. Reduced levels of Hsp90 have been demonstrated to induce 
HSF1 activation in vitro. Similarly, low levels of geldanamycin, which binds to the ATP-
binding pocket of Hsp90 and specifically inhibits its activity, has been shown to activate 
HSF1 and induce the HSR in vivo (Zou et al., 1998). In contrast, Hsp70 and the co-
chaperone Hsp40 (also known as DNAJB1) interacts with the activated HSF1 trimers, 





The activation-attenuation mechanism of HSF1 is multifaceted and also involves 
extensive post-translational modifications, including acetylation, phosphorylation and 
SUMOylation (Figure 1.3-1) (Akerfelt et al., 2010). HSF1 exists as a phosphoprotein even 
under unstressed conditions. As revealed by mass spectrometry and phosphopeptide 
mapping analysis, at least 12 serine residues are phosphorylated (Guettouche et al., 2005), 
among which stress-inducible phosphorylation of Ser230 and Ser326 in the regulatory 
domain contributes to the transactivation function of HSF1 (Guettouche et al., 2005; 
Holmberg et al., 2001). In addition, phosphorylation mediated SUMOylation on a single 
lysine residue in the regulatory domain occurs rapidly and transiently upon exposure to 
heat shock: phosphorylation of Ser303 is required for the conjugation of SUMO (small 
ubiquitin-like modifier) to Lys298 (Hietakangas et al., 2003). Though SUMOylation 
could positively modulate HSF1 activity under moderate stress conditions, the kinetics of 
phosphorylation-dependent SUMOylation of HSF1 correlates inversely with the severity 
of heat stress (Hietakangas et al., 2006). Thus, the mechanisms through which SUMO 
modification regulates the activity of HSF1, and the functional relationship between 
SUMOylation and other post-translational modifications of HSF1 are the subject of 
future studies. 
In contrast to phosphorylation and SUMOylation of HSF1 which occur rapidly upon 
heat shock, acetylation is delayed and coincides with the attenuation phase of the HSF1 
activation cycle. The acetylation of HSF1 is regulated by the balance between acetylation 
by p300-CBP (CREB-binding protein) and deacetylation by the NAD+-dependent sirtuin, 
SIRT1. During the activation phase, SIRT1 maintains HSF1 in a state that is competent 





and diminishes the DNA binding activity of HSF1. In accordance with this theory, 
increased expression and activity of SIRT1 has been found to enhance the DNA-binding 
activity of HSF1 at the human Hsp70.1 promoter. In contrast, downregulation of SIRT1 
enhances the acetylation of HSF1 and attenuates its DNA-binding without affecting the 
formation of HSF1 trimers (Westerheide et al., 2009). The acetylation of HSF1, together 
with feedback regulation by increased levels of HSPs (e.g., Hsp70-Hsp40 complex) 
mediates the attenuation phase of the HSF1 activation cycle and ensures proper 
functioning of HSF1. 
 
Figure 1.3-1: The activation cycle of HSF1.  
In the resting state, HSF1 exists as a monomer and interacts with Hsp90 as a phosphoprotein. 
Upon cellular stresses, HSFl dissociates from Hsp90 and acquires DNA-binding activity through 
a monomer-to-trimer transition and binds to the HSE in HSP genes. Several posttranslational 





transactivation capacity of HSF1. The transcriptional activity of HSF1 is abrogated during the 
attenuation phase, which involves two regulatory steps: negative feedback from the Hsp70-Hsp40 
complex, which represses the transactivation activity of DNA-bound HSF1; and acetylation of 
Lys80 in the DBD of HSF1, which inhibits its DNA binding activity. The acetylation of HSF1 is 
mediated by p300–CBP, whereas the sirtuin SIRT1 negatively regulates the attenuation phase of 
the HSR by preventing HSF1 acetylation. (adapted from Akerfelt et al., 2010) 
Classification of Heat Shock Proteins 
HSPs can be assigned into different families on the basis of their molecular weights: 
Hsp110, Hsp100, Hsp90, Hsp70, Hsp60, Hsp40, Hsp10, and small HSP families. In 
eukaryotes, these families comprise multiple members that differ in inducibility, 
intracellular localization, and function. Among these HSP families, members of the 
Hsp70 and Hsp90 function as the main chaperones that determine the destiny of proteins 
and integrate signaling functions (Saibil, 2013).  
a. Hsp70 Family 
The Hsp70 family of proteins is the most abundant HSPs that exists as many 
paralogues in different cellular compartments. They are also highly conserved across 
species, demonstrating a 60–80% base identity among eukaryotic cells (Kregel, 2002). 
The human Hsp70 family comprises at least eight members that differ from each other by 
amino acid sequences, expression levels and sub-cellular localizations (Table 1.3-1) 
(Daugaard et al., 2007). Most Hsp70 family members reside in the cytosol and nucleus 
except for Hsp70-5 (also known as Bip, Grp78) and Hsp70-9 (also known as Grp75, 
mtHsp70, Mortalin) which are confined in the lumen of the ER and the matrix of the 
mitochondrial, respectively. These Hsp70 proteins share a highly conserved domain 
structure consisting of an ATPase domain, a middle region with protease sensitive sites, a 





the proteins to bind co-chaperones and other HSPs (Tavaria et al., 1996). The members 
that have special localizations also possess a signal sequence in their N-terminus, 
ensuring their translocation to the proper cellular compartments.  
Table 1.3-1: The human HSP70 family. 




Hsp70-1a, Hsp70, Hsp72, Hsp70-1  HSPA1A Cytosol, Nucleus, Lysosomes Yes 
Hsp70-1b, Hsp70, Hsp72, Hsp70-1 HSPA1B Cytosol, Nucleus, Lysosomes Yes 
Hsp70-1t, Hsp70-hom HSPA1L Cytosol, Nucleus No 
Hsp70-2, Hsp70-3, HspA2 HSPA2 Cytosol, Nucleus No 
Hsp70-5, Bip, Grp78 HSP70A5 ER No 
Hsp70-6, Hsp70B HSP70A6 Cytosol, Nucleus Yes 
Hsc70, Hsp70-8, Hsp73 HSPA8 Cytosol, Nucleus No 
Hsp70-9, Grp75, mtHsp70, Mortalin HSPA9 Mitochondria No 
(modified from Daugaard et al., 2007) 
The Hsp70 proteins are associated with a wide variety of cellular activities. The 
Hsp70 system coordinates cellular functions by directing substrates for unfolding, 
disaggregation, refolding or degradation, and it is also an important component of the 
organelle translocation system. Monomeric Hsp70 recognizes short hydrophobic peptide 
segments such as those exposed in nascent polypeptide chains. The binding of a 
polypeptide chain to Hsp70 prevents mis-folding and aggregation and maintains the 
substrate in an unfolded state for its subsequent folding/refolding or translocation to a 
cellular compartment (Saibil, 2013). The nucleotide binding state of the ATPase domain 
determines the opening and closing of the substrate binding domain: ATP binding leads 
to substrate binding and ATP hydrolysis leads to substrate release. Two co-chaperones, 
Hsp40 and a nuclear exchange factor (NEF) (Hsp110 in eukaryotic cells), act together 





and stimulates the Hsp70 ATPase activity, and the NEF opens up the nucleotide cleft for 
nucleotide exchange (Jiang et al., 2007; Polier et al., 2008).   
Among the Hsp70 protein family, Hsp70-5 and Hsp70-9, facilitate chaperone-
dependent transport and folding of proteins targeted for the ER and mitochondria, 
respectively. The rest of the Hsp70 proteins can be divided into constitutively present and 
stress-inducible forms, with the constitutive Hsp70s essential for basic housekeeping 
functions. The stress-inducible Hsp70-1 functions as the major chaperone that enables the 
cell to cope with aggregation of denatured proteins during and following cellular stress: 
mice lacking Hap70.1 and Hsp70.3 (the murine homologues of human Hsp70-1a and -1b) 
are more susceptible to stress, but develop normally under unstressed conditions (Hunt et 
al., 2004; Singleton and Wischmeyer, 2006). In contrast, knockout of Hsp70-2 in mice 
leads to developmental defects in spermatogenesis (Dix et al., 1996), and Hsc70 appears 
to be absolutely essential for cell viability (Florin et al., 2004). 
b. Hsp90 Family 
Hsp90 is another highly abundant molecular chaperone that accounts for 1–2% of 
cellular proteins under normal growth conditions. Unlike Hsp70 which is essential for 
nascent protein folding, most of the known substrates for eukaryotic cytosolic Hsp90 are 
signal transduction proteins, making it a cellular signaling hub for many pathways (Xu 
and Lindquist, 1993). At a molecular level, Hsp90 binds to substrate proteins that are in a 
near native state and acts at a late stage of folding through maturation and conformational 
maintenance of its client proteins. The Hsp90 family comprises mainly the cytosolic 
Hsp90 (termed variously Hsp90α and β in humans), the ER-specific Grp94, and 





exists constitutively as homodimers and consists of an N-terminal domain that serves as 
the binding site for ATP, a middle segment that is essential for client protein binding, and 
a C-terminal homodimerization domain (Saibil, 2013). Hsp90 also dimerizes transiently 
through its N-terminal ATPase domain upon ATP binding. This enables the ATP-bound 
Hsp90 to bind stably with substrate polypeptides while hydrolysis of ATP releases the 
substrate by opening up the Hsp90 dimer (Young et al., 2001). 
The activity of Hsp90 is modulated by a variety of co-chaperone proteins, most of 
which interact via a tetratricopeptide repeat (TPR) motif with the C-terminal EEVD motif 
of Hsp90. These co-chaperones, together with Hsp90 and Hsp70, arrange into a 
functional multi-chaperone complex that plays an essential role in cellular proteome 
maintenance in vivo. For example, Hsp70-Hsp90 Organizing Protein (HOP) is a multi-
TPR domain containing protein that recruits Hsp70 to Hsp90, thus creating a complex for 
substrate handover (Chen and Smith, 1998). On the other hand, C terminus of Hsc70-
Interacting Protein (CHIP) is a single TPR domain-containing co-chaperone that links 
Hsp90 to the ubiquitination apparatus, thereby controlling protein degradation through 
the proteasome (Connell et al., 2001).  
Though Hsp90 displays substrate specificity during normal cell developmental 
processes, under stress conditions such as heat shock, Hsp90 contributes more generally 
to the refolding of denatured proteins (Nathan et al., 1997). The exact structural features 
recognized by Hsp90 are yet to be established, however, denatured proteins do seem to 
share a similar character with signaling proteins as they all possess some degree of 





interactions of substrate proteins with Hsp90 likely arise from structural properties at the 
molecular level rather than via a specific biological function. 
1.3.2. Heat Shock Proteins in Diabetic Peripheral Neuropathy 
The profound role of HSPs in cellular protection and recovery has led to the idea of 
treating protein mis-folding diseases through chaperone induction. In diabetes, chronic 
hyperglycemia imposes glucotoxicity and causes changes in metabolic fluxes that are 
metabolically stressful and ultimately detrimental to cells. Although the progression of 
DPN seems unrelated to the accumulation of any one specific mis-folded or aggregated 
protein, hyperglycemia can increase oxidative modification of amino acids, which can 
lead to damaged protein structure, impaired protein folding, decreased refolding of 
damaged proteins and increased protein aggregation. In this regard, it has been reported 
that proteins associated with mitochondrial dysfunction, oxidative phosphorylation, 
ubiquinone biosynthesis, and the citric acid cycle were downregulated in the DRG of 22-
week-old STZ-diabetic rats, corresponding to the development of mitochondrial 
dysfunction (Akude et al., 2011). In the well-characterized leptin receptor deficient 
(db/db) mice, oxidative stress induces carbonylation and misfolding of sciatic 
nerve/myelin proteins, which may have important implications in deficits of myelin 
integrity and nerve conduction in peripheral neuropathies (Hamilton et al., 2013).  
Many pathological states, including diabetes, neurodegenerative diseases and the 
aging process, are characterized by dysregulation of the HSR, which has a pathogenic 
role in either initiating or worsening the diseases. Thus, the vulnerability of postmitotic 
neurons to stress-induced protein denaturation might be associated with decreased 





markedly reduced Hsp70 levels in DRG from the spontaneously diabetic BB/Worcester 
rats, a model of type 1 diabetes (Kamiya et al., 2006). In contrast, 4-month of diabetes 
increased Hsp27 and Hsp70 in DRG of BB/Worcester rats (Kamiya et al., 2005). It is 
conceivable that chaperone expression varies as degeneration of peripheral nerves 
progresses. Whereas the level of endogenous chaperones may be sufficient to counter 
early glycemic insults, increased chaperone expression may represent a cytoprotective 
response as the disease progresses. However, this response may be eventually 
overwhelmed by the excessive metabolic disturbances associated with chronic 
hyperglycemia.  
Studies of the role of HSPs in the pathogenesis and treatment of metabolic diseases 
have been ongoing for decades. It has been reported that the expression of Hsp72 was 
decreased in both type 1 and type 2 diabetes patients (Bruce et al., 2003; Strokov et al., 
2000). This may contribute to diabetes since glucose metabolism could be improved by 
Hsp72 restoration through overexpression of the protein, administration of 
pharmacological inducers or long-term mild hyperthermia (Kondo et al., 2011). In a 
clinical study using α-lipoic acid for the treatment and prevention of diabetic 
polyneuropathy, it has been shown that induction of Hsp72 seem to be essential for the 
effectiveness of α-lipoic acid treatment in reversing clinical and electrophysiological 
manifestations of DPN (Strokov et al., 2000). The important role for Hsp72 in 
neuroprotection is also implicated in a study where the degree of protection provided by a 
pre-conditioning stress closely correlated with the amount of Hsp72 it induced in the 
DRG neurons (Amin et al., 1995). That being said, reinforcing the HSR in sensory 





1.3.3. Inhibiting Hsp90 as a Novel Therapeutic Strategy against Diabetic 
Peripheral Neuropathy 
The most widely characterized pharmacological inducer of the HSR are Hsp90 
inhibitors. In unstressed cells, the activity of HSF-1 is under tight negative regulation by 
the Hsp90 and release of HSF-1 represents a crucial step in its activation during stress 
conditions. As many of the Hsp90 client proteins are involved in signal transduction 
pathways associated with cellular growth, differentiation and survival, inhibition of 
Hsp90 was initially investigated for treatment of cancer (Peterson and Blagg, 2009). The 
best characterized Hsp90 inhibitors, geldanamycin (GDA) and its derivative 17-
allylamino-17-demethoxygeldanamycin (17-AAG), function through competitive 
interaction with the N-terminal ATP-binding site of Hsp90, and thus disrupt the ATP-
dependent interaction of Hsp90 with its client proteins (Roe et al., 1999). One important 
aspect of these N-terminal Hsp90 inhibitors in cancer therapy is that they preferentially 
inhibit Hsp90 and induce client protein degradation in malignant versus normal cells 
(Luo et al., 2008). The selectivity of Hsp90 inhibition in malignant cells is likely 
conferred by the enhanced expression of Hsp90 in malignant tumor cells to accommodate 
their high metabolic requirements (Chiosis et al., 2003). However, the application of 
these Hsp90 inhibitors in cancer treatment has been hampered as induction of client 
protein degradation and cytotoxicity can occur at drug concentrations that also induce the 
cytoprotective HSR. In this regard, N-terminal Hsp90 inhibitors have been shown to 
decrease τ protein aggregation in Alzheimer’s disease models (Dickey et al., 2007) and 
improve motor function in spinal and bulbar muscular atrophy (Waza et al., 2005). 





effects of Hsp90 inhibition, enabling Hsp90 inhibitors to be used as both 
chemotherapeutic and neuroprotective agents.  
The 12-kDa C-terminal domain of Hsp90 is responsible for its homodimerization, as 
well as coordinating interactions with Hsp90 partner proteins. The C-terminal domain 
also contains a putative nucleotide-binding site, which facilitates nucleotide exchange at 
the N-terminus (Soti et al., 2003). Thus, targeting the C-terminus of Hsp90 seems to be 
another feasible strategy for the inhibition of Hsp90 activity. Indeed, coumarin antibiotics 
such as novobiocin and chlorobiocin, disrupt Hsp90 function through binding to the C-
terminal region of the protein (Marcu et al., 2000). However, as with the N-terminal 
Hsp90 inhibitors, novobiocin also promotes client protein degradation and induces a HSR 
at similar drug concentrations. Thus, systematic modification of novobiocin was 
undertaken to identify structure-activity relationships that yield high-affinity C-terminal 
analogues that could diverge client protein degradation from Hsp70 induction. As a result, 
KU-32 (N-(Farmer et al., 2012b 5R)-3, 4-dihydroxy-5-methoxy-6, 6-dimethyl-
tetrahydro-2H-pyran-2-yloxy]-8-methyl-2-oxo-2H-chromen-3-yl) acetamide) was 
identified as a lead compound that exhibits at least a 500-fold divergence of client protein 
degradation from induction of Hsp70 (Figure 1.3-2) (Urban et al., 2010). This divergence 
provides an excellent therapeutic window for treating neurodegenerative disease without 
inducing cytotoxicity. In support of its cytoprotective property, KU-32 has been shown to 
protect against neuronal death induced by amyloid β-peptide and glucotoxicity (Ansar et 
al., 2007; Kusuma et al., 2012). Moreover, weekly administration of 20mg/kg KU-32 to 
STZ-diabetic mice reversed multiple clinical indices of DPN, including mechanical and 





essential role of Hsp70 in neuroprotection, mice with genetic ablation of the stress-
inducible Hsp70 (Hsp70.1 and Hsp70.3) failed to respond to KU-32 despite the 
development of similar diabetes-associated neuronal deficits as compared to wild type 
(WT) mice. Of note, the neuroprotective effects of KU-32 in WT diabetic mice are not 
accompanied by significant alternation of metabolic parameters, despite the apparent 
effects on increasing insulin secretion and survival of isolated human pancreatic islets 
(Farmer et al., 2012a). In vitro assessments of primary sensory neurons indicate that KU-
32 protects unmyelinated and myelinated neuronal cultures against DPN-associated 
neuropathic changes. To be more specific, KU-32 dose-dependently prevented 
neuregulin-1 (NRG1)-induced myelin degeneration in myelinated sensory 
neuron/Schwann cell co-cultures in an Hsp70-dependent manner, indicating a chaperone-
mediated intervention of aberrant growth factor signaling (Li et al., 2012; Urban et al., 
2010). In addition, KU-32 has been shown to decrease mitochondrial superoxide levels 
and significantly enhance respiratory activity in hyperglycemically stressed rat 
embryonic sensory neurons, which correlated with  increased translation of Mn 
superoxide dismutase (MnSOD) and several cytosolic and mitochondrial chaperones 






Figure 1.3-2: Structure-activity relationships of novobiocin analogs. 
Structure of novobiocin analogues and the schematic representation of dose effects in client 
protein degradation (dotted lines) and chaperone induction (solid lines) for novobiocin (black), 
KU-32 (blue) and KU-174 (red). (adapted from Urban et al., 2010) 
As discussed previously, mitochondrial dysfunction plays an essential role in the 
pathogenesis of DPN. Although the mechanisms underlying the protective effect of KU-
32 in antagonizing the proneuropathic action of the established biochemical mediators of 
DPN remains unclear, induction of Hsp70 improves mitochondrial function in the 
sensory neurons of diabetic mice (Urban et al., 2012b). Several lines of evidence have 
implicated a role for Hsp70 in the maintenance of multiple aspects of mitochondrial 
function. For example, the cytosolic Hsp70 plays an important role in the biogenesis as 
well as the proper translocation of mitochondrial protein into the mitochondrial matrix 
through the outer mitochondrial membrane import receptor, Tom70 (Stuart et al., 1994; 
Young et al., 2003). Likewise, induction of Hsp70 is essential to maintain normal 





astrocytes increased mitochondrial function and decreased neuronal injury after basal 
forebrain ischemia (Xu et al., 2010). Additionally, upregulation of Hsp70 protected 
against ischemia-reperfusion injury in heart tissue through improving mitochondrial 
function (Jayakumar et al., 2001). Consistent with this theory, KU-32 has been shown to 
decrease mitochondrial superoxide levels and improve mitochondrial bioenergetics 
(mtBE) in hyperglycemically stressed primary neurons (Zhang et al., 2012). Thus, in the 
current study, we sought to determine whether the effect of KU-32 to correct the clinical 
deficits associated with DPN relied on an improvement in mtBE in sensory neurons.  
Also, using animal models of both type 1 and type 2 diabetes, we sought to determine 
whether deficits in mtBE show a similar relationship to the temporal onset of sensory 
hypoalgesia in models of type 1 and type 2 diabetes and ascertain if KU-32 improves 







Chapter 2: Heat Shock Protein 70 is Necessary to Improve Mitochondrial 
Bioenergetics and Reverse Diabetic Sensory Neuropathy Following KU-32 Therapy 
Portions of this chapter are directly exerted from the following publication: 
Ma J, Farmer KL, Pan P, Urban MJ, Zhao H, Blagg BS, et al. Heat shock protein 70 
is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory 
neuropathy following KU-32 therapy. The Journal of pharmacology and experimental 
therapeutics 2014; 348: 281-92.  
Abstract 
Impaired neuronal mitochondrial bioenergetics contributes to the pathophysiologic 
progression of diabetic peripheral neuropathy (DPN) and may be a focal point for disease 
management. We have demonstrated that modulating Hsp90 and Hsp70 with the small-
molecule drug KU-32 ameliorates psychosensory, electrophysiologic, morphologic, and 
bioenergetic deficits of DPN in animal models of type 1 diabetes. The current study used 
mouse models of type 1 and type 2 diabetes to determine the relationship of changes in 
sensory neuron mitochondrial bioenergetics to the onset of and recovery from DPN. The 
onset of DPN showed a tight temporal correlation with a decrease in mitochondrial 
bioenergetics in a genetic model of type 2 diabetes. In contrast, sensory hypoalgesia 
developed 10 weeks before the occurrence of significant declines in sensory neuron 
mitochondrial bioenergetics in the type 1 model. KU-32 therapy improved mitochondrial 
bioenergetics in both the type 1 and type 2 models, and this tightly correlated with a 
decrease in DPN. Mechanistically, improved mitochondrial function following KU-32 
therapy required Hsp70, since the drug was ineffective in diabetic Hsp70 knockout mice. 





nerve dysfunction in type 2 diabetes, but not type 1 diabetes, and that modulating Hsp70 
offers an effective approach toward correcting sensory neuron bioenergetic deficits and 
DPN in both type 1 and type 2 diabetes.  
2.1. Introduction 
Diabetic peripheral neuropathy (DPN) is experienced by a majority of patients with 
type 1 or type 2 diabetes (Callaghan et al., 2012a). The development of DPN is associated 
with a small-fiber neuropathy resulting from dysfunction of unmyelinated or thinly 
myelinated sensory fibers and the gradual degeneration of larger myelinated fibers. 
Although numerous pathologic mechanisms contribute to DPN (Urban et al., 2010), 
altered mitochondrial bioenergetics (mtBE) may be a central facilitator in its 
development (Fernyhough et al., 2010). For example, mitochondrial function is impaired 
in adult sensory neurons or dorsal root ganglia isolated from diabetic rats (Akude et al., 
2011; Chowdhury et al., 2010; Huang et al., 2003). Additionally, in-depth bioenergetic 
analysis of adult sensory neurons isolated from models of type 1 diabetic mice (Urban et 
al., 2012b) or rats (Chowdhury et al., 2012) found substantive decreases in mtBE. 
However, since the etiologic development of DPN in type 1 and type 2 diabetes does not 
necessarily share identical mechanisms, it is unclear whether deficits in mtBE may have a 
kinetically similar relationship to the onset of sensory hypoalgesia that is symptomatic of 
DPN. Moreover, the efficacy of interventional therapies is also not identical in patients 
with type 1 versus type 2 diabetes. For example, tight control of blood glucose more 
effectively ameliorates DPN in patients with type 1 diabetes (Callaghan et al., 2012a). 
Similarly, enalapril improved nerve blood flow and electrophysiology in a type 1 diabetic 





type 2 model (Oltman et al., 2008). These results underscore that an effective therapy for 
DPN should be equally efficacious regardless of the underlying diabetic phenotype. To 
this end, we have been exploring the potential of pharmacologically manipulating 
molecular chaperones for treating DPN. 
Hsp90 and Hsp70 are molecular chaperones that are critical for folding nascent 
proteins into their biologically active conformations (Evans et al., 2010). Hsp90 contains 
N- and C-terminal ATP-binding domains and has intrinsic ATPase activity. Because 
pharmacologic agents that inhibit the N- or C-terminal ATPase activity can prevent 
protein folding, inhibiting Hsp90 is an attractive target for treating malignancies, as many 
oncoproteins require Hsp90 for proper folding (Peterson and Blagg, 2009). However, 
Hsp90 also binds the transcription factor, heat shock factor 1. Upon exposure to Hsp90 
inhibitors, heat shock factor 1 dissociates from Hsp90, translocates to the nucleus, and 
upregulates a heat shock response that promotes synthesis of cytoprotective antioxidant 
genes and chaperones, such as Hsp70. This response can antagonize the desired goal of 
cytotoxicity in treating cancers. On the other hand, inducing the heat shock response can 
increase molecular chaperones and decrease misfolded protein aggregates. Thus, 
stimulating this aspect of Hsp90 biology may have utility for treating neurodegenerative 
diseases (Morimoto, 2011; Zhao et al., 2012). However, developing an effective Hsp90 
inhibitor for treating neurodegeneration requires establishing a therapeutic window that 
leads to upregulation of cytoprotective chaperones, such as Hsp70, in the absence of 
client protein degradation that can antagonize the protective heat shock response. 
Novobiocin is the prototypic ligand that binds to the C-terminal site of Hsp90, and 





neuroprotective lead compound that exhibits a 500-fold divergence of Hsp70 induction 
from client protein degradation (Urban et al., 2010). This divergence provides an 
excellent therapeutic window to promote neuroprotection in the absence of toxicity; 
weekly administration of KU-32 reversed psychosensory, electrophysiologic, 
bioenergetic, and morphologic indices of DPN in diabetic mice (Urban et al., 2012a; 
Urban et al., 2010). Mechanistically, KU-32 binds Hsp90 directly (Matts et al., 2011), but 
the drug’s neuroprotective efficacy depends upon the downstream action of Hsp70 (Li et 







Figure 2.1-1: Dose response of KU-32 in improving mechanical hypoalgesia and NCV 
deficits in diabetic Swiss Webster mice.  
(A) Structure of KU-32. (B) Swiss Webster mice were rendered diabetic with STZ and 
mechanical sensitivity was assessed at the indicated weeks. After 8 weeks of diabetes, mice were 
treated once per week with 2, 10, or 20 mg/kg KU-32 for 6 weeks and mechanical sensitivity 
measured weekly. One group of nondiabetic mice was treated with only 20 mg/kg KU-32 as a 
control. *P < 0.05 versus time-matched vehicle (Veh) + Veh; ^P < 0.05 versus time-matched STZ 
+ Veh; #P < 0.05 versus time-matched STZ+ 2 mg/kg KU-32. (C) Effect of 6 weeks of KU-32 
therapy on MNCV and SNCV. *P < 0.05 versus Veh + Veh; ^P < 0.05 versus STZ + Veh; #P < 







The current study sought to determine whether deficits in mtBE in models of type 1 
and type 2 diabetes show a similar relationship to the temporal onset of sensory 
hypoalgesia and ascertain if KU-32 improves mtBE and reverses DPN in an Hsp70-
dependent manner. Our results indicate that the development of a sensory hypoalgesia 
preceded substantial changes in mtBE in type 1 diabetic mice. In contrast, the onset of 
mitochondrial dysfunction and sensory hypoalgesia were tightly correlated in type 2 
diabetic mice. KU-32 improved the bioenergetic profile of sensory neurons in an Hsp70-
dependent manner and effectively reversed insensate DPN in both diabetic models. These 
data provide novel insight into the role of mitochondrial dysfunction in the onset of 
insensate DPN and indicate that Hsp70 can have beneficial effects on mtBE. 
2.2. Materials and Methods 
Streptozotocin (STZ), carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone 
(FCCP), oligomycin, rotenone, antimycin A, Percoll, and poly(DL)ornithine were 
obtained from Sigma-Aldrich (St. Louis, MO). KU-32, [N-(7-((2R,3R,4S,5R)-3,4-
dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-
chromen-3-yl)acetamide] and trideutero KU-32 were synthesized and structural purity 
(>95%) verified as described previously (Huang and Blagg, 2007). Collagenase and 
laminin were purchased from Gibco/Invitrogen (Carlsbad, CA). 
Animals 
Male and female wild-type (WT) C57Bl/6 and Hsp70.1/70.3 double knockout (KO) 
mice on a C57Bl/6 background (Hsp70 KO) were used in the study and obtained from in-
house breeding colonies (Urban et al., 2010). Male Swiss Webster mice were purchased 





male and female mice were fasted for 6 hours and rendered diabetic with an 
intraperitoneal injection of STZ (100 mg/kg) given on two consecutive days. One week 
after the second injection, mice were fasted as above, blood was obtained from the tail 
vein, and animals with fasting blood glucose (FBG) ≥ 290 mg/dl (16 mM) were deemed 
diabetic. 
To model type 2 diabetes, heterozygous BKS.Cg-Dock7m+/+ Leprdb/J mice were 
acquired from The Jackson Laboratory (Bar Harbor, ME) to generate animals 
homozygous (Leprdb/db) for the lepr mutation. Heterozygous (Leprdb/+) mice served as 
controls. At ∼4–6 weeks of age, the Leprdb/db mice became identifiably obese and 
exhibited elevated FBG compared with their heterozygous littermates. Similar numbers 
of male and female animals between the genotypes were enrolled in the study when they 
were 8 weeks old. 
All animals were maintained on a 12-hour light/dark cycle with ad libitum access to 
water and Purina 5001 rodent chow. Preliminary dose-response studies indicated that 
after 8 weeks of diabetes, once a week dosing of 20 mg/kg KU-32 administered 
intraperitoneally in 0.2 ml of 0.1 M Captisol (β-cyclodextrin sulfobutylethers; CyDex 
Pharmaceuticals, Lenexa, KS) gave maximal recovery of mechanical hypoalgesia (Figure 
2.1-1B) and nerve conduction velocity deficits (Figure 2.1-1C). All subsequent studies 
were performed using a once per week 20 mg/kg dosing of the drug. At the termination 
of each study and prior to sacrifice of the animals, FBG and hemoglobin A1c levels (A1c 
Now+) were determined. All animal procedures were performed in accordance with 





compliance with standards and regulations for the care and use of laboratory rodents set 
by the National Institutes of Health. 
Psychosensory and Electrophysiologic Analyses 
Mechanical sensitivity was assessed in Leprdb/db mice using a nylon Semmes-
Weinstein von Frey monofilament (Stoelting, Wood Dale, IL). The filament that 
possesses a buckling force of 1.4g was applied to the plantar surface of the right and left 
hind paw. A positive response was recorded after lifting or flinching of the animal’s paw. 
This procedure consisted of six trials, which alternated between right and left hind paws. 
The percent response was obtained by determining the number of withdrawals in 
response to 12 separate monofilament applications (Jack et al., 2011). Alternatively, 
mechanical sensitivity was assessed in the type 1 animal models using a Dynamic Plantar 
Aesthesiometer (Stoelting Inc.) fitted with a stiff monofilament that was applied to the 
plantar surface at an upward force of 10g in the Swiss Webster mice or 8g for the 
C57Bl/6 and Hsp70 KO mice. Thermal sensitivity was assessed by paw withdrawal 
latency to a ramping, focal heat using a Hargreaves Analgesiometer (Stoelting Inc.) 
(Urban et al., 2010). Responses from each animal were measured four times on alternate 
feet and averaged. Sensory assessments were performed once a week at approximately 
the same time of day. In animals treated with KU-32, sensory measures were taken 1 
week after drug administration. At select time points, animals were anesthetized prior to 
measuring motor and sensory nerve conduction velocities (MNCV and SNCV, 
respectively) as previously described (McGuire et al., 2009). Animals were then 





Isolation of Adult Sensory Neurons 
Adult sensory neurons were isolated from L4–L6 dorsal root ganglia (DRG) of three 
to five mice per treatment with minor modifications (Delree et al., 1989; Urban et al., 
2012b). After removing connective tissue and trimming, the cleaned ganglia were 
maintained in 1 ml of serum-free Ham’s F10 medium at 37°C and dissociated with 1 ml 
of 1.25% collagenase for 45 minutes, followed by a secondary digestion with 1 ml of 2% 
trypsin for 30 minutes. Cells were isolated by centrifugation at 1000 × g for 5 minutes, 
and the pellet was further dissociated by triturating in F10 medium with a fire-polished 
glass pipette. The cell suspension was layered on a 10-ml gradient of sterile iso-osmotic 
Percoll and centrifuged at 800g for 20 minutes. The cell pellet was resuspended in fresh 
F10 medium, passed through a 40-µm nylon mesh (Mt. Baker Bio, Everett, WA), and the 
filter washed with 5 ml of serum-free medium. The cells in the filtrate were recovered by 
centrifugation and resuspended in maintenance medium: Ham’s F10 medium (6.1 mM 
glucose) containing 50 ng/ml nerve growth factor and 1 ng/ml neurotrophin 3 and N2 
supplement without insulin (Invitrogen, Carlsbad, CA). Neurons were plated onto 
poly(DL)ornithine (0.5 mg/ml overnight)/laminin (2 mg/ml for 3 hours)–coated 96-well 
plates at 5000–8000 cells per well. Neurons from control and diabetic animals were 
incubated in maintenance medium for 1 day prior to use in the bioenergetic analysis on 
day 2 in vitro. 
Mitochondrial Bioenergetic Assessment 
Oxygen consumption rate (OCR) was assessed in intact lumbar DRG sensory 
neurons using an XF96 Extracellular Flux Analyzer (Seahorse Biosciences, North 





unbuffered Dulbecco’s modified Eagle’s medium supplemented with 1 mM pyruvate and 
5.5 mM D-glucose and the cells incubated at 37°C. The plate was introduced into the 
XF96 analyzer, a 3-minute mix cycle used to oxygenate the medium, and respiration was 
assessed in a 4-minute measurement cycle. As a general description of a mitochondrial 
stress assay, the initial rates provide a measure of the basal OCR prior to assessing 
mitochondrial dysfunction using respiratory chain poisons (Brand and Nicholls, 2011). 
The portion of basal OCR that is coupled to ATP synthesis was estimated by the decrease 
in OCR following addition of the ATP synthase inhibitor, oligomycin (1 µg/ml). The 
residual OCR that persists after oligomycin treatment is from uncoupled respiration 
(proton leak). Next, maximal respiratory capacity (MRC) was assessed following 
dissipation of the proton gradient across the inner mitochondrial membrane with the 
protonophore FCCP (1 µM). Non-mitochondrial respiration was then assessed by 
coinjection of 1 µM rotenone or rotenone + 1 µM antimycin A. 
After the respiratory measures, the cells were harvested and OCR values were 
normalized to the total protein content of each well. ATP-linked respiration, proton leak, 
maximal respiratory capacity, spare respiratory capacity, and respiratory control ratio 
were determined as described previously (Brand and Nicholls, 2011; Chowdhury et al., 
2012). 
In Vivo Pharmacokinetics 
Mice were fasted for 4 hours and Captisol or 20 mg/kg KU-32 given via oral gavage. 
After 1 hour, food was given ad libitum, the animals sacrificed at the indicated time, and 
lumbar dorsal root ganglia, sciatic nerve, and plantar foot pads harvested and rapidly 





water), and spiked with 50 ng/ml trideutero KU-32 as the internal standard. The 
homogenate was extracted with 1 ml of t-butyl methyl ether and centrifuged. An aliquot 
(0.95 ml) of the supernatant was recovered and evaporated to dryness, and the resulting 
residue was resuspended in 0.05 ml of 20% CH3CN. After a second centrifugation, 0.045 
ml was transferred to autosampler vials. Chromatographic separation was performed 
using a 5-micron Agilent Zorbax SB C18 column (2.1 × 50 mm; Santa Clara, CA) and a 
linear gradient of CH3CN:H2O:formic acid (5:95:0.1) to CH3CN:H2O:formic acid 
(95:5.0:0.1) at a flow rate of 0.30 ml/min. The effluent was introduced to a Sciex 
API3200 Linear Ion Trap detector (Framingham, MA) using turbo ion spray in the 
positive ion mode. Linear calibration curves were constructed in each tissue matrix over a 
range of 0–1000 ng/ml, and analyte recoveries ranged from 65% to 75%. 
Mitochondrial Copy Number 
Real-time polymerase chain reaction (PCR) was used to measure mitochondrial copy 
number using primers for murine cytochrome b, cytochrome c oxidase subunit II (COII, 
mitochondrial genes), and β-actin (nuclear gene) (Santos et al., 2011). Forward and 
reverse primer sequences for mouse cytochrome b were 5'-
GCAACCTTGACCCGATTCTTCGC-3' and 5'-TGAACGATTGCTAGGGCCGCG-3'. 
Forward and reverse primer sequences for mouse COII were 5'-ATTGCCCTCCCCT-
CTCTACGCA-3' and 5'-CGTAGCTTCAG-TATCATTGGTGCCC-3'. PCR was 
performed using 25–50 ng of genomic DNA, 200 nM concentration of each primer, and 
the SYBR Green PCR master mix from Applied Biosystems (Grand Island, NY). 
Products were amplified following DNA denaturation at 95°C for 5 minutes followed by 





minutes. Melting curve analysis and gel electrophoresis verified the specific 
amplification of the expected product. Differences in gene expression were determined 
after normalization to β-actin using the ΔΔC(T) method. 
Statistical Analysis 
Student’s t tests, one-way analysis of variance (ANOVA), and repeated measures 
one-way ANOVA were applied for between-group comparisons. Post hoc analyses were 
conducted using Tukey’s test, and nonparametric data were analyzed with a Kruskal-
Wallis and Dunn’s test. All data are presented as mean ± S.E.M.  
2.3. Results 
2.3.1. KU-32 Reverses DPN in Leprdb/db Mice  
Beginning at 8 weeks of age, FBG, body weight, and psychosensory measures were 
assessed weekly in the Leprdb/db and Leprdb+ mice. Each genotype was subdivided into two 
groups at 10 weeks of age and given a weekly injection of KU-32 or Captisol for up to 8 
weeks (Figure 2.3-1A). After 4 weeks of drug therapy, a subgroup of the KU-32-treated 
Leprdb/db mice was administered Captisol for the final 4 weeks to investigate the effects of 
drug withdrawal. To examine the effect of diabetes and drug treatment on mitochondrial 
bioenergetic (mtBE), sensory neurons were isolated from five mice prior to drug 
treatment and at 4 and 8 weeks after administering KU-32.  
Consistent with the onset of type 2 diabetes, the Leprdb/db mice showed significant 
increases in total body weight and FBG and at 18 weeks of age had elevated glycated 
hemoglobin levels compared with aged-matched Leprdb/+ mice (Table 2.3-1). However, 





improve glucose disposal following a 3-hour glucose tolerance test (6-hour fast and 0.5-g 
glucose given intraperitoneally; data not shown). 
By 8 weeks of age, the Leprdb/db mice showed a significantly lower percent 
withdrawal response to a von Frey hair indicative of a mechanical hypoalgesia (Figure 
2.3-1B). In agreement with a prior study (Wright et al., 2007), the Leprdb/db mice did not 
develop a thermal hypoalgesia (Table 2.3-1) and did not show a significant decrease in 
intra-epidermal nerve fiber density in the foot pad at 18 weeks of age (data not shown). 
Weekly administration of KU-32 significantly improved mechanical sensitivity in the 
Leprdb/db mice, but had no effect on the Leprdb/+ mice. MNCV and SNCV decreased 
significantly in the untreated 18-week-old Leprdb/db mice, and KU-32 therapy improved 
these electrophysiologic deficits (Figure 2.3-1C). 
After 4 weeks of KU-32 therapy, drug withdrawal led to a gradual redevelopment of 
the mechanical hypoalgesia. In contrast, MNCV and SNCV rates remained similar to 
those observed in the Leprdb/db mice that received the drug continuously. Although the 
reason for this distinction is unclear, it is not related to differences in the rate of drug 
clearance since pharmacokinetic analysis showed that KU-32 is rapidly distributed to and 
quickly cleared from dorsal root ganglia, sciatic nerve, and plantar foot pads, with a half-







Figure 2.3-1: KU-32 improves mechanical hypoalgesia and NCV deficits in Leprdb/db 
mice.  
(A) Scheme of the study design using the Leprdb/db and Leprdb/+ mice. (B) Mechanical 
hypoalgesia was assessed in the Leprdb/db and Leprdb/+ mice at the indicated age and weekly KU-32 
therapy initiated at 10 weeks of age. KU-32 was then withdrawn in a subgroup of these mice after 
4 weeks of treatment. *, p < 0.05 versus time-matched Leprdb/+ + vehicle (Veh); ^, p < 0.05 versus 
Leprdb/db + Veh; # =, p < 0.05 versus Leprdb/db + KU-32 withdrawal. (C) The effect of genotype 
and treatments on MNCV (solid bars) and SNCV (striped bars) at 18 weeks. Group colors are the 
same as indicated in (B). *, p < 0.05 versus time-matched Leprdb/+; ^, p < 0.05 versus Leprdb/db + 




















10 db+ + Veh 24.8 ± 1.2 5 135 ± 45 5 — 3.5 ± 0.8 5 
  db+ + KU-32 24.0 ± 2.1 5 144 ± 14 5 — 4.9 ± 1.4 5 
  db/db + Veh 46.6 ± 2.7* 5 317 ± 108* 12 — 4.3 ± 0.3 7 
  db/db + KU-32 42.1 ± 4.0* 10 357 ± 111* 23 — 4.3 ± 0.6 1
5 
12 db+ + Veh 25.0 ± 3.6 20 124 ± 17 5 — 4.5 ± 1.3 5 
  db+ + KU-32 26.1 ± 3.4 22 129 ± 20 5 — 4.4 ± 0.8 5 
  db/db + Veh 46.5 ± 5.3* 18 478 ± 98* 18 — 4.9 ± 0.7 7 
  db/db + KU-32 45.7 ± 4.0* 37 475 ± 102* 37 — 4.2 ± 0.7 1
5 
14 db+ + Veh 25.8 ± 3.6 20 130 ± 21 10 — 4.5 ± 0.9 5 
  db+ + KU-32 26.8 ± 3.4 22 118 ± 36 9 — 4.8 ± 0.9 5 
  db/db + Veh 48.7 ± 5.6* 18 496 ± 70* 18 — 5.2 ± 0.9 7 
  db/db + KU-32 48.4 ± 4.8* 37 518 ± 89* 37 — 4.4 ± 0.9 1
5 
16 db+ + Veh 27.8 ± 4.7 10 139 ± 26 5 — 5 ± 0.7 5 
  db+ + KU-32 26.8 ± 3.0 8 144 ± 29 5 — 5.2 ± 1.4 5 
  db/db + Veh 49.1 ± 5.0* 10 533 ± 61* 13 — 4.9 ± 0.9 7 
  db/db + KU-32 49.4 ± 6.5* 12 506 ± 103* 13 — 4.9 ± 0.9 8 
  db/db + KU-32 
withdrawal 
50.6 ± 7.0* 11 501 ± 73* 16 — 5.5 ± 1.0 7 
18 db+ + Veh 28.0 ± 5.0 10 122 ± 17 5 4.3 ± 0.1 (23 
± 1.1) 
5.2 ± 0.6 5 
  db+ + KU-32 26.9 ± 3.6 8 137 ± 33 5 4.4 ± 0.1 (24 
± 1.1) 
4.8 ± 0.2 5 
  db/db + Veh 48.8 ± 5.8* 10 499 ± 78* 10 10.8 ± 
0.5* (95 ± 
5.6) 
4.9 ± 0.7 6 
  db/db + KU-32 50.1 ± 8.2* 12 504 ± 90* 12 10.3 ± 
0.4* (89 ± 
4.6) 
5.5 ± 1.3 8 
  db/db + KU-32 
withdrawal 
51.4 ± 8.4* 11 495 ± 54* 11 10.5 ± 
0.4* (91 ± 
4.2) 
5.4 ± 0.6 7 
Veh, vehicle. 
a mmol of HbA1c/mol of hemoglobin. 
b Paw withdrawal latency to thermal stimuli. 





2.3.2. Diabetes-Induced Hypoalgesia Coincides with Decreased Mitochondrial 
Function in Leprdb/db Mice 
The L4–L6 lumbar ganglia provide the cell bodies for the motor and sensory fibers 
that are affected in DPN and whose physiology was improved by KU-32. To determine 
whether the improvement in psychosensory function and NCV was associated with a 
change in mtBE, sensory neurons were isolated from these ganglia at 6, 8, 10, 14, and 18 
weeks of age. The neurons were cultured in vitro for 2 days and the OCR was determined 
for 2 hours in the intact cells (Zhang et al., 2012). 
At 6 weeks of age, Leprdb/db mice showed a modest decline in maximal respiratory 
capacity and spare respiratory capacity (SRC), but these parameters were significantly 
decreased by 8 weeks (Figure 2.3-2A) and 10 weeks (Figure 2.3-2B) of age. To gain 
broader insight into the effect of diabetes on cellular respiration, the ATP-linked OCR, 
proton leak, SRC, and nonmitochondrial OCR were expressed as a percent of the MRC 
(Figure 2.3-2B). At 10 weeks of age, Leprdb/db showed a significant decrease in SRC and 
an increase in proton leak, ATP-linked OCR, and nonmitochondrial respiration, 







Figure 2.3-2: Deficits in mitochondrial bioenergetics in Leprdb/db mice correlate with the 
development of mechanical hypoalgesia.  
Sensory neurons were obtained from 8–10-week-old Leprdb/db and Leprdb/+ mice, cultured for 
2 days, and mtBE assessed using an XF96 Extracellular Flux Analyzer. (A) MRC and SRC are 
significantly decreased in 8-week-old Leprdb/db mice compared with age-matched Leprdb/+ mice. 
Respiratory parameters are expressed as the percent of control using values from the Leprdb/+ mice. 
(B) Ten-week-old Leprdb/db mice have a significant decrease in SRC and an increase in ATP-
linked and nonmitochondrial respiration compared with age-matched Leprdb/+ mice. *, p < 0.05 
versus Leprdb/+ + vehicle (Veh). Respiratory parameters are expressed as the percent of the MRC 






2.3.3. KU-32 Therapy Improves mtBE and Sensory Hypoalgesia in Leprdb/db Mice 
Deficits in mtBE worsened by 14 weeks of age (Figure 2.3-3, A and B) and while the 
extent of ATP-linked and nonmitochondrial respiration increased, SRC declined between 
10 and 14 weeks of age (compare Figures 2.3-2B and 2.3-3B). The respiratory control 
ratio (RCR) is an indication that the mitochondria have a high capacity for substrate 
oxidation and ATP synthesis and a low proton leak (Brand and Nicholls, 2011). At 14 
weeks of age, diabetes decreased the RCR from 14.8 ± 1.6 in the Leprdb/+ mice to 6.8 ± 
0.03 in the untreated Leprdb/db animals. Leprdb/db animals treated for 4 weeks with KU-32 
showed a significant improvement in MRC and SRC, and the RCR increased to 12.5 ± 
0.5 versus untreated Leprdb/db animals, suggesting that modulating molecular chaperones 
increased the capacity for mitochondrial substrate oxidation. 
Not surprisingly, MRC and SRC remained significantly impaired in the 18-week-old 
Leprdb/db animals compared with the Leprdb/+ mice, and continued therapy with KU-32 
improved MRC and SRC, but not really beyond levels observed after 4 weeks of drug 
administration (Figure 2.3-3, C and D). However, KU-32 therapy exerted a prolonged 
effect on neuronal mitochondrial function because the improvement in SRC promoted by 
4 weeks of KU-32 therapy (Figure 2.3-3B) was maintained 4 weeks after drug 
administration was terminated (Figure 2.3-3D). This result was similar to the continued 
increase in nerve electrophysiology that was observed 4 weeks after drug withdrawal. 
Lastly, to determine whether the improved bioenergetics might be due to an increase 
in mitochondrial biogenesis, the levels of cytochrome b and cytochrome c oxidase 
subunit II (mitochondrial genes) in the DRG from the 18-week-old mice were assessed 





expression of both genes was expressed as the fold of the level present in vehicle-treated 
Leprdb/+ mice. However, no differences were observed in the untreated (1.01 ± 0.08, n = 3) 







Figure 2.3-3: KU-32 improves mitochondrial bioenergetics in Leprdb/db mice.  
Sensory neurons were obtained from 14- (A and B) or 18-week- (C and D) old Leprdb/db and 
Leprdb/+ mice treated with KU-32 or Captisol and prepared for bioenergetic analysis. (A) MRC 
was significantly impaired in untreated Leprdb/db compared with age-matched Leprdb/+ mice, and 
this deficit was significantly improved by KU-32 treatment. (B) Fourteen-week-old Leprdb/db mice 
have a significant decrease in SRC and an increase in ATP-linked and nonmitochondrial 
respiration compared with age-matched Leprdb/+ mice, and these parameters were significantly 
improved by KU-32 therapy. (C) At 18 weeks of age MRC remained significantly impaired in the 
Leprdb/db compared with age-matched Leprdb/+ mice. However, MRC was essentially unchanged 
from 14-week-old untreated Leprdb/db. (D) MRC and SRC remained significantly improved in 
KU-32 treated Leprdb/db mice regardless of whether the drug was give continuously or withdrawn 
for the final 4 weeks of the study. In (A–D), *, p < 0.05 versus Leprdb/+ + vehicle (Veh); ^, p < 






2.3.4. Diabetes-Induced Hypoalgesia Precedes Decreased Mitochondrial Function 
in a Model of Type 1 Diabetes  
Because it is unclear whether changes in mtBE and sensory function follow similar 
patterns in type 1 and type 2 diabetes, this was examined using Swiss Webster mice 
rendered diabetic with STZ (Table 2.3-2). By 12 weeks of diabetes, the mice developed a 
significant mechanical (Figure 2.3-4A) and thermal (Figure 2.3-5A) hypoalgesia. 
However, these early sensory deficits were not associated with a significant impairment 
in mitochondrial respiration since SRC was significantly impaired only after 16 weeks of 
diabetes (Figure 2.3-4B).  
To determine whether improved sensory function following treatment with KU-32 
was linked to an improvement in mtBE, drug therapy was initiated at week 17, and 
sensory neurons were harvested 1, 3, and 5 weeks after drug administration. Prior to drug 
treatment, the mice showed significant decreases in nerve conduction velocities (Figure 
2.3-5B) along with the thermal and mechanical hypoalgesia. Although 1 week of KU-32 
administration did not increase the diabetes-induced decline in mitochondrial respiration, 
continued treatment revealed a tight temporal correlation between an improved SRC 
(Figure 2.3-4B) and recovery from the mechanical hypoalgesia (Figure 2.3-4C), MNCV 







Figure 2.3-4: Sensory hypoalgesia precedes the onset of mitochondrial bioenergetics 
deficits in a type 1 model of diabetes.  
Swiss Webster mice were rendered diabetic with STZ, mechanical sensitivity measured at 
the indicated weeks, and sensory neurons isolated after 10, 12, and 16 weeks of diabetes to assess 
mitochondrial function. After 17 weeks of diabetes, KU-32 was given weekly and sensory 
neurons isolated 1, 3, and 5 weeks after drug administration to assess mitochondrial function. (A) 
Diabetes induced a mechanical hypoalgesia that was maximal after 13 weeks and was reversed by 
KU-32 treatment. *, p < 0.05 versus time-matched vehicle (Veh) + Veh; ^, p < 0.05; ^^, p < 0.01; 
^^^, p < 0.001, versus time-matched STZ + Veh for all p values. (B) SRC was significantly 
decreased after 16 weeks of diabetes, and initiation of KU-32 therapy led to a time-dependent 
recovery of SRC that correlated with improvements in mechanical hypoalgesia (C) and MNCV 








Figure 2.3-5: Effect of Diabetes and KU-32 Therapy on Thermal Hypoalgesia, NCV 
and Mitochondrial Bioenergetics.  
Swiss Webster mice were rendered diabetic with STZ and thermal sensitivity assessed at the 
indicated weeks. After 17 weeks of diabetes, KU-32 was given weekly and at 1, 3 and 5 weeks 
after drug administration, NCV was measured and sensory neurons were isolated to assess 
mitochondrial bioenergetics. A) Diabetes induced a thermal hypoalgesia that was reversed by 
KU-32 treatment. *, p < 0.05, **, p < 0.01 vs time-matched Veh + Veh; ^, p < 0.05 vs time-
matched STZ + Veh. B) Both MNCV and SNCV were decreased after 16 weeks of diabetes (0 
weeks KU-32) and drug therapy improved these deficits. *, p < 0.05 vs Veh + Veh; ^, p < 0.05 vs 
STZ + Veh; #, p < 0.05 vs STZ + 1 week KU-32. (C) Correlation between recovery of SRC and 






Table 2.3-2: Weight, FBG, and HbA1c of Swiss Webster mice. 
Veh, vehicle. 
a mmol of HbA1c/mol of hemoglobin. 










10 Veh + Veh 34.1 ± 2.5 127 ± 12 — 4 
STZ + Veh 27.3 ± 1.1* 540 ± 96* — 4 
12 Veh + Veh 34.0 ± 1.7 122 ± 10 5.0 ± 0.4 (31 ± 4.4) 6 
  STZ+ Veh 30.3 ± 3.9* 600* 12.9 ± 0.2* (117 ± 2.2)  7 
16 Veh + Veh 43.0 ± 3.1 117 ± 6 5.4 ± 0.7 (36 ± 7.7) 4 
STZ + Veh 28.6 ± 4.1* 573 ± 54* 11.7 ± 0.9* (104 ± 9.8)  4 
18 Veh + Veh 43.8 ± 3.1 114 ± 15 4.7 ± 0.2 (28 ± 2.2) 4 
STZ + Veh 29.3 ± 4.2* 564 ± 35* 9.9 ± 1.8* (85 ± 19.7) 4 
Veh + KU-32 39.2 ± 2.2 138 ± 18 4.6 ± 0.3 (27 ± 3.3) 4 
STZ + KU-32 30.8 ± 1.7* 589 ± 21* 10.7 ± 0.8 * (93 ± 8.7) 4 
20 Veh + Veh 40.2 ± 3.9 125 ± 9 4.9 ± 0.2 (30 ± 2.2) 4 
STZ + Veh 32.7 ± 2.8* 600* 12.1 ± 0.6* (109 ± 6.6)  4 
Veh + KU-32 41.4 ± 2.6 120 ± 1 5.2 ± 0.6 (33 ± 6.6) 4 
STZ + KU-32 33.0 ± 6.0* 600* 12.1 ± 0.9* (109 ± 9.8)  3 
22 Veh + Veh 44.0 ± 0.6 123 ± 10 5.1 ± 0.1 (32 ± 1.1) 4 
STZ + Veh 30.3 ± 2.6* 600* 10.2 ± 1.7 * (88 ± 18.6)  3 
Veh + KU-32 43.0 ± 2.6 120 ± 1 4.8 ± 0.3 (29 ± 3.3) 4 





2.3.5. Hsp70 Is Necessary to Improve Mitochondrial Bioenergetics following KU-32 
Therapy  
We have shown previously that Hsp70 was necessary for the beneficial effect of KU-
32 on improving insensate DPN (Urban et al., 2010). To examine whether the 
improvement in mtBE also required Hsp70, we compared the effect of KU-32 therapy on 
WT and Hsp70 KO mice rendered diabetic with STZ (Table 2.3-3). Diabetic WT and 
Hsp70 KO mice developed a mechanical hypoalgesia (Figure 2.3-6, A and B) and 
MNCV deficits (Figure 2.3-6, C and D). Thermal sensitivity and SNCV responded 
similarly (Figure 2.3-7, A–D). After 12 weeks of diabetes, the sensory deficits were well 
established, and although initiating weekly KU-32 therapy improved all the sensory 
endpoints in the WT mice, this response was totally absent in the drug-treated, diabetic, 
Hsp70 KO mice.  
After 15 or 18 weeks of diabetes, MRC (Figure 2.3-8, A and B) and SRC (Figure 
2.3-8, C and D) showed a similar decline in WT and Hsp70 KO mice. Thus, Hsp70 does 
not contribute to the diabetes-induced decline in mtBE. On the other hand, 3–6 weeks of 
KU-32 therapy improved MRC and SRC in diabetic WT mice but neither respiratory 
parameter was altered by the drug in diabetic Hsp70 KO mice. Importantly, the lack of 
efficacy of KU-32 in the Hsp70 KO mice is unlikely to result from differences in drug 
uptake or metabolism, since similar levels of KU-32 were present in DRG, sciatic nerve, 
and foot pads of WT and Hsp70 KO mice (data not shown). These data support the 
conclusion that Hsp70 is required to improve mtBE and sensory function following KU-







Figure 2.3-6: Hsp70 is necessary for KU-32 to reverse mechanical deficits of DPN.  
C57Bl/6 wild type (A and C) and Hsp70 KO (B and D) mice were rendered diabetic with 
STZ and after 12 weeks of diabetes, KU-32 was given weekly for 6 weeks. Mechanical 
sensitivity (A and B) was assessed at the indicated weeks and MNCV (C and D) was assessed 
after 18 weeks of diabetes. In all panels, *, p < 0.05 versus time matched vehicle (Veh) + Veh; ^, 







Figure 2.3-7: Hsp70 is necessary for KU-32 to reverse thermal deficits DPN.  
C57Bl/6 (A, C) and Hsp70 KO (B, D) mice were rendered diabetic with STZ and at 12 
weeks of diabetes, KU-32 was given weekly for 6 weeks. Thermal sensitivity (A, B) was assessed 
at the indicated weeks and SNCV (C, D) was assessed after 15 (3 weeks KU-32) and 18 weeks (6 
weeks KU-32) of diabetes. *, p < 0.05 vs Veh + Veh; ^, p < 0.05 vs STZ + Veh. Symbol and bar 







Figure 2.3-8: Hsp70 is necessary for KU-32 to improve mitochondrial bioenergetics. 
C57Bl/6 wild-type (A and C) and Hsp70 KO (B and D) mice were rendered diabetic with 
STZ and after 12 weeks of diabetes, KU-32 was given weekly for 6 weeks. Sensory neurons were 
isolated 3 and 6 weeks after drug administration to assess mtBE. Diabetes decreased MRC (A and 
B) and SRC (C and D) in both C57Bl/6 and Hsp70 KO, but KU-32 therapy only improved these 
deficits in the diabetic C57Bl/6 mice. Oligomycin, FCCP, and rotenone/antimycin were injected 
at the times indicated by a, b, and c, respectively. *, p < 0.05 versus vehicle (Veh) + Veh; ^, p < 






Table 2.3-3: Weight, FBG, and HbA1c of C57Bl/6 and Hsp70 KO mice. 
Weeks Treatment 



















4.7 ± 0.2 (28 ± 
2.2) 




4.6 ± 0.2 (27 ± 
2.2) 
7 




9.9 ± 1.58 (85 ± 
17) 













4.5 ± 0.2 (26 ± 
2.2) 













8.0 ± 1.5* (64 ± 
17) 




8.4 ± 1.2* (68 ± 
13.1) 
5 




4.7 ± 0.1 (28 ± 
1.1) 




5.0 ± 0.1 (31 ± 
1.1) 
8 




8.2 ± 0.7* (66 ± 
7.7) 













4.8 ± 0.2 (29 ± 
2.2) 













8.5 ± 1.9* (69 ± 
21) 








a mmol of HbA1c/mol of hemoglobin. 
* p < 0.05 versus Veh + Veh. 
2.4. Discussion 
Mitochondrial Dysfunction and the Onset of DPN in Type 2 Diabetes 
Similar to previous results in models of type 1 diabetes (Chowdhury et al., 2012; 
Urban et al., 2012b), we observed deficits in multiple bioenergetic parameters in sensory 
neurons obtained from Leprdb/db animals, a genetic model of type 2 diabetes. Although 
prior results have clearly implicated mitochondrial dysfunction in the development of 
insensate DPN in type 1 diabetes (Chowdhury et al., 2013; Fernyhough et al., 2010), our 
results are the first to temporally link the kinetics of onset of the bioenergetic deficits 
with the developing hypoalgesia in a model of type 2 diabetes. 
The Leprdb/db mice showed significant deficits in MRC and SRC 4–6 weeks after the 
onset of hyperglycemia, which correlated with the rapidly developing sensory 





oxidation that the sensory neurons can achieve in the absence of limitations imposed by 
the proton gradient across the inner mitochondrial membrane. The decrease in MRC 
suggests that electron transport in the diabetic mitochondria was impaired or that 
availability of substrates such as glucose and pyruvate was limiting. Although substrate 
availability might be affected by decreased activity of glycolysis and the tricarboxylic 
acid cycle as observed in 24-week-old Leprdb/db mice (Hinder et al., 2013b), the rate of 
extracellular acidification, a measure of glycolytic activity, was relatively similar 
between the Leprdb/db and Leprdb/+ mice (data not shown). The similar levels of 
extracellular acidification suggest that the deficit in ATP production is either not 
sufficient to stimulate glycolysis or the diabetic neurons do not effectively revert to 
glycolysis to help produce ATP. Indeed, as observed by others (Chowdhury et al., 2012), 
the percent of the basal OCR that was attributable to ATP-linked respiration increased in 
the 10–18-week-old Leprdb/db compared with the Leprdb/+ mice. Presumably, since the 
maximal rate of electron transport and substrate oxidation is compromised in the diabetic 
neurons, a greater portion of total respiration is commitment toward ATP-production to 
meet cellular demands. 
SRC provides an indication of how close a cell is functioning to its bioenergetic limit 
(Sansbury et al., 2011). The progressive decline in SRC suggests that the diabetic neurons 
have a diminished energetic reserve to respond to the continued metabolic challenges 
associated with the chronic hyperglycemia and dyslipidemia in the Leprdb/db mice. 
Because KU-32 significantly improved SRC and NCV even after 4 weeks of drug 
withdrawal, moderate improvements in respiratory function via modulating chaperones 





ATPase activity is associated with slowing of MNCV in DPN (Coppey et al., 2001), and 
improved mitochondrial function may contribute to ameliorating this deficit. 
Lastly, an unexpected outcome of our study was the significant improvement in SRC 
in the nondiabetic Leprdb/+ mice treated with KU-32 for 8 weeks. The underlying reason 
for this improvement is unclear but may be related to the decreased mitochondrial 
respiratory capacity that was observed in the vehicle-treated 18-week-old Leprdb/+ mice 
(compare black squares in Fig. 4, A and C). The decreased respiratory capacity between 
untreated 14- and 18-week-old Leprdb/+ mice was observed in the testing of two separate 
groups of animals from different litters and suggests that the Lepr mutation may have an 
age-related effect on mitochondrial function. 
Mitochondrial Dysfunction and the Onset of DPN in Type 1 Diabetes 
In the type 1 model, diabetic mice developed a mechanical and thermal hypoalgesia 
between 6–12 weeks in the absence of significant decreases in SRC. However, 
mitochondrial respiration was significantly reduced after 16 weeks of diabetes. These 
data suggest that a fundamental difference may exist in the temporal role of altered mtBE 
in contributing to the early onset of hypoalgesia in type 1 versus type 2 diabetes. Because 
both models showed relatively similar levels of hyperglycemia, differences in the kinetics 
of onset of the bioenergetic decline may be influenced by insulin resistance, which is 
coincident with mitochondrial dysfunction in tissues such as oxidative skeletal muscle 
and liver of the Leprdb/db mice (Holmstrom et al., 2012). Alternatively, dyslipidemia is 
often associated with type 2 diabetes and has been suggested to contribute to DPN 
(Vincent et al., 2009). However, genetic deletion of apolipoprotein E to increase 





(Hinder et al., 2013a), suggesting that dyslipidemia may not significantly worsen sensory 
neuron mitochondrial dysfunction in type 2 diabetes. 
Modulating Hsp70 Improves mtBE and DPN 
Although the onset of a thermal and mechanical hypoalgesia does not require a 
significant change in mtBE in the type 1 model, the improvement in the psychosensory 
and electrophysiologic measures of nerve function in both diabetic animal models tightly 
correlated with an increase in mtBE following KU-32 therapy. The absence of this 
correlation in the diabetic Hsp70 KO mice provides the first evidence that modulating 
Hsp70 is a necessary effector for KU-32 to improve the bioenergetic profile of the 
sensory neurons and nerve function. This benefit was unrelated to any effect of KU-32 or 
Hsp70 on improving glucose disposal or any of the metabolic parameters in either model. 
However, a clear limitation of this work is that although a tight, Hsp70-dependent 
correlation exists between improved mtBE and the various measures of nerve function, a 
causal relationship between them is not established. Thus, we cannot rule out that Hsp70 
may have independent and parallel effects on mtBE and other targets that contribute to 
improving psychosensory and electrophysiologic function following KU-32 therapy. 
Although the etiology of DPN is not attributed to the accumulation of a specific 
misfolded or aggregated protein, the efficacy of Hsp70 in improving mtBE suggests that 
diabetic mitochondria are undergoing some level of proteotoxic stress. Because KU-32 
can decrease oxidative stress and increase mitochondrial and cytosolic chaperones in 
hyperglycemically stressed primary sensory neurons, these factors may directly 
contribute to improving mtBE and SRC in diabetic mice (Zhang et al., 2012). In this 





amino acids (Akude et al., 2010) that may impair protein folding within mitochondria 
(Muchowski and Wacker, 2005), decrease mitochondrial protein import (Baseler et al., 
2011), and promote mitochondrial dysfunction (Tomlinson and Gardiner, 2008). In the 
mitochondrial proteome, ~99% of the mitochondrial proteins are encoded by nuclear 
genes and imported into the organelle from cytosol and Hsp70 serves as a chaperone for 
hydrophobic precursors of inner mitochondrial membrane proteins (Schmidt et al., 2010). 
Because Hsp70 is not a resident mitochondrial chaperone, determining whether it might 
mitigate diabetes-induced dysfunction in mtBE by facilitating the import, removal, and/or 
replacement of damaged mitochondrial proteins is an important biologic question with 
clear therapeutic relevance to treating DPN. 
The reliance on Hsp70 for the tight correlation between improved mtBE and the 
physiologic measures of DPN adds to the evidence that modulating molecular chaperones 
may benefit various neurodegenerative diseases where mitochondrial respiratory function 
is compromised (Ouyang et al., 2006; Xu et al., 2010). However, it may be critical to 
limit the extent of Hsp70 induction since overexpression of Hsp70 in HeLa cells inhibited 
oxidative phosphorylation and augmented anaerobic glycolysis (Wang et al., 2012). As 
certain malignant phenotypes are characterized by Hsp70 overexpression and increased 
glycolytic rates, the efficacy of modulating Hsp70 to enhance neuronal mtBE might rely 
on pharmacologic agents that are weak or cell-selective inducers of Hsp70. Although 
glycolytic activity decreases in diabetic nerve (Hinder et al., 2013b), additional work will 
be needed to determine if long-term modulation of Hsp70 might negatively affect 





In summary, numerous approaches toward treating insensate DPN have centered on 
inhibiting specific pathogenic pathways linked to glucotoxicity, with limited translational 
success (Calcutt et al., 2009). The pharmacologic management of insensate DPN is 
difficult since no single etiologic event has been unequivocally identified to contribute to 
disease development in a temporally and/or biochemically uniform fashion over the long 
natural history of the disease. Since pharmacologic modulation of endogenous 
neuroprotective chaperones does not rely on targeting a specific pathogenic enzyme (i.e., 
aldose reductase) or pathway (i.e., oxidative stress) that contributes to DPN, it provides a 
venue to complement etiocentric therapies. Coupled with close attention toward obtaining 
glycemic goals, modulating molecular chaperones may aid the medical management of 






Chapter 3: Novologue Therapy Improves Mitochondrial Bioenergetics and 
Modulates Transcriptome Changes Involved in Inflammatory Pathways and 
Production of Reactive Oxygen Species in Diabetic Sensory Neurons 
Abstract 
We have previously demonstrated that modulating heat shock protein 90 (Hsp90) 
and Hsp70 with the small molecule drug, KU-32, ameliorates physiologic and 
bioenergetic deficits of DPN in animal models of both type 1 and type 2 diabetes. In the 
current study, we sought to determine whether KU-596, an analogue of KU-32, offers 
similar therapeutic potential for treating DPN. Similar to KU-32, KU-596 improved 
psychosensory and bioenergetic deficits of DPN in a dose-dependent manner. However, 
the drug could not improve DPN in Hsp70 KO mice. Transcriptomic analysis using RNA 
sequencing (RNA-Seq) of DRG from diabetic wild type (WT) and Hsp70 KO mice 
revealed that KU-596 modulated transcription of genes involved in inflammatory 
pathways independently of Hsp70. In contrast, the effects of KU-596 on genes involved 
in the production of reactive oxygen species (ROS) are Hsp70-dependent. Our data 
indicate that modulation of molecular chaperones offers an effective approach towards 
correcting nerve dysfunction, and that normalization of inflammatory pathways alone by 
novologue therapy seems to be insufficient to reverse the deficits associated with 
insensate DPN in our model of type 1 diabetes.  
3.1. Introduction  
Diabetes has emerged as a major public health care concern worldwide, with the 
number of diabetic patients estimated to exceed 500 million by 2030 (Whiting et al., 





complications, affects patients with both type 1 and type 2 diabetes and greatly reduces 
quality of life. Thus, great efforts have been put into identifying mechanisms of disease 
pathogenesis in order to develop therapeutic approaches for its effective control and 
treatment. However, despite our increased understanding of the etiology of DPN, little 
progress has been made in treating the disease. To date, none of the agents targeting the 
pathogenic pathways have shown effectiveness in reversing, preventing, or even slowing 
disease progression. Currently, the only effective control of DPN remains to be tight 
glycemic control and lifestyle interventions, and this is only more effective in type 1 
versus type 2 diabetics. Therefore, we have sought to target the disease from a different 
angle, through reinforcing innate cytoprotective mechanisms. Our results indicated that 
pharmacological manipulation of molecular chaperones might offer the therapeutic 
potential for reversing sensory deficits associated with DPN (Urban et al., 2010).   
Hsp90 and Hsp70 function as molecular chaperones that are essential for the folding 
of nascent polypeptides and refolding of denatured proteins. Pharmacological inhibition 
of Hsp90 with KU-32, a first-generation novobiocin-based, C-terminal Hsp90 inhibitor, 
decreased glucose-induced death of primary sensory neurons and improved 
psychosensory, electrophysiologic, morphologic and bioenergetic deficits of DPN in an 
Hsp70-dependent manner (Li et al., 2012; Ma et al., 2014; Urban et al., 2012a; Urban et 
al., 2010; Zhang et al., 2012). Though KU-32 was found to be quite efficacious in 
treating DPN, it is cumbersome to make synthetically and efforts had been made to 
determine if diversification of its coumarin ring scaffold could identify structure-activity 
relationships (SAR) that might enhance the neuroprotective properties of the analogs, 





Based on molecular modeling of KU-32 docked to the Hsp90 C-terminal binding 
pocket, it was observed that the coumarin lactone of KU-32 appeared too distant from 
Lys539 to provide complementary interactions with this residue. Additionally, the 3-
amido side chain of KU-32 projected into a large hydrophobic pocket that could 
accommodate more flexible linkers. Consequently, novologues (novobiocin analogues) 
were designed to contain a biphenyl scaffold that replaced the coumarin lactone of KU-
32 (Figure 3.1-1A). It was hypothesized that the B-ring of the biphenyl would project into 
the Hsp90 C-terminal binding pocket and serve as a lead compound for further 
diversification. Subsequent modifications identified that electronegative atoms placed at 
the meta-position of the benzene ring exhibited improved cytoprotective activity, which 
is believed to result from favorable interactions with Lys539 in the Hsp90 C-terminal 
binding pocket (Kusuma et al., 2012). Consistent with these results, KU-596 (Figure 3.1-
1B) was identified as a meta-3-fluorophenyl substituted novologue that exhibited a 14-
fold lower ED50 for protecting primary sensory neurons against glucotoxicity compared 
with KU-32. In addition, treating 50B11 cells (an immortalized sensory neuron cell line) 
with KU-596 led to increased Hsp70 expression in the absence of client protein 
degradation (Kusuma et al., 2012). Thus, in the current study, we sought to determine if 
the novologue KU-596 displays similar cytoprotective effects in animal models of DPN 






Figure 3.1-1: Structure-activity relationships of KU-32 analogues.  
(A) Structure of novologue and its attributes. (B) Structure of KU-596.  
Our previous studies have shown that manipulating molecular chaperones through 
improved multiple clinical indices of DPN, and that these neuroprotective effects were 
dependent on the stress-inducible form of Hsp70. Mechanistic studies have revealed that 
KU-32 restored mitochondrial respiratory capacity and reduced oxidative stress in the 
sensory neurons, which likely contributes to its protective efficacy (Zhang et al., 2012). 
However, since Hsp70 may contribute to improving insensate DPN by affecting diabetes-
induced changes in protein folding, stability and clearance (Evans et al., 2010), we 
hypothesized that multiple genes/gene networks within sensory neurons may contribute 
to the reversal of insensate DPN in an Hsp70-dependent manner.  
The application of system biology approaches has yielded novel insight into gene 
networks that contribute to the development of DPN in animal models of type 2 diabetes 
(Hinder et al., 2013b; Pande et al., 2011) and which distinguish humans with progressive 
versus non-progressive DPN, i.e., induction of the c-jun network (Hur et al., 2011). 
Though the use of microarrays has successfully defined diabetes-induced changes in the 





fold) and lack sensitivity for quantifying genes expressed either at low or very high levels 
due to background array signals or signal saturation (Wang et al., 2009). In contrast, high 
throughput transcript sequencing (RNA-Seq) has a dynamic range spanning five orders 
of magnitude and permits detecting abundant and even very rare transcripts, with 
sufficient sequencing depth (Mortazavi et al., 2008). RNA-Seq allows identifying and 
quantifying splice variants and provides a digital readout of gene expression since it is 
based on counting reads (# of sequence events), a direct measure of transcript abundance. 
Since RNA-Seq is emerging as a more versatile approach for quantitative transcriptomics, 
we examined transcriptomic changes within sensory neurons that contribute to the 
reversal of insensate DPN using RNA-Seq.  
The RNA-Seq approach utilizes deep-sequencing technologies and is gaining 
prominence as a means of accurate transcriptome profiling (Wang et al., 2009). This 
method provides millions of sequences from expressed RNA molecules, and has been 
shown to provide highly accurate and reproducible results for quantitative 
characterization of the expressed complement of a genome with the requirement of less 
RNA sample (t Hoen et al., 2008). In general, a population of RNA (total or fractionated, 
for example poly(A)+ selected) is fragmented and converted to a library of cDNA 
fragments with adapters attached to one or both ends. The cDNA library is then 
sequenced in a high-throughput manner to obtain short sequences from one end (single-
end sequencing) or both ends (paired-end sequencing). The reads are typically 30-400 
base pairs (bp), depending on the DNA sequencing technology used. Following 
sequencing, the resulting reads are either aligned to a reference genome, or assembled de 





can be obtained through bioinformatics analysis of the sequencing data (Wang et al., 
2009). Recent studies have shown that the RNA-Seq approach is more sensitive at 
detecting low expression transcripts compared to microarray technology. Direct 
determination of the cDNA sequences also circumvents background noise associated with 
fluorescence quantification in traditional microarrays (Fang et al., 2012). In addition, the 
entire transcriptome can be surveyed without the requirement of a priori knowledge of 
transcribed regions, which enables the discovery of novel transcripts. Furthermore, since 
RNA-Seq allows genome-wide analysis of transcription at single nucleotide resolution, 
transcript structures including alternatively spliced transcript isoforms and post-
translational RNA editing events can also be identified (Wilhelm and Landry, 2009). 
In this study, we define changes in the transcriptome of sensory neurons from 
C57Bl/6 and Hsp70 KO mice to determine the transcriptome targets of KU-596 and the 
Hsp70 dependency of these changes. Our results indicate that KU-596 improved sensory 
function and bioenergetic profile of sensory neurons. However, the effects of KU-596 on 
mitochondrial bioenergetics (mtBE) was likely exerted through post-translational 
modulation of mitochondrial proteins rather than through transcriptional modification of 
mitochondrial genes. In contrast, KU-596 reversed diabetes-associated transcriptome 
changes involved in inflammatory pathways and the production of ROS. Despite the lack 
of efficacy in reversing sensory deficits of DPN, the effects of KU-596 on inflammatory 
genes persisted in the absence of Hsp70. This finding suggests that normalization of 
inflammatory pathways alone might not be enough to reverse sensory deficits associated 
with insensate DPN. These data provide novel insight into the role of mitochondrial 





consolidate the therapeutic potential of modulating molecular chaperones as a treatment 
for DPN. 
3.2. Materials and Methods 
Streptozotocin (STZ), carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone 
(FCCP), oligomycin, rotenone, antimycin A, Percoll, and poly(DL)ornithine were 
obtained from Sigma-Aldrich (St. Louis, MO). KU-596, N-(2-(5-(((3R,4S,5R)-3,4-
Dihydroxy-5-methoxy-6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3’-fluoro-[1,1’-
biphenyl]-2-yl)ethyl)-acetamide, was synthesized and structural purity (>95%) verified as 
described previously (Kusuma et al., 2012).  
Animals 
Male Swiss Webster Mice were purchased from Harlan Laboratories (Indianapolis, 
IN). Male and female wild-type (WT) C57Bl/6 and Hsp70.1/70.3 double knockout (KO) 
mice on a C57Bl/6 background (Hsp70 KO) were obtained from in-house breeding 
colonies (Urban et al., 2010). Diabetes was rendered in 8-week-old male and female mice 
with an intraperitoneal injection of 100 mg/kg STZ given on two consecutive day after 6-
hour of fasting. Mice were fasted 6 hours for fasting blood glucose (FBG) measurement 
one week after the second injection, and mice with FBG ≥ 290 mg/dl (16 mM) were 
deemed diabetic. KU-596 was introduced to Swiss Webster mice after 8 weeks of 
diabetes through intraperitoneal injections with a dose of 2 mg/kg, 10 mg/kg, or 20 mg/kg 
in 0.1 M Captisol (β-cyclodextrin sulfobutylethers; CyDex Pharmaceuticals, Lenexa, KS). 
In C57Bl/6 and Hsp70 KO mice, a dose of 20 mg/kg KU-596 in 0.1 M Captisol was 
given through oral gavage after 12 weeks of diabetes. Weekly administration of KU-596 





for 4 weeks. Each group contained at least 8 mice and were randomly assigned to each of 
the 6 treatment groups using a random number generator. 
All animals were maintained on a 12-hour light/dark cycle with ad libitum access to 
water and 7022 NIH-07 rodent chow (5.2% fat). All animal procedures were performed 
in accordance with protocols approved by the Institutional Animal Care and Use 
Committee and in compliance with standards and regulations for the care and use of 
laboratory rodents set by the National Institutes of Health. 
Psychosensory and Electrophysiologic Analyses 
Mechanical sensitivity was assessed using a Dynamic Plantar Aesthesiometer 
(Stoelting Inc.) fitted with a stiff monofilament that was applied to the plantar surface at 
an upward force of 10g for Swiss Webster mice or 8g for C57Bl/6 and Hsp70 KO mice. 
Thermal sensitivity was assessed by paw withdrawal latency to a ramping, focal heat 
using a Hargreaves Analgesiometer (Stoelting Inc.) (Urban et al., 2010). Responses from 
each animal were measured four times on alternate feet and averaged. At the end point of 
a study, animals were anesthetized prior to measuring motor and sensory nerve 
conduction velocities (MNCV and SNCV) as previously described (McGuire et al., 2009). 
Animals were then euthanized prior to tissue collection. 
Mitochondrial Bioenergetics Assessment 
Oxygen consumption rate (OCR) was assessed in intact lumbar DRG sensory 
neurons using the XF96 Extracellular Flux Analyzer (Seahorse Biosciences, North 
Billerica, MA). Lumbar sensory neurons were isolated as previously described (Ma et al., 
2014), and maintained overnight in Ham’s F10 medium (6.1 mM glucose) containing 50 





(Invitrogen, Carlsbad, CA). The following day, the cells were placed in assay medium 
(unbuffered Dulbecco’s modified Eagle’s medium supplemented with 1 mM sodium 
pyruvate and 5.5 mM D-glucose) at 37°C for one hour before being introduced to the 
XF96 analyzer. The initial readings provide a measure of the basal OCR before the 
addition of respiratory chain poisons (Brand and Nicholls, 2011). The addition of 
oligomycin (1 µg/ml), the ATP synthase inhibitor, leads to a decrease in OCR which 
represents the portion of basal OCR that is coupled to ATP synthesis. The residual OCR 
that persists after addition of oligomycin is from uncoupled respiration (proton leak). 
Next, maximal respiratory capacity (MRC) was assessed following addition of the 
protonophore FCCP (1 µM) which dissipates the proton gradient across the inner 
mitochondrial membrane. Non-mitochondrial respiration was then assessed by 
coinjection of 1 µM rotenone + 1 µM antimycin A. After the respiratory measures, the 
cells were harvested and OCR values were normalized to the total protein content of each 
well. Maximal respiratory capacity (MRC) and spare respiratory capacity (SRC) were 
determined and quantified as described previously (Brand and Nicholls, 2011; 
Chowdhury et al., 2012). 
Isolation of RNA 
L4-L6 lumbar DRG from two animals were pooled together for the isolation of one 
total RNA sample. Each treatment group consists of 3-4 biological replicates. Tissues 
were harvested and rapidly frozen in liquid nitrogen for storage, and subsequently ground 
in liquid nitrogen. After the homogenization, 900 ml of Trizol was added to each sample 
and RNA was isolated following the standard protocol of the Qiagen RNeasy Plus 





checked with the Agilent 2200 TapeStation (Agilent Technologies, Santa Clara, CA) and 
Qubit Fluorometric Quantitation (Life Technologies, Carlsbad, CA), respectively. RNA 
with an integrity number (RIN) ≥ 7 was used for RNA-Seq analysis or qRT-PCR analysis 
(Figure 3.2-1).  
 
Figure 3.2-1: An example of RNA integrity analysis using the 2200 TapeStation 
instrument.  
Tiny amounts of RNA samples (1-2 μl) were separated in the channels of the 
microfabricated chips according to their molecular weights and subsequently detected via laser-
induced fluorescence detection. (A) Electrophoresis micro-gel image of the ladder (left lane) and 
the RNA sample (right lane). The two high intensity bands at the upper part of the gel indicated 
by arrow heads comprise the 28S and 18S ribosomal RNA (rRNA) species and other bands 
represent the migration of smaller RNA species. Increased intensity of lower molecular weight 
bands indicates RNA degradation. (B) Electropherogram of the RNA sample. The amplitude of 
each slope corresponds to the band intensity on the gel. A shift towards shorter fragment sizes 







For RNA-seq analysis, 100 ng of total RNA was used to prepare cDNA libraries with 
the TruSeq Stranded Total RNA Library Prep Kit (Illumina Inc., San Diego, CA). The 
procedures of library preparation is shown in Figure 3.2-2 (Corney, 2013). In general, 
poly(A)+ containing mRNA molecules were purified with oligo-dT attached magnetic 
beads. Purified mRNA was then fragmented and primed with random hexamers, which 
were subsequently reverse transcribed into first strand cDNA using reverse transcriptase. 
The RNA templates were then removed from the single-strand cDNA, and a replacement 
strand was synthesized to generate double-strand cDNA. The double-strand cDNA was 
end-repaired and adenylated at the 3’ ends. For each sample, Illumina-specific adaptors 
that contain a unique 6 bp index sequence that specifically identifies each sample were 
ligated to the 3’ adenine-tail of the fragments to permit the single read, multiplex 
sequencing of transcripts within each lane of the flow cell. cDNA products (~260 bp) 
were amplified and submitted to quality control with the Agilent 2200 TapeStation 
(Agilent Technologies, Santa Clara, CA). cDNA libraries prepared from 3-4 biological 
replicates from each treatment group were then randomly assigned to two lanes of the 
flow cell for subsequent single-end sequencing with a read length of 100 bases using the 






Figure 3.2-2: Process of library preparation.  
Poly(A)+ RNA is enriched using oligo(dT) beads followed by fragmentation and reverse 
transcription. The 5’ and 3’ ends of cDNA fragments are next prepared to allow efficient ligation 
of “Y” adapters containing a unique barcode and primer binding sites. Finally, ligated cDNAs are 






Bioinformatics Analysis of RNA-Seq Data 
After the initial processing and de-multiplexing steps, the resulting FASTQ files 
were analyzed via the Galaxy Project web-based interface (http://usegalaxy.org/) linked 
to the freely available Tuxedo Suite (Figure 3.2-3) (Trapnell et al., 2012). FASTQ files 
were quality checked, groomed if necessary, and then submitted to the Tophat module to 
align the short read sequences to the mouse genome (mm9). The Cufflinks package was 
then used for transcript assembly, and annotation of each sample. The resulting files were 
merged using CuffMerge. The CuffMerge output and Tophat files were loaded into the 
CuffDiff module to quantify significant changes in transcript expression between groups 
(Goecks et al., 2010; Trapnell et al., 2013). Gene level expression data were normalized 
to obtain fragments per kb per millions of aligned reads (FPKM), and the log 2 fold 
changes between groups were calculated based on the FPKM data. A t-test was used to 
calculate the p-value for differential gene expression in the Cuffdiff module, the resulting 
p values were adjusted by the Benjamini-Hochberg method to compute false discovery 
rate (FDR, i.e. q-value) (Rapaport et al., 2013). Those with q-value < 0.05 were deemed 
significant. CummeRbund was used for data visualization, and Ingenuity Pathway 
Analysis (http://www.ingenuity.com/products/ipa) was employed to identify and model 






Figure 3.2-3: An overview of the Tuxedo protocol.  
In an experiment involving various conditions, reads (FASTQ files) are first mapped to the 
genome with TopHat. The reads for each biological replicate are mapped independently. These 
mapped reads are provided as input to Cufflinks, which produces one file of assembled transcripts 
for each replicate. The assembly files are merged with the reference transcriptome annotation into 
a unified annotation for further analysis. This merged annotation is quantified in each condition 
by Cuffdiff, which produces expression data in a set of tabular files. These files are indexed and 
visualized with CummeRbund to facilitate exploration of genes identified by Cuffdiff as 








Quantitative Real-time PCR (qRT-PCR) was performed using the Step One Plus 
Real-Time PCR System (Life Techonologies, Carlsbad, CA). Total RNA (150 ng) was 
reverse transcribed with oligo(dT)20 primers and superscript III reverse transcriptase (Life 
Techonologies, Carlsbad, CA). 1 μl of the cDNA was used as template in subsequent 
qRT-PCR reactions. The qRT-PCR reaction was performed with the Power SYBR Green 
Master Mix (Life Techonologies, Carlsbad, CA) and custom primers (Appendix 1). The 
integrity of the PCR reaction was verified by melt curve analysis.   
Statistical Analysis 
Student’s t tests, one-way analysis of variance (AVONA), and repeated measures 
one-way ANOVA were used for between-group comparisons. Post hoc analysis were 
conducted using Tukey’s test. All data are presented as mean ± S.E.M. 
3.3. Results 
3.3.1. KU-596 Improves Sensory Functions and Mitochondrial Bioenergetics in 
Diabetic Swiss Webster Mice in a Dose-dependent Manner 
Because it is unclear whether KU-596 exhibited similar in vivo effects on improving 
sensory and bioenergetic deficits of DPN, this was examined using Swiss Webster mice 
rendered diabetic with STZ. By 8 weeks of diabetes, the mice developed significant 
mechanical and thermal hypoalgesia (Figure 3.3-1, B and C). Once a week dosing of 2 
mg/kg, 10 mg/kg, or 20 mg/kg KU-596 was initiated at week 9, and the treatment was 
continued for 6 weeks before termination of the study. After 14 weeks of diabetes, STZ-
rendered diabetic mice displayed significantly elevated FBG and HbA1c levels, and KU-





week of KU-596 treatment resulted in significantly improved mechanical, thermal 
sensitivity. KU-596 also dose-dependently improved motor and sensory NCV (Figure 
3.3-1, B-D). Both the 10 and 20 mg/kg doses showed similar efficacy in improving the 
sensory and NCV deficits suggesting that 10 mg/kg is likely a saturating dose. As the 
drug is dosed once per week, this translates to 1.42 mg/kg/day. Based on allometric 
scaling, the corresponding dose in a 70 kg human would be 0.73 mg/kg/day. 
Table 3.3-1: Weight, FBG, and HbA1c of Swiss Webster mice. 
Veh, vehicle. 
a mmol of HbA1c/mol of hemoglobin. 











Veh + Veh 35.6 ± 2.4 153 ± 42 5.2 ± 0.1 (33.3 ± 1.1) 6 
STZ + Veh 27.9 ± 2.2* 596 ± 7* 13.0 ± 0.0* (118.6 ± 0.0) 5 
STZ + 2mg/kg KU-596 30.4 ± 2.5* 554 ± 113* 12.6 ± 0.6* (114.2 ± 6.6) 6 
STZ + 10mg/kg KU-596 30.6 ± 2.1* 525 ± 128* 11.9 ± 1.3* (106.6 ± 14.3) 7 
STZ + 20mg/kg KU-596 29.0 ± 2.0* 600* 12.9 ± 0.1* (117.5 ± 1.1) 7 






Figure 3.3-1: Dose response of KU-596 in reversing mechanical, thermal hypoalgesia 
and NCV deficits in diabetic Swiss Webster mice. 
(A) Mechanical and (B) Thermal hypoalgesia in Swiss Webster mice at the indicated week 
of diabetes and weekly KU-596 therapy initiated after being diabetic for 8 weeks. (C) Effects of 6 
weeks of KU-596 treatment on MNCV and SNCV. *, p < 0.05 vs. Veh+Veh; ^, p < 0.05 vs. 







To determine whether the changes in psychosensory function and NCV were 
accompanied by improvements in mtBE, sensory neurons were isolated from the L4-L6 
lumbar ganglia at the end point of the study for bioenergetics measurement. After 14 
weeks of diabetes, the diabetic sensory neurons showed a significant decline in maximal 
respiratory capacity (MRC) and spare respiratory capacity (SRC) (Figure 3.3-2). 
Consistent with improvements in the sensory parameters of DPN, 6-week of KU-596 
treatment significantly improved mtBE of diabetic sensory neurons in a dose-dependent 
manner, with the 20mg/kg dose being the most effective. Thus, all subsequent studies 







Figure 3.3-2: KU-596 improves mitochondrial bioenergetics in Swiss Webster mice. 
(A) KU-596 improves mitochondrial bioenergetics in the sensory neurons of diabetic Swiss 
Webster mice in a dose-dependent manner. B) Spare respiratory capacity (SRC) was quantified 
and expressed as percent of the control group (Veh +Veh).  Weekly injection of KU-596 
increased SRC in a dose-dependent manner. *, p < 0.05 vs. Veh+Veh; ^, p < 0.05 vs. STZ+Veh; #, 






3.3.2. KU-596 Improves Sensory Parameters in an Hsp70-dependent Manner 
In our previous studies, the neuroprotective efficacy of KU-32 in reversing the 
psychosensory, electrophysiologic and bioenergetic deficits required the presence of 
Hsp70 as neuropathic Hsp70 KO mice were insensitive to drug treatment (Ma et al., 2014; 
Urban et al., 2010). In the current study, we determined whether the efficacy of KU-596 
also requires stress-inducible Hsp70. In this regard, C57Bl/6 and Hsp70 KO mice were 
rendered diabetic with STZ. After 12 weeks of diabetes, the mice were administered 20 
mg/kg KU-596 via oral gavage weekly for 4 weeks. By 12 weeks of diabetes, WT and 
Hsp70 KO diabetic mice showed significant decreases in their response to mechanical or 
thermal stimuli (Figure 3.3-3). In contrast, whereas 4-week of KU-596 treatment 
significantly reversed sensory hypoalgesia in the WT mice (Figure 3.3-3, A and C), drug 
treatment did not alter any of the sensory parameters in Hsp70 KO mice (Figure 3.3-3, B 
and D). Similar to our previous results with KU-32, both genotypes developed extensive 
diabetes and neither FBG, a measure of immediate blood glucose levels, nor HbA1c, a 
long-term measure of blood glucose control, were affected by novologue therapy (Table 
3.3.2). Thus, the above results suggest that the novologue KU-596 also reverses sensory 
deficits of DPN in an Hsp70-dependent manner. 
Of note, since RNA-Seq analysis of the DRG was to be performed, we did not assess 
NCV in these animals to avoid any potential changes in transcript expression due to 
insertion of the electrophysiolgic probes. Similarly, mtBE were not assessed as the DRG 






Table 3.3-2: Weight and FBG of C57Bl/6 and Hsp70 KO Mice. 














Veh + Veh 34.6 ± 
6.7 
145 ± 12 4.6 ± 0.2 
(26.8 ± 2.2) 
7 28.1 ± 
5.5 
177 ± 20 5.0 ± 0.3 
(31.1 ± 3.3) 
9 
STZ + Veh 22.6 ± 
2.0* 
540 ± 48* 9.1 ± 1.3* 
(76.0 ± 14.3) 
6 23.2 ± 
3.0* 
524 ± 80* 11.1 ± 3.3* 






157 ± 20 4.4 ± 0.2 
(24.6 ± 2.2) 
7 27.0 ± 
5.1  
168 ± 19 5.2 ± 0.2 






499 ± 82* 9.3 ± 2.7* 
(78.1 ± 29.7) 
7 22.0 ± 
2.8* 
573 ± 32* 10.3 ± 2.4* 
(89.1 ± 26.4) 
9 
Veh, vehicle. 
a mmol of HbA1c/mol of hemoglobin. 








Figure 3.3-3: KU-596 Reverses Sensory Deficits in Diabetic Mice in an Hsp70-
dependent manner.  
STZ-rendered diabetic mice developed significant sensory hypoalgesia regardless of 
genotype by 12-week of diabetes, at which time point KU-596 treatment was initiated. 
Mechanical (A) and thermal (C) hypoalgesia was partially reversed by 4 weeks of KU-596 
treatment in C57Bl/6 mice. In contrast, 4-week of drug treatment did not have any effect in 
reversing mechanical (B) or thermal (D) deficits in the Hsp70 KO mice. *, p < 0.05 vs. Veh+Veh; 







3.3.3. RNA-Seq Analysis of Sensory Neurons in C57Bl/6 Mice  
To determine the transcriptome changes within sensory neurons that contribute to the 
reversal of insensate DPN, we performed a RNA-Seq analysis using RNA isolated from 
L4-L6 lumbar DRG. In diabetic sensory neurons from WT mice, of the 23,112 genes 
detected by RNA-Seq, 39.6% were expressed too low or went undetected for statistical 
analysis yielding 13,959 genes that were statistically analyzed. Of these genes, 343 were 
significantly modified in diabetic WT compared to control neurons (Figure 3.3-4A). KU-
596 treatment induced significant alterations in 174 genes in diabetic sensory neurons 
(Figure 3.3-4B) and 42 genes in control sensory neurons. Among the subset of transcripts 
that were significantly altered by diabetes in the absence or presence of KU-596, 67/70 
were increased in expression in the diabetic neurons. Impressively, KU-596 treatment 
reversed this trend and consistently decreased transcript expression in an almost 






Figure 3.3-4: Volcano plots for differential gene expression in C57Bl/6 mice.  
Volcano plots comparing the normalized expression of genes in the sensory neurons of 
STZ+Veh versus Veh+Veh group (A), and STZ+KU-596 versus STZ+Veh group (B). Y-axis, 
negative log of p value; x-axis, log2-transformed fold change; red dots, significantly altered genes; 






Table 3.3-3: List of significantly altered transcripts common to diabetic sensory 
neurons from vehicle and KU-596 treated mice.  
 
Veh+Veh vs 
STZ+Veh   
STZ+Veh vs 
STZ+KU-596 

















Acer2 0.90 -0.94 Lrg1 1.17 -1.15 
Agxt2l1 1.47 -0.83 Ltf 0.98 -1.43 
Alas2 1.66 -1.25 Ly6c2 1.38 -1.53 
Anxa1 0.91 -1.03 Lyz2 1.29 -0.98 
Arhgdib 1.15 -0.99 Mki67 0.63 -1.02 
Beta-s 2.01 -1.40 Mmp8 1.45 -1.68 
C1qa 1.17 -0.84 Mmp9 1.10 -1.52 
C1qb 1.06 -0.61 Mpeg1 0.75 -0.71 
C1qc 1.30 -0.68 Mpo 1.26 -1.66 
C3 0.70 -0.92 Ms4a6b 1.34 -1.10 
Camp 1.36 -1.20 Mt2 1.53 -0.87 
Ccl6 1.51 -1.24 Ncf1 1.15 -1.01 
Cd163 1.59 -1.09 Nckap1l 0.84 -0.74 
Cd177 1.52 -1.83 Net1 0.89 -0.53 
Cd53 1.16 -0.98 Ngp 1.25 -1.43 
Chi3l3 1.89 -1.82 Npy1r 0.77 -0.51 
Ctgf 1.38 -0.91 Plbd1 1.00 -0.93 
Ctss 0.91 -0.66 Pld4 1.10 -0.79 
Cybb 0.97 -0.99 Prg2 1.53 -1.58 
F13a1 1.05 -0.84 Prtn3 1.45 -1.34 
F3 0.81 -0.60 Rac2 1.08 -0.91 
Fabp4 1.62 -1.69 Retnlg 1.51 -1.69 
Fam107a 1.18 -0.71 S100a8 1.26 -1.57 
Fcgr3 1.04 -0.85 S100a9 1.30 -1.54 
Fkbp5 0.54 -0.56 Slc4a1 1.31 -1.60 
Fmo2 0.73 -0.54 Slfn2 1.43 -1.10 
Galntl2 1.04 -0.85 Sult1a1 1.00 -0.56 
Gypa 1.25 -1.33 Txnip 1.12 -0.46 
Hbb-b1/2 2.08 -1.44 Tyrobp 1.17 -1.12 
Hcls1 1.02 -0.94 Zbtb16 1.00 -1.09 
Hp 1.52 -1.68 4632428N05Rik 0.87 -0.96 
Ifitm6 1.55 -1.56       
Igj 1.66 -1.57 Hal -1.17 0.82 
Itgam 0.87 -1.12 Hivep3 -0.73 0.55 
Itgb2 1.00 -1.12 Zfhx2 -0.76 0.52 






Ingenuity Pathway Analysis of differentially expressed transcripts revealed that 
inflammatory pathways were among the top canonical pathways enriched in STZ+Veh as 
well as STZ+KU-596 genes (Figure 3.3-5). Other top enriched canonical pathways 
mainly involved chemotaxis of immune cells, which are also indicative of altered 
inflammatory responses. The majority of inflammatory genes altered in STZ+Veh group 
were upregulated (Figure 3.3-6A), which further support the involvement of 
inflammation in the pathogenesis of DPN (Navarro and Mora, 2005). KU-596 
significantly reversed diabetes-induced changes in a number of inflammatory genes in the 
sensory neurons (Figure 3.3-6B), suggesting that modulation of inflammatory pathways 
might contribute to the neuroprotective effects of KU-596. Unexpectedly, differential 
expression of the mitochondrial transcriptome was not overrepresented in either 
STZ+Veh or STZ+KU-596 group. This observation suggests that the alterations in mtBE 
observed in our study were not due to transcriptome changes in genes involved in 
mitochondrial function, although we have previously reported that diabetes decreases the 
expression of numerous mitochondrial proteins (Akude et al., 2011). Thus, diabetes and 
KU-596 likely exert effects on mtBE at the protein level. In contrast, a number of genes 
encoding proteins involved in the production of ROS were increased in the STZ+Veh 
group (Figure 3.3-7A) and decreased in the STZ+KU-596 group (Figure 3.3-7B). These 
data are consistent with the ability of KU-32 to decrease glucose-induced superoxide 










Figure 3.3-5: Heatmap representation of significantly altered gene categories in 
C57Bl/6 mice.  
Significantly altered gene categories in STZ+Veh versus Veh+Veh group (A), and 
STZ+KU-596 versus STZ+Veh group (B). The squares represent significantly altered genes 
under each category; the size of the square was determined by the negative log of the p-value of 
the gene it represents; the color of the square was determined by the activation z-score, with 
orange representing increasing and blue representing decreasing. Genes with a z-score ≥ 2 in (A) 











Figure 3.3-6: Significantly altered genes involved in inflammatory response in 
C57Bl/6 mice.  
Significantly altered genes involved in inflammatory response between Veh+Veh and 
STZ+Veh conditions (A), and between STZ+Veh and STZ+KU-596 conditions (B). Red 
indicates upregulation of the genes, and green indicates downregulation of the genes. The 
degree of change is indicated by the color intensity, a higher color intensity indicating a more 
extreme change. Different colors of the connecting lines represent predicted effects of the 
change of a molecule to the inflammatory response: orange line leads to activation, blue line 
leads to inhibition, yellow line indicates a finding inconsistent with the activation state of the 










Figure 3.3-7: Significantly altered genes involved in the production of ROS in C57Bl/6 
mice. 
Significantly altered genes involved in ROS production between Veh+Veh and STZ+Veh 
conditions (A), and between STZ+Veh and STZ+KU-596 conditions (B). Red indicates 
upregulation of the genes, and green indicates downregulation of the genes. The degree of 
change is indicated by the color intensity, the higher the color intensity indicates a more 
extreme change. Different colors of the connecting lines represent the predicted effects of the 
change of a molecule to the production of ROS: orange line leads to activation, blue line leads 
to inhibition, yellow line indicates a finding inconsistent with the activation state of the 









To validate the RNA-seq analysis, several genes that were altered in both STZ+Veh 
and STZ+KU-596 group were chosen for qRT-PCR analysis in independent samples. 
Due to limits in the amounts of RNA we obtained from each DRG sample, we selected 8 
genes with FPKM ≥ 5 for qRT-PCR analysis (TXNIP, S100A8, LTF, FKBP5, 
ARHGDIB, FABP4, LCN2, CCL6). Although due to small sample sizes (n=3 in each 
group), only TXNIP and FKBP5 showed statistical significance, the other selected genes 
also followed similar trends in the qRT-PCR analysis (Figure 3.3-7A) as compared to the 
RNA-Seq data (Figure 3.3-7B). Collectively, these data suggest that KU-596 can reverse 







Figure 3.3-8: qRT-PCR validation of RNA-Seq data in C57Bl/6 mice.  
(A) Total RNA was prepared for mRNA quantification by standard qRT-PCR. Tubulin was 
used as the internal control. Each group consisted of three samples. The data were expressed as 
fold change versus Veh+Veh for each gene. *, p < 0.05 vs. Veh+Veh; ^, p < 0.05 vs. STZ+Veh; 
n=3. (B) Fold change versus Veh+Veh using the FPKM normalized reads obtained from RNA-






3.3.4. RNA-Seq Analysis of Sensory Neurons from Hsp70 KO Mice 
To determine transcriptome changes induced by KU-596 that were Hsp70-dependent, 
RNA was isolated from the Hsp70 KO mice and used for RNA-seq analysis. The 
genomic structures of Hsp70 in WT versus the Hsp70 KO mice were displayed in the 
Appendix 2. Unexpectedly, of the 23,112 genes detected by RNA-seq, only 101 were 
significantly modified in diabetic sensory neurons (Figure 3.3-9A). On the other hand, 
KU-596 treatment significantly altered 242 genes in the diabetic sensory neurons (Figure 
3.3-9B) and 37 genes in control sensory neurons. Among the significantly altered 
transcripts, 31 were increased in diabetic neurons and decreased by KU-596 treatment 
(Table 3.3-4). Comparison between genes significantly altered in WT and Hsp70 KO 
mice revealed little overlap: of the genes affected by KU-596 in diabetic sensory neurons, 
there were 8 genes altered in both genotypes and 8 genes altered only in C57Bl/6 but not 






Figure 3.3-9: Volcano plots for differential gene expression in Hsp70 KO mice.  
Volcano plots comparing the normalized expression of genes in the sensory neurons of 
STZ+Veh versus Veh+Veh group (A), and STZ+KU-596 versus STZ+Veh group (B). Y-axis, 
negative log of p value; x-axis, log2-transformed fold change; red dots, significantly altered genes; 






Table 3.3-4：List of genes upregulated in diabetic sensory neurons and downregulated 























1500015A07Rik 2.0436 -0.62406 H2-Ab1 0.317947 -0.65519 
Acp5 1.31424 -1.5356 Ifi27l2a 0.881136 -1.05258 
Apod 0.344651 -0.64443 Ifit1 0.396187 -0.40826 
C1qa 0.57526 -0.76349 Ifitm3 0.408975 -0.34488 
C1qb 0.39586 -0.76585 Iigp1 0.973369 -0.53836 
C1qc 0.390653 -0.56792 Lyz2 0.525966 -0.55338 
Ccl8 1.7593 -1.11681 Mmp9 0.530685 -0.63794 
Cd74,Mir5107 0.331849 -0.60352 Mpo 0.655659 -1.06418 
Col1a1 0.588773 -0.94085 Ms4a7 0.921042 -0.94733 
Col1a2 0.393786 -0.5556 Nckap1l 0.594368 -0.6136 
Cst3 0.294541 -0.27093 Ndufb2 0.351165 -0.51403 
Ctss 0.56015 -0.71955 Rpl39 0.477781 -0.55082 
Cxcl16 0.564734 -0.81446 S100a1 0.379494 -0.52036 
Fam65a,Mir1966 2.557 -2.48583 S100a4 0.456091 -0.55616 
Gfap 1.18752 -0.97605 Trf 0.374662 -0.48973 







Despite the stark difference between the gene sets affected in the Hsp70 KO and WT 
mice, Ingenuity Pathway Analysis revealed that inflammation was still among the top 
canonical pathways significantly enriched in the STZ+Veh and STZ+KU-596 groups 
(Figure 3.3-10 and Figure 3.3-11). This observation suggests that KU-596 likely 
decreased the inflammatory response in diabetic sensory neurons through an Hsp70-
independent pathway. In contrast to inflammatory pathways, the effects of KU-596 on the 
production of ROS was blunted (Figure 3.3-12), suggesting that KU-596 may reduce 
oxidative stress in diabetic sensory neurons in an Hsp70-dependent manner. 
Unexpectedly, KU-596 slightly decreased the transcription of several mitochondrial 
genes in diabetic sensory neurons (Table 3.3-5). This effect was not observed in either 
Hsp70 KO control mice or WT mice treated with KU-596. Though mtBE was not 
measured in KU-596-treated Hsp70 KO mice, the decrease in mRNA levels of these 
mitochondrial proteins was unlikely to result in changes in mitochondrial respiration 
since KU-32 did not decrease mtBE in sensory neurons isolated from diabetic Hsp70 KO 
mice in our previous study (Ma et al., 2014). In addition to affecting mitochondrial 
transcripts, KU-596 also decreased a subset of 25 genes involved in the eIF2 pathway in 
diabetic sensory neurons, all of which encoded ribosomal proteins. Considering the role 
of eIF2 pathway in protein synthesis and translation, the decrease in genes involved in 
this pathway would suggest an overall decrease in protein synthesis. Regardless of the 
consequence of these changes, they are not associated with changes in sensory 
pathophysiology since KU-596-treated Hsp70 KO diabetic mice behaved similar to 










Figure 3.3-10: Heat map representation of significantly altered gene categories in 
Hsp70 KO mice. 
Significantly altered gene categories in STZ+Veh versus Veh+Veh group (A), and 
STZ+KU-596 versus STZ+Veh group (B). The squares represent significantly altered genes 
under each category; the size of the square was determined by the negative log of the p-value of 
the gene it represents; the color of the square was determined by the activation z-score, with 
orange representing increasing and blue representing decreasing. Genes with a z-score ≥ 2 in (A) 











Figure 3.3-11: Significantly altered genes involved in inflammatory response in 
Hsp70 KO mice.  
Significantly altered genes involved in inflammatory response between Veh+Veh and 
STZ+Veh conditions (A), and between STZ+Veh and STZ+KU-596 conditions (B). Red 
indicates upregulation of the genes, and green indicates downregulation of the genes. The 
degree of change is indicated by the color intensity, a higher color intensity indicating a more 
extreme change. Different colors of the connecting lines represent predicted effects of the 
change of a molecule to the inflammatory response: orange line leads to activation, blue line 
leads to inhibition, yellow line indicates a finding inconsistent with the activation state of the 








Figure 3.3-12: Significantly altered genes involved in the production of ROS in Hsp70 
KO mice. 
Significantly altered genes involved in ROS production between Veh+Veh and STZ+Veh 
conditions. Red indicates upregulation of the genes, and green indicates downregulation of the 
genes. The degree of change is indicated by the color intensity, the higher the color intensity 
indicates a more extreme change. Different colors of the connecting lines represent the 
predicted effects of the change of a molecule to the production of ROS: orange line leads to 
activation, blue line leads to inhibition, yellow line indicates a finding inconsistent with the 








Table 3.3-5: List of mitochondrial genes downregulated by KU-596 treatment in 
diabetic sensory neurons in Hsp70 KO mice.  




ATP synthase, H+ transporting, mitochondrial F1 complex, 
epsilon subunit -0.757 
ATP5J2 
ATP synthase, H+ transporting, mitochondrial Fo complex, 
subunit F2 -0.363 
COX17 COX17 cytochrome c oxidase copper chaperone -0.340 
COX6B1 cytochrome c oxidase subunit VIb polypeptide 1 (ubiquitous) -0.274 
Cox6c cytochrome c oxidase subunit VIc -0.358 
Cox7a2/Cox7a2l2 cytochrome c oxidase subunit VIIa polypeptide 2-like 2 -0.363 
COX7B cytochrome c oxidase subunit VIIb -0.438 
FIS1 
fission 1 (mitochondrial outer membrane) homolog (S. 
cerevisiae) -0.286 
GPX4 glutathione peroxidase 4 -0.359 
NDUFA4 NDUFA4, mitochondrial complex associated -0.448 
NDUFA7 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 
14.5kDa -0.325 
NDUFB2 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 
8kDa -0.514 
NDUFB9 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 
22kDa -0.284 
NDUFB11 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11, 
17.3kDa -0.321 
UQCR10 ubiquinol-cytochrome c reductase, complex III subunit X -0.370 
UQCR11 ubiquinol-cytochrome c reductase, complex III subunit XI -0.396 
UQCRQ 








3.4. Summary and Discussion 
KU-596 Reverses Physiologic and Bioenergetic Deficits of DPN 
In the current study, the next-generation novologue KU-596 reversed psychosensory, 
electrophysiologic and bioenergetic deficits of DPN in animal models of type 1 diabetes. 
KU-596 was identified through SAR analysis of KU-32 derivatives. Mechanistically, 
substitution of the coumarin lactone of KU-32 with a 3'-fluoro-benzene ring in KU-596 
may enhance the molecule’s interaction with Lys539 in the Hsp90 C-terminal binding 
pocket. In addition, the flexible ethyl amide projecting from KU-596 accommodates a 
number of orientations that could better occupy the large hydrophobic pocket of Hsp90 
that remains vacant in the presence of KU-32. Previous studies have shown that KU-596 
induced Hsp70 expression and exhibited enhanced neuroprotective properties in in vitro 
models of glucotoxicity (Kusuma et al., 2012). In the current study, we provided further 
evidence that KU-596 is orally bioavailable, and is effective at reversing multiple clinical 
indices of DPN in in vivo models of type 1 diabetes in an Hsp70-dependent manner.  
KU-596 Reverses Transcriptome Changes involved in Inflammatory Pathways 
and Production of ROS 
Transcriptome analysis of sensory neurons using the RNA-Seq approach revealed 
that KU-596 primarily modulated genes involved in inflammatory responses (Figure 3.3-
5). Inflammation has been proposed as a key mechanism underlying the pathogenesis as 
well as progression of DPN (Zhou and Zhou, 2014). Patients with diabetic neuropathy 
exhibit features of low-grade subclinical inflammation (Herder et al., 2009). Increased 
levels of pro-inflammatory cytokines, especially interleukin (IL)-6 and C-reactive 





et al., 2009; Shelbaya et al., 2012). These pro-inflammatory cytokines produced locally 
by resident and infiltrating immune cells exhibit neuropoietic effects on glial and 
neuronal cells, further disturbing cellular homeostasis in diabetic tissues (Skundric and 
Lisak, 2003).  
In the current study, diabetic sensory neurons exhibited enhanced markers of 
inflammation and immune cell infiltration, which were partially abolished by 4 weeks of 
KU-596 treatment. Among these inflammation genes, one of interest is CD163. CD163 is 
an endocytic haptoglobin–hemoglobin receptor expressed on macrophages and 
monocytes and serves as a macrophage-derived low-grade inflammation marker 
reflecting macrophage activation (Kristiansen et al., 2001). It was increased ~3-fold in 
diabetic sensory neurons and decreased ~2-fold by KU-596 treatment. A case-control 
study involving a small number of type 2 diabetic patients indicated that an increase in 
soluble CD163 levels in cerebrospinal fluid and serum was associated with impaired 
peripheral nerve function and incidence of DPN (Kallestrup et al., 2015). Thus, the 
upregulation of cytokines, chemokines and genes such as CD163 in diabetic sensory 
neurons suggests that recruitment of activated macrophages and activation of 
inflammatory pathways are likely involved in the pathogenesis of DPN. KU-596 reduced 
inflammatory markers in the sensory neurons, suggesting that modulation of molecular 
chaperones alters inflammatory responses in the sensory neurons, which might contribute 
to reversing the sensory deficits. CD163 was also upregulated 1.4 fold in diabetic Hsp70 
KO neurons, but this did not quite reach statistical significance (q < 0.06). However, 
CD163 was significantly increased when comparing non-diabetic animals to diabetic 





as strongly increased between the diabetic WT and Hsp70 KO mice and its expression 
was not decreased by novologue treatment of the diabetic Hsp70 KO mice. Therefore, 
Hsp70 may have a role in altering the expression of CD163. Given the putative link that 
diabetic patients with neuropathy show a greater increase in serum CD163 levels than 
diabetic patients without neuropathy (Kallestrup et al., 2015), the ability of KU-596 
therapy to decrease its expression may provide a biomarker for drug efficacy.    
Another overrepresented biologic process in diabetic sensory neurons comprised 
genes involved in the production of ROS (Figure 3.3-6A). Oxidative stress has been 
considered as an essential pathogenic mechanism for DPN (Figueroa-Romero et al., 2008; 
Kasznicki et al., 2012; Vincent et al., 2004b). Hyperglycemia changes multiple 
biochemical and metabolic pathways, including the polyol pathway, activation of PKC 
isoforms and the AGE/RAGE pathway. In addition to causing damage to the peripheral 
nerves themselves, these pathophysiological changes intersect at the level of ROS 
production to further contribute to the development and progression of DPN (Edwards et 
al., 2008). Our previous study indicated that KU-32 increased the translation of MnSOD 
and decreased oxidative stress in hyperglycemically stressed rat embryonic sensory 
neurons (Zhang et al., 2012). In the current study, transcriptome analysis of sensory 
neurons revealed that KU-596 also affected gene networks involved in the production of 
ROS (Figure 3.3-6B). For example, Cybb (also known as cytochrome b(558) subunit beta 
or NADPH oxidase 2/Nox2), a superoxide generating enzyme that forms ROS 
(Tammariello et al., 2000), increased ~2-fold in diabetic sensory neurons and was 
reduced ~2-fold by KU-596 treatment. Thioredoxin interacting/inhibiting protein (Txnip) 





promotes oxidative stress through interacting with thioredoxin (Trx) and blocking its 
ROS scavenging activity (Schulze et al., 2004). In the current study, Txnip was also 
upregulated ~2-fold in diabetic neurons and downregulated about 1.4-fold by KU-596. 
Similarly, diabetes significantly increased the expression of Txnip in the Hsp70 KO DRG 
but this was unaffected by KU-596 treatment. Therefore, limiting ROS production and 
reducing oxidative stress in the sensory neurons might represent an important Hsp70-
dependent pathway through which KU-596 exhibits efficacy on reversing sensory deficits 
of DPN.   
KU-596 (Figure 3.1-1B) and KU-32 (Ma et al., 2014) have been shown to reverse 
mtBE deficits in diabetic sensory neurons. Thus, we were expecting that transcriptome 
analysis would reveal gene clusters connecting to aspects of mitochondrial function. 
However, none of the genes involved in cellular bioenergetic activities were significantly 
altered in WT mice of the STZ+Veh or STZ+KU-596 groups. These results suggest that 
modulation of molecular chaperones likely exerts effects on mitochondrial function post-
translationally, for example, through refolding of damaged proteins, directing protein 
import into mitochondria, or as mentioned above by decreasing oxidative stress. In 
addition, it has been suggested that inflammatory signaling leads to changes in the 
phosphorylation state of mitochondrial proteins, which results in an inhibition of 
respiratory chain activity, a reduction of the mitochondrial membrane potential, and 
consequently a lack of energy production (Lee and Huttemann, 2014). Thus, modulation 
of mtBE could also be achieved indirectly through mediating inflammatory responses. In 





partially attributed to its effects in ameliorating inflammatory signaling in the sensory 
neurons.  
Hsp70 KO Mice Display Different Gene Sets altered by STZ and KU-596  
Comparison between genes significantly altered in WT and Hsp70 KO mice revealed 
little overlap in either STZ+Veh or STZ+KU596 group (Figure 3.4-1). Compared to 343 
genes in WT mice, only 101 genes were significantly altered in diabetic sensory neurons 
of Hsp70 KO mice. Further analysis of the genes revealed decreases in the number of 
genes involved in inflammatory pathways, immune cell recruitment and ROS production. 
Though unexpected, this change might be related to a role of Hsp70 in the stimulation of 
pro-inflammatory cytokine production and recruitment of macrophages/monocytes 
(Huang et al., 2013; Senf et al., 2013). A recent study revealed that Hsp70.1-deficent 
mice were more resistant to developing autoimmune encephalomyelitis, suggesting the 
involvement of Hsp70.1 in promoting an effective myelin oligodendrocyte glycoprotein 
T cell response (Mansilla et al., 2014). It has been reported that under stress conditions, 
Hsp70 is actively released into the extracellular milieu to promote innate and adaptive 
immune responses (Hunter-Lavin et al., 2004). Recent studies indicate that the 
physiological function of Hsp70 largely depends on the location of the protein (Krause et 
al., 2015). For example, increased extracellular Hsp70 is associated with inflammatory 
and oxidative stress conditions (Whitham and Fortes, 2008), whereas increased 
intracellular Hsp70 confers cellular protection through anti-inflammatory effects (Jones 
et al., 2011). In this regard, increased concentrations of extracellular Hsp70 and 
decreased concentrations of intracellular Hsp70 have been reported in type 2 diabetic 





mediated the activation of inflammatory pathways in WT diabetic sensory neurons, 
which may contribute to the partial blockage of transcriptome changes involved in these 
pathways in the Hsp70 KO mice.  
 
Figure 3.4-1: Heatmap representation of top canonical pathways enriched in WT and 
Hsp70 KO mice.  
Top canonical pathways revealed by comparison analysis of transcriptomic changes in WT 
versus Hsp70 KO mice. The squares were colored by the activation z-score: red indicates 
increasing, blue indicates decreasing, intensity of the color is indicative of the degree of change.  
 
In contrast to decreased number of affected genes in STZ+Veh group, KU-596 
induced changes in 242 genes in diabetic sensory neurons in Hsp70 KO mice (compared 
to 174 in C57Bl/6 mice). Among these altered genes, 220 out of 242 were decreased, 
including 17 genes involved in mitochondrial function and oxidative phosphorylation. 
Although the exact underlying reason is unknown, this effect of KU-596 on 
mitochondrial transcripts might be associated with a role of Hsp90 in mitochondrial 
protein turnover. In the absence of Hsp70, the effects of KU-596 on transcriptome 





showed that Hsp90 inhibition led to post-translational accumulation of several 
mitochondrial oxidative phosphorylation complex subunits without corresponding 
changes in mRNA abundance (Margineantu et al., 2007). Thus, the decrease in 
transcription observed in our study might be an innate response mechanism to the 
accumulation of these mitochondrial proteins due to inhibition of Hsp90 over the 4 weeks 
of drug treatment. As an essential molecular chaperone that assures the correct folding 
and maturation of a number of cellular proteins, Hsp90 inhibition leads to a global 
repression of protein synthesis and an increase in the degradation of its client proteins 
(Fierro-Monti et al., 2013). A recent proteomics study using human T cells revealed that 
Hsp90 inhibition resulted in the depletion of proteins involved in transcription and DNA 
damage response as well as a mild but general decrease of ribosomal proteins and other 
components of the protein synthesis machinery (Quadroni et al., 2015). This finding is 
consistent with our observation that KU-596 led to a decrease in the eIF2 signaling 
pathway and an overall decrease in transcription. In this regard, the differences in the 
gene sets affected by KU-596 in WT versus Hsp70 KO mice might be explained by the 
different downstream pathways induced by drug treatment in the different genotypes: 
whereas KU-596 exerts cytoprotective effects through induction of Hsp70 in WT cells, 
the effects of KU-596 are largely exerted through inhibiting the activity of Hsp90 in 
Hsp70 KO cells.  
KU-596 Exerts Alterations in Transcriptome through both Hsp70-dependent 
and Hsp70-independent mechanisms  
An anti-inflammatory role of Hsp70 has been implicated by various studies. It is 





production of pro-inflammatory cytokines (Dokladny et al., 2010; Shi et al., 2006). 
Mechanistic studies suggest that the modulatory effect of Hsp70 on the inflammatory 
response is likely through directing the degradation of the p65 subunit of NF-κB (Tanaka 
et al., 2014). However, in the current study, KU-596-induced alterations in inflammatory 
pathways were not solely dependent on Hsp70 (Figure 3.3-9). Mechanistically, different 
Hsp90 inhibitors may attenuate inflammation through disparate pathways. For example, 
the N-terminal Hsp90 inhibitor 17-AAG suppressed glial inflammatory responses in 
experimental autoimmune encephalomyelitis through transcriptional activation of HSF-1 
and induction of a HSR (Dello Russo et al., 2006). In contrast, novobiocin inhibited pro-
inflammatory cytokine production through disruption of Hsp90 chaperone function and 
decreasing the level of IKK-α. The decease of IKK-α in novobiocin-treated cells 
subsequently led a reduction in the nuclear translocation of the NF-κB p65 subunit and 
inhibition of inflammatory pathway (Collins et al., 2014). As a structural analogue of 
novobiocin, KU-596 may mediate inflammatory responses through degradation of IKK-α 
but not induction of Hsp70, which might explain its Hsp70-independent anti-
inflammatory effects in diabetic sensory neurons. However, the preserved anti-
inflammatory effects of KU-596 in Hsp70 KO mice was not associated with 
improvements in psychosensory functions of diabetic mice. This suggests that inhibition 
of inflammatory responses alone was not sufficient to reverse sensory deficits of 
insensate DPN in our model of type 1 diabetes.   
In contrast to the Hsp70-independent anti-inflammatory effects, KU-596 exerted its 
effects on the production of ROS in an Hsp70-dependent manner (Figure 3.3-10). The 





Cybb and Txnip, were blunted in Hsp70 KO mice. Though the exact mechanism through 
which Hsp70 modulates ROS production remains undetermined, overexpression of 
Hsp70 has been associated with protection against age-related oxidative stress (Broome 
et al., 2006). In our previous study, we identified that modulation of molecular 
chaperones reversed deficits in sensory functions and mitochondrial bioenergetics in an 
Hsp70-dependent manner (Ma et al., 2014). The reliance on Hsp70 for a tight correlation 
between reduced gene networks involved in ROS production and improved mtBE 
suggests that the effects of KU-596 to improve mitochondrial respiration might be partly 









Chapter 4: Outlooks  
Progress in developing effective therapies for DPN has largely been disappointing 
despite increased understanding of its pathophysiological mechanisms. The multifaceted 
biochemical abnormalities associated with DPN occur in an individual-based, non-
uniform fashion, hindering disease treatment with simple monotherapeutic strategies that 
directly target a specific pathogenic factor. In this regard, modulating molecular 
chaperones offers promising therapeutic alternatives and may provide a powerful tool for 
ameliorating deficits of DPN through reinforcing innate protective mechanisms. In other 
words, modulating molecular chaperones may help neurons and glia to more effectively 
tolerate ongoing diabetic stress.  
Mitochondrial dysfunction, oxidative stress and activation of the inflammatory 
pathways have been implicated as important pathogenic factors for DPN (Callaghan et al., 
2012a). We have shown that novologues improved mitochondrial bioenergetics and 
reversed transcriptomic changes associated with the production of ROS in an Hsp70-
dependent manner, which correlated with the Hsp70-dependent improvements in sensory 
performances. However, the exact mechanism through which modulation of Hsp70 
mediates mitochondrial bioenergetics remains to be elucidated. As revealed by the RNA-
Seq analysis of sensory neurons, the effects of KU-596 on mitochondrial function were 
not exerted through transcriptional modulation of genes encoding proteins involved in 
cellular bioenergetic activities. Therefore, KU-596 likely modulates mitochondrial 
bioenergetics post-translationally, for example, through facilitating the import, removal, 
and/or replacement of damaged mitochondrial proteins. Despite the presence of mtDNA, 





organelle. In this regard, Hsp70 serves as a chaperone for importing hydrophobic 
precursors of inner mitochondrial membrane proteins (Schmidt et al., 2010). Our 
previous proteomic study using hyperglycemically-stressed rat embryonic sensory 
neurons indicated that KU-32 increased the level of MnSOD, which correlated with 
decreased mitochondrial superoxide production and enhanced bioenergetic profile (Zhang 
et al., 2010a). MnSOD is synthesized in the cytosol and imported into the mitochondrial 
matrix, and it has been reported that the import of MnSOD is dependent on its interaction 
with the inducible HSP70 (Afolayan et al., 2014). Therefore, it seems reasonable to 
hypothesize that modulation of Hsp70 might improve mitochondrial bioenergetics 
through enhancing the mitochondrial protein import machinery. 
Txnip was identified in the RNA-Seq study as a KU-596 target gene which displayed 
Hsp70 dependency. It acts as a physiological inhibitor of thioredoxin (Trx) and promotes 
oxidative stress through blocking the ROS scavenging activity of Trx (Schulze et al., 
2004). It was later found that Txnip shuttles between various intracellular locations, and 
its actions largely depend on its intracellular distribution. Whereas under basal conditions, 
Txnip is located entirely in the nucleus where it binds to a number of intranuclear 
proteins such as PARP-1, it translocates to mitochondria or cell surface under certain 
stress conditions (Spindel et al., 2012). For example, in response to oxidative stress, 
Txnip translocated to mitochondria where it bound thioredoxin-2 (Trx-2), the 
mitochondrial isoform of Trx, and led to mitochondrial dysfunction and activation of 
apoptosis (Saxena et al., 2010). Furthermore, binding of Txnip to Trx-2 is critical to the 
development of intra-mitochondrial redox stress and activation of inflammatory pathways 





mitochondrial dysfunction and inflammatory responses in diabetic sensory neurons, and 
might represent a critical target for Hsp70 modulation in the treatment of DPN.  
The RNA-Seq analysis revealed that KU-596 reversed transcriptomic changes 
associated with the inflammatory pathways in an Hsp70-independent manner, and that 
reversing the inflammatory responses alone was not enough to reverse sensory deficits of 
insensate DPN in our type 1 diabetes model. However, the efficacy of KU-596 to reverse 
activation of the inflammatory pathways might enable the expansion of its application to 
other sensory neuropathies that exhibit more profound features of inflammation, for 
example, painful diabetic peripheral neuropathy (PDPN). The symptoms of PDPN range 
from uncomfortable tingling, pain with a variety of different characteristics (burning, 
lancinating, shooting, electric-shock-like, aching and crawling pain) to evoked pain such 
as allodynia or hyperaesthesia (Gandhi and Selvarajah, 2015). PDPN is associated with 
an increased pro-inflammatory cytokine profile (Doupis et al., 2009), implicating the role 
of cytokine-mediated neuroimmune interactions in the development and maintenance of 
pain. Therefore, as a modulator of inflammatory responses, KU-596 might be effective in 
ameliorating neuropathic pain associated with PDPN. Management of the chemotherapy-
induced peripheral neuropathy (CIPN) represents another possible application for KU-
596. CIPN is a common dose-limiting complication of cancer chemotherapy and exhibits 
bilaterally symmetrical sensory symptoms (numbness, tingling, and pain) appearing in 
the extremities after cumulative dosing (Argyriou et al., 2012; Paice, 2011). Recent 
studies indicated that chemotherapeutics, such as paclitaxel and oxaliplatin, produced a 
long-lasting dysfunction in mitochondria in primary afferent sensory neurons (Xiao and 





peripheral neuropathy was characterized by macrophage infiltration in both the DRG and 
peripheral nerve, and microglial activation within the spinal cord (Peters et al., 2007). 
Therefore, considering its role in improving mitochondrial bioenergetics and reducing the 
inflammatory responses, KU-596 might provide a novel therapy against CIPN and aid in 
the treatment of cancer. However, caution must be taken in the application of KU-596 as 
an adjuvant therapy to treat CIPN. As certain cancers are characterized by Hsp70 
overexpression (Ricaniadis et al., 2001; Yoshida et al., 2009), modulation of Hsp70 in 
cancer subjects might lead to deterioration of the malignant phenotypes. Though KU-32 
and KU-596 were shown to be weak inducers of Hsp70 and demonstrated safety in 
animal models of DPN, their actions in malignant phenotypes are hard to predict without 
careful experimental examinations.    
In summary, this dissertation provides further evidence that pharmacologic 
modulation of endogenous neuroprotective chaperones offers a novel therapeutic 
opportunity for the management of DPN. Though future studies are needed to further 
elucidate the protective mechanism of novologue therapy, we have identified mtBE and 
oxidative stress as key targets for Hsp70 modulation which correlated closely with 
improved sensory parameters in animal models of DPN. Coupled with close attention 
towards good glycemic control, modulating molecular chaperones shows great promise in 






Table 5-1: List of primer sequences. 
TUBA1A Forward 5'-TCTTGTCACTTGGCATCTGG-3' 
 
Reverse 5'-CGCGAAGCAGCAACCAT-3' 
TXNIP Forward 5'-TCTTTTGAGGTGGTCTTCAACG-3' 
 
Reverse 5'-GCTTTGACTCGGGTAACTTCACA-3' 
S100A8 Forward 5'-AAATCACCATGCCCTCTACAAG-3' 
 
Reverse 5'-CCCACTTTTATCACCATCGCAA-3' 
LTF Forward 5'-TGAGGCCCTTGGACTCTGT-3' 
 
Reverse 5'-ACCCACTTTTCTCATCTCGTTC-3' 
FKBP5 Forward 5'-TGAGGGCACCAGTAACAATGG-3' 
 
Reverse 5'-CAACATCCCTTTGTAGTGGACAT-3' 
ARHGDIB Forward 5'-ATGACGGAGAAGGATGCACAG-3' 
 
Reverse 5'-CTCCCAGCAGTGTTTTCTTGTA-3' 
FABP4 Forward 5'-AAGGTGAAGAGCATCATAACCCT-3' 
 
Reverse 5'-TCACGCCTTTCATAACACATTCC-3' 
LCN2 Forward 5'-ATGTATGGCCGGTACACTCAG-3' 
 
Reverse 5'-AACAAATGCGACATCTGGCAC-3' 










Figure 5-1: RNA-seq confirmation of the Hsp70 KO phenotype. 
The phenotype of the Hsp70.1/70.3 double KO mice used in our study was confirmed by 
RNA-seq. (A) Accepted hits of Hspa1a (Hsp70.3) in WT (upper band) versus Hsp70 KO mice 
(lower band). (B) Accepted hits of Hspa1b (Hsp70.1) in WT (upper band) versus Hsp70 KO mice 
(lower band). (C) Genomic structure of Hsp70.1/3 and design of targeting construct. The Hsp70 
gene deletion vector was constructed by replacement of approximately 11 kb of genomic DNA 
separating the 5’ end of the Hsp70.3 gene and the 3’ end of the Hsp70.1 gene with a 3.1 kb neo 
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